Acquired Resistance of Lung Adenocarcinomas to Gefiti a Second Mutation in the EGFR Kinase Domain

PLoS Medicine 2, e73 DOI: 10.1371/journal.pmed.0020073

Citation Report

#	Article	IF	CITATIONS
1	Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 419-426.	1.1	100
2	Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 73-81.	1.1	37
3	Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 499-515.	1.1	31
4	Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 3-13.	2.3	137
5	Characterisation of kinase-selective inhibitors by chemical proteomics. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 183-190.	2.3	34
6	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics, 2005, 37, 1315-1316.	21.4	468
7	Aurora kinases: shining lights on the therapeutic horizon?. Oncogene, 2005, 24, 5005-5015.	5.9	175
8	Role of Epidermal Growth Factor Receptor Mutations in Predicting Sensitivity or Resistance to Targeted Agents in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2005, 6, 338-339.	2.6	0
9	Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer, 2005, 5, 125.	2.6	12
10	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. International Journal of Cancer, 2005, 117, 883-888.	5.1	173
11	Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer. Cancer Research, 2005, 65, 7525-7529.	0.9	143
12	Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors. Clinical Cancer Research, 2005, 11, 5668-5670.	7.0	27
13	EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head. PLoS Medicine, 2005, 2, e75.	8.4	24
14	Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R. PLoS Medicine, 2005, 2, e269.	8.4	26
15	Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?. Journal of Clinical Oncology, 2005, 23, 6813-6816.	1.6	56
16	Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. PLoS Medicine, 2005, 2, e313.	8.4	603
17	A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of "Allele Dilution―on Gefitinib Sensitivity?. Journal of the National Cancer Institute, 2005, 97, 621-623.	6.3	22
18	EGFRMutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 353, 207-208.	27.0	166

#	ARTICLE Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat	IF	CITATIONS
19	Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins. Cancer Research, 2005, 65, 6401-6408.	0.9	242
20	Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva \hat{A}^{\circledast}) and Gefitinib (Iressa \hat{A}^{\circledast}). Oncologist, 2005, 10, 579-589.	3.7	107
21	An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 7096-7101.	0.9	250
22	Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib. Clinical Cancer Research, 2005, 11, 8872-8879.	7.0	33
23	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncology, 2005, 1, 449-460.	2.4	26
24	Erlotinib hydrochloride. Nature Reviews Drug Discovery, 2005, 4, S14-S15.	46.4	22
25	EGFRMutation and Response of Lung Cancer to Gefitinib. New England Journal of Medicine, 2005, 352, 2136-2136.	27.0	118
26	EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Nature Clinical Practice Oncology, 2005, 2, 296-297.	4.3	16
27	Gefitinib in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 985-993.	1.8	55
28	EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 554-561.	4.3	77
29	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11011-11016.	7.1	529
30	CELL BIOLOGY: Lessons in Rational Drug Design for Protein Kinases. Science, 2005, 308, 1266-1267.	12.6	17
31	Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. Clinical Cancer Research, 2005, 11, 8686-8698.	7.0	485
32	Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194.	6.3	294
33	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2005, 10, 855-874.	2.4	8
34	Genomic Profiling of Cancer: What Next?. Journal of Clinical Oncology, 2005, 23, 7253-7256.	1.6	13
35	Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression. Cancer Research, 2005, 65, 8968-8974.	0.9	165
36	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology, 2005, 1, 461-466.	2.4	6

#	Article	IF	CITATIONS
37	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology, 2005, 23, 8081-8092.	1.6	608
38	Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 6829-6837.	1.6	701
39	Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class. Cell Cycle, 2005, 4, 4057-4059.	2.6	12
40	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	3.4	55
41	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. Expert Opinion on Therapeutic Targets, 2005, 9, 1009-1030.	3.4	47
42	Pharmacogenetics and Drug Development. Annual Reports in Medicinal Chemistry, 2005, , 417-427.	0.9	1
43	Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resistance Updates, 2005, 8, 119-129.	14.4	37
44	Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates, 2005, 8, 298-310.	14.4	84
45	Mutated kinases as targets for cancer drugs. Drug Discovery Today Disease Mechanisms, 2005, 2, 139-144.	0.8	7
46	Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 2006, 354, 2531-2541.	27.0	1,606
47	The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue Des Maladies Respiratoires, 2006, 23, 137-147.	1.7	2
48	Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors in??the Treatment of Cancer. Drugs in R and D, 2006, 7, 73-86.	2.2	23
49	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	5.0	3
50	Prospective Phase II Study of Gefitinib for Chemotherapy-NaÃ⁻ve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. Journal of Clinical Oncology, 2006, 24, 3340-3346.	1.6	490
51	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer, 2006, 52, 225-233.	2.0	31
52	Tyrphostins and Other Tyrosine Kinase Inhibitors. Annual Review of Biochemistry, 2006, 75, 93-109.	11.1	205
53	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy. Clinical Cancer Research, 2006, 12, 5268-5272.	7.0	776
54	Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178.	12.6	437

#	Article	IF	CITATIONS
55	Est-il nécessaire de sélectionner les patients pour prescrire des thérapeutiques ciblées dans les cancers bronchiques non à petites cellules de stade IV ?. Revue De Pneumologie Clinique, 2006, 62, 41-44.	0.0	0
56	Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 379-396.	1.0	12
57	Novel Targeted Therapies for Non–Small Cell Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 353-366.	1.0	1
58	A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer. Journal of Molecular Diagnostics, 2006, 8, 335-341.	2.8	178
59	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. Clinical Lung Cancer, 2006, 7, S138-S144.	2.6	76
60	Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2158-2163.	1.6	143
61	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer, 2006, 51, 71-77.	2.0	51
62	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer, 2006, 51, 363-368.	2.0	75
63	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer, 2006, 53, 117-121.	2.0	56
64	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer, 2006, 53, 339-345.	2.0	15
65	A review of the benefit–risk profile of gefitinib in Asian patients with advanced nonâ€smallâ€cell lung cancer. Current Medical Research and Opinion, 2006, 22, 561-573.	1.9	85
66	ErbB receptors and epithelial-cadherin–catenin complex in human carcinomas. Future Oncology, 2006, 2, 765-781.	2.4	34
67	Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. Clinical Cancer Research, 2006, 12, 4283-4287.	7.0	154
68	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Annals of Diagnostic Pathology, 2006, 10, 306-315.	1.3	36
69	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochemical and Biophysical Research Communications, 2006, 340, 469-475.	2.1	57
70	Chemical genetic approaches to the development of cancer therapeutics. Current Opinion in Genetics and Development, 2006, 16, 85-91.	3.3	3
71	Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.	2.2	1,744
72	Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy. European Journal of Cancer, 2006, 42, 17-23.	2.8	153

#	ARTICLE	IF	CITATIONS
73	Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. European Journal of Cancer, 2006, 42, 109-111.	2.8	153
74	Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310.	0.4	6
75	Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases, 2006, 60, 123.	1.8	0
76	Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies. Scientific World Journal, The, 2006, 6, 918-930.	2.1	22
77	Bcr-Abl Kinase Inhibitors. Topics in Medicinal Chemistry, 2006, , 407-444.	0.8	4
78	Kinase mutations in cancer: chinks in the enemy's armour?. Current Opinion in Oncology, 2006, 18, 69-76.	2.4	9
79	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events. Biochemical Journal, 2006, 396, 79-88.	3.7	16
80	Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood, 2006, 108, 286-291.	1.4	250
81	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 740-743.	1.1	2
82	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 1010-1019.	1.1	7
83	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	1.1	6
84	Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. Current Signal Transduction Therapy, 2006, 1, 67-95.	0.5	43
85	Signal Transduction Therapy for Cancer - Whither Now?. Current Signal Transduction Therapy, 2006, 1, 1-12.	0.5	14
86	Monitoring EGFR-Mutant Lung Cancers By Means of the Blood. Journal of Thoracic Oncology, 2006, 1, 199-200.	1.1	1
87	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 635-647.	1.1	12
88	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 740-743.	1.1	5
89	Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2006, 65, 331-346.	2.6	60
90	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology, 2006, 11, 687-692.	2.3	32

#	Article	IF	CITATIONS
91	Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology, 2006, 11, 693-698.	2.3	22
92	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 22-31.	1.1	2
93	Recent trends in the treatment of advanced lung cancer. Cancer Science, 2006, 97, 448-452.	3.9	16
94	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine, 2006, 12, 852-855.	30.7	313
95	The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Reviews Drug Discovery, 2006, 5, 741-754.	46.4	557
96	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. British Journal of Cancer, 2006, 94, 896-903.	6.4	132
97	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Laboratory Investigation, 2006, 86, 981-986.	3.7	80
98	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Modern Pathology, 2006, 19, 986-998.	5.5	17
99	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	4.4	50
100	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2006, 133, 93-102.	2.5	25
101	Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology, 2006, 11, 190-198.	2.2	194
102	Resistance to gefitinib. International Journal of Clinical Oncology, 2006, 11, 487-491.	2.2	31
104	Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 5-9.	2.3	4
105	Defining clinically relevant molecular subsets of lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 11-15.	2.3	17
106	The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 25-31.	2.3	7
107	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	16.8	427
108	EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans. Cancer Cell, 2006, 9, 421-423.	16.8	47
109	Targeting ADAMS and ERBBs in lung cancer. Cancer Cell, 2006, 10, 7-11.	16.8	36

#	Article	IF	CITATIONS
110	Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 9-16.	2.2	27
111	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics, 2006, 7, 289.	2.8	66
112	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 2006, 107, 1207-1218.	4.1	165
113	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 1866-1872.	4.1	3
114	FrequentEGFR mutations in noninvasive bronchioloalveolar carcinoma. International Journal of Cancer, 2006, 118, 2498-2504.	5.1	43
115	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews, 2006, 26, 569-594.	10.5	122
116	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.9	112
117	Is There a Role for the Irreversible Epidermal Growth Factor Receptor Inhibitor EKB-569 in the Treatment of Cancer? A Mutation-Driven Question. Journal of Clinical Oncology, 2006, 24, 2225-2226.	1.6	19
118	Using molecular information to guide brain tumor therapy. Nature Clinical Practice Neurology, 2006, 2, 232-233.	2.5	16
119	Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 2243-2261.	1.8	27
121	Pharmacogenomics: from bedside to clinical practice. Human Molecular Genetics, 2006, 15, R89-R93.	2.9	64
122	The population dynamics of cancer: a Darwinian perspective. International Journal of Epidemiology, 2006, 35, 1151-1159.	1.9	57
123	Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study. Clinical Cancer Research, 2006, 12, 6049-6055.	7.0	197
124	High-throughput mutational analysis of the human cancer genome. Pharmacogenomics, 2006, 7, 597-612.	1.3	15
125	Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19466-19471.	7.1	136
126	Different Responses to Gefitinib in Lung Adenocarcinoma Coexpressing Mutant- and Wild-Type Epidermal Growth Factor Receptor Genes. Japanese Journal of Clinical Oncology, 2006, 36, 523-526.	1.3	10
127	Social Medicine in the Twenty-First Century. PLoS Medicine, 2006, 3, e445.	8.4	39
128	Salvage Therapy for Advanced Non mall Cell Lung Cancer: Factors Influencing Treatment Selection. Oncologist, 2006, 11, 655-665.	3.7	47

#	Article	IF	CITATIONS
129	Update on <i>Epidermal Growth Factor Receptor</i> Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 7232-7241.	7.0	357
130	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells. Molecular Cancer Therapeutics, 2006, 5, 1154-1165.	4.1	90
131	A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening. Clinical Cancer Research, 2006, 12, 751-758.	7.0	212
132	Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels. Clinical Cancer Research, 2006, 12, 7117-7125.	7.0	118
133	Molecular On/Off Switch. Journal of Clinical Oncology, 2006, 24, 4940-4942.	1.6	11
134	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. Journal of Medical Genetics, 2006, 44, 166-172.	3.2	47
135	Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer: Table 1 Clinical Cancer Research, 2006, 12, 4441s-4445s.	7.0	82
136	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9244-9249.	7.1	104
137	Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680. Cancer Research, 2006, 66, 1007-1014.	0.9	282
138	Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272. Cancer Research, 2006, 66, 6487-6491.	0.9	141
139	Erlotinib: Optimizing Therapy with Predictors of Response?. Clinical Cancer Research, 2006, 12, 2961-2963.	7.0	20
140	Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors. Genes and Development, 2006, 20, 1496-1510.	5.9	426
141	Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 4416s-4420s.	7.0	127
142	A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer: Fig. 1 Clinical Cancer Research, 2006, 12, 3875-3877.	7.0	11
143	Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer. Cancer Research, 2006, 66, 7854-7858.	0.9	422
144	Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction. Journal of Clinical Oncology, 2006, 24, 3319-3321.	1.6	7
145	Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non‣mall Cell Lung Cancer. Oncologist, 2006, 11, 358-373.	3.7	60
146	Mouse Modeling in Oncologic Preclinical and Translational Research. Clinical Cancer Research, 2006, 12, 5305-5311.	7.0	60

#	Article	IF	CITATIONS
147	Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients: Fig. 1 Clinical Cancer Research, 2006, 12, 4403s-4408s.	7.0	74
148	Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clinical Cancer Research, 2006, 12, 5764-5769.	7.0	577
149	Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation. Nature Clinical Practice Oncology, 2006, 3, 50-57.	4.3	114
150	Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18033-18034.	7.1	31
151	BAY 43-9006 Inhibition of Oncogenic RET Mutants. Journal of the National Cancer Institute, 2006, 98, 326-334.	6.3	458
152	Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research, 2006, 12, 3652-3656.	7.0	62
153	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 3908-3914.	7.0	550
154	Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research, 2006, 12, 2538-2544.	7.0	245
155	Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival. Cancer Research, 2006, 66, 5542-5548.	0.9	199
156	Genomic Approaches to Lung Cancer: Fig. 1 Clinical Cancer Research, 2006, 12, 4384s-4391s.	7.0	49
157	Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 5659-5667.	7.0	199
158	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 6494-6501.	7.0	783
159	Lung cancer genetics and pharmacogenomics. Cytogenetic and Genome Research, 2006, 115, 298-302.	1.1	2
160	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	1.2	93
161	Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib. Journal of Clinical Oncology, 2006, 24, 4517-4520.	1.6	235
162	The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors: Fig. 1 Clinical Cancer Research, 2006, 12, 4372s-4376s.	7.0	77
163	Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 291-323.	6.1	15
164	Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations. Journal of Biological Chemistry, 2006, 281, 40183-40192.	3.4	85

#	Article	IF	CITATIONS
165	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7817-7822.	7.1	248
166	Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation. Cancer Research, 2006, 66, 9601-9608.	0.9	207
167	Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors. Cancer Research, 2006, 66, 6990-6997.	0.9	76
168	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor. Cancer Research, 2006, 66, 3162-3168.	0.9	222
169	Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3915-3921.	7.0	312
170	Secondâ€Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€Small Cell Lung Cancer. Oncologist, 2007, 12, 325-330.	3.7	61
171	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	3.1	12
172	Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization. Cancer Research, 2007, 67, 3594-3600.	0.9	65
173	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Molecular Cancer Therapeutics, 2007, 6, 2642-2651.	4.1	53
174	Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor. Clinical Cancer Research, 2007, 13, 1540-1551.	7.0	102
175	The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. Clinical Cancer Research, 2007, 13, 1911-1925.	7.0	64
176	Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib. Cancer Research, 2007, 67, 2325-2330.	0.9	173
177	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	7.1	1,557
178	Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2007, 71, 508-518.	2.3	24
179	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma. Molecular Cancer Therapeutics, 2007, 6, 1683-1691.	4.1	249
180	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nature Clinical Practice Oncology, 2007, 4, 603-607.	4.3	18
181	BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Medicine, 2007, 4, e315.	8.4	444
182	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788.	0.9	107

#	Article	IF	CITATIONS
183	Why Do Cancer Cells Become "Addicted―to Oncogenic Epidermal Growth Factor Receptor?. PLoS Medicine, 2007, 4, e321.	8.4	5
184	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	7.0	114
185	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220.	3.7	44
186	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849.	3.7	100
187	Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. Clinical Cancer Research, 2007, 13, 5150-5155.	7.0	279
188	Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Chest, 2007, 132, 597-602.	0.8	200
189	A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343.	1.1	274
190	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics, 2007, 8, 1211-1220.	1.3	2
191	Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model. Molecular Therapy, 2007, 15, 279-286.	8.2	87
192	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology and Therapy, 2007, 6, 661-667.	3.4	83
193	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology, 2007, 3, 277-283.	2.4	32
194	Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 805-817.	3.3	51
195	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. , 2007, , 959-992.		2
196	Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line. Cancer Research, 2007, 67, 7807-7814.	0.9	170
197	Relationship of <i>EGFR</i> Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines. Clinical Cancer Research, 2007, 13, 6788-6795.	7.0	59
198	Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells. Clinical Cancer Research, 2007, 13, 3413-3422.	7.0	190
199	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing <i>EGFR</i> Gene Mutation and Amplification. Cancer Research, 2007, 67, 2046-2053.	0.9	166
200	Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647. Clinical Cancer Research, 2007, 13, 3713-3723.	7.0	82

#	Article	IF	CITATIONS
201	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes and Development, 2007, 21, 3214-3231.	5.9	377
202	Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion. Cancer Research, 2007, 67, 11867-11875.	0.9	146
203	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib. Cancer Research, 2007, 67, 11924-11932.	0.9	674
204	HKI-272 in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4593s-4596s.	7.0	47
205	Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. Cancer Research, 2007, 67, 7319-7326.	0.9	136
206	Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney. Clinical Cancer Research, 2007, 13, 4360-4364.	7.0	35
207	Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies. Cancer Research, 2007, 67, 10417-10427.	0.9	63
208	Targeted Cancer Therapy: Promise and Reality. Advances in Cancer Research, 2007, 97, 295-319.	5.0	15
209	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells. Molecular Cancer Therapeutics, 2007, 6, 2515-2524.	4.1	117
210	Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors. PLoS ONE, 2007, 2, e810.	2.5	107
211	EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity. Cancer Research, 2007, 67, 4665-4670.	0.9	92
212	Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib <i>In vitro</i> and <i>In vivo</i> and Acquires Resistance through a Novel Point Mutation in the HER2/neu. Cancer Research, 2007, 67, 6825-6843.	0.9	42
213	Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer. Clinical Cancer Research, 2007, 13, 1892-1902.	7.0	130
214	Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4589s-4592s.	7.0	11
215	Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation, 2007, 117, 2562-2569.	8.2	357
216	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology, 2007, 3, 151.	7.2	128
217	Remarkable Effect of Gefitinib Retreatment in a Patient with Nonsmall Cell Lung Cancer Who Had a Complete Response to Initial Gefitinib. American Journal of the Medical Sciences, 2007, 333, 221-225.	1.1	31
218	P3-160: Histoculture drug response assay for gefitinib in non–small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S747-S748.	1.1	0

#	Article	IF	CITATIONS
219	EGFR Targeting of Solid Tumors. Cancer Control, 2007, 14, 295-304.	1.8	245
220	Pharmacology of Epidermal Growth Factor Inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	10
221	Signal Transduction Therapy: Challenges to Clinical Trial Design. Current Signal Transduction Therapy, 2007, 2, 21-30.	0.5	1
222	Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nuclear Medicine and Biology, 2007, 34, 55-70.	0.6	67
223	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	14.4	74
224	Rational bases for the development of EGFR inhibitors for cancer treatment. International Journal of Biochemistry and Cell Biology, 2007, 39, 1416-1431.	2.8	115
225	The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends in Molecular Medicine, 2007, 13, 527-534.	6.7	117
226	Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. American Journal of Pathology, 2007, 170, 366-376.	3.8	141
227	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer, 2007, 58, 30-35.	2.0	20
228	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	1.6	218
229	Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic <i>EGFR</i> Mutation Testing. Oncologist, 2007, 12, 90-98.	3.7	156
230	Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. PLoS Medicine, 2007, 4, e125.	8.4	130
231	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13092-13097.	7.1	247
232	Inhibiting kinases in malignant gliomas. Expert Opinion on Therapeutic Targets, 2007, 11, 473-496.	3.4	41
233	How could pharmacogenomics help improve patient survival?. Lung Cancer, 2007, 57, S35-S41.	2.0	10
235	The Role of EGFR Inhibition in Colorectal Cancer. , 2007, , 99-118.		1
236	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
237	Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 587-595.	1.6	593

#	Article	IF	CITATIONS
240	EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer, 2007, 56, 445-448.	2.0	33
241	Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer, 2007, 58, 149-155.	2.0	52
242	Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer, 2007, 58, 414-417.	2.0	37
243	Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Molecular Oncology, 2007, 1, 26-41.	4.6	206
244	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents. Molecular Cancer Research, 2007, 5, 203-220.	3.4	378
246	A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Molecular Cancer, 2007, 6, 30.	19.2	22
247	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. Molecular Cancer, 2007, 6, 56.	19.2	22
248	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-11±. Molecular Cancer, 2007, 6, 63.	19.2	55
249	Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1125-1138.	10.9	15
250	Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood, 2007, 110, 2102-2109.	1.4	11
251	Principles of Chemotherapy and Pharmacology. , 2007, , 33-53.		2
252	Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2579-2592.	1.8	11
253	Protein kinases as targets for cancer treatment. Pharmacogenomics, 2007, 8, 1005-1016.	1.3	68
254	Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas. PLoS Medicine, 2007, 4, e294.	8.4	287
255	Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4. PLoS ONE, 2007, 2, e426.	2.5	77
256	MTP23-01: Salvage therapy for NSCLC. Journal of Thoracic Oncology, 2007, 2, S289-S290.	1.1	0
257	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14.	1.1	6
258	Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. BioEssays, 2007, 29, 558-565.	2.5	83

#	Article	IF	CITATIONS
259	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Human Mutation, 2007, 28, 760-770.	2.5	51
260	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer, 2007, 120, 1239-1247.	5.1	120
261	Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer, 2007, 110, 980-988.	4.1	197
262	EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2007, 62, 53-61.	4.4	123
263	Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients. Clinical Oncology, 2007, 19, 499-506.	1.4	47
264	The effect of the [F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety—An EGFR putative irreversible inhibitor. Applied Radiation and Isotopes, 2007, 65, 1140-1151.	1.5	29
265	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene, 2007, 26, 5023-5027.	5.9	105
266	EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy. Oncogene, 2007, 26, 5693-5701.	5.9	76
267	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene, 2007, 26, 6968-6978.	5.9	131
268	Mixing cocktails. Nature, 2007, 449, 993-995.	27.8	59
268 269	Mixing cocktails. Nature, 2007, 449, 993-995. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238.	27.8 8.0	59 190
268 269 270	Mixing cocktails. Nature, 2007, 449, 993-995. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238. HER3 and mutant EGFR meet MET. Nature Medicine, 2007, 13, 675-677.	27.8 8.0 30.7	59 190 64
268 269 270 271	Mixing cocktails. Nature, 2007, 449, 993-995. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238. HER3 and mutant EGFR meet MET. Nature Medicine, 2007, 13, 675-677. Where lies the blame for resistanceâ€"tumor or host?. Nature Medicine, 2007, 13, 1144-1145.	27.8 8.0 30.7 30.7	 59 190 64 11
268 269 270 271 272	Mixing cocktails. Nature, 2007, 449, 993-995.Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238.HER3 and mutant EGFR meet MET. Nature Medicine, 2007, 13, 675-677.Where lies the blame for resistanceâ€"tumor or host?. Nature Medicine, 2007, 13, 1144-1145.Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.	27.8 8.0 30.7 30.7 28.4	 59 190 64 11 2,741
268 269 270 271 272	Mixing cocktails. Nature, 2007, 449, 993-995. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238. HER3 and mutant ECFR meet MET. Nature Medicine, 2007, 13, 675-677. Where lies the blame for resistance—tumor or host?. Nature Medicine, 2007, 13, 1144-1145. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863.	27.8 8.0 30.7 30.7 28.4 6.4	 59 190 64 11 2,741 90
268 269 270 271 272 273	Mixing cocktails. Nature, 2007, 449, 993-995.Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238.HER3 and mutant ECFR meet MET. Nature Medicine, 2007, 13, 675-677.Where lies the blame for resistanceâ€"tumor or host?. Nature Medicine, 2007, 13, 1144-1145.Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863.The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 2007, 75, 770-787.	27.8 8.0 30.7 30.7 28.4 6.4	 59 190 64 11 2,741 90 289
 268 269 270 271 272 273 274 275 	Mixing cocktails. Nature, 2007, 449, 993-995. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238. HER3 and mutant ECFR meet MET. Nature Medicine, 2007, 13, 675-677. Where lies the blame for resistanceâ€"tumor or host?. Nature Medicine, 2007, 13, 1144-1145. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181. Which biomarker predicts benefit from ECFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 2007, 75, 770-787. Reliability of the peptide nucleic acida€cocked nucleic acid polymerase chain reaction clampâ€based test for epidermal growth factor receptor mutations integrated into the clinical practice for nona€small cell lung cancers. Scancer Science, 2007, 98, 246-252.	 27.8 8.0 30.7 30.7 28.4 6.4 1.9 3.9 	 59 190 64 11 2,741 90 289 99

#	Article	IF	CITATIONS
277	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	3.9	554
278	Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 66-78.	1.1	14
279	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	1.3	72
280	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer, 2007, 7, 128.	2.6	36
281	Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer, 2007, 7, 51.	2.6	76
282	Crosstalk between Aurora-A and p53: Frequent Deletion or Downregulation of Aurora-A in Tumors from p53 Null Mice. Cancer Cell, 2007, 11, 161-173.	16.8	82
283	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. Cancer Cell, 2007, 11, 217-227.	16.8	933
284	The EGF Receptor Hokey-Cokey. Cancer Cell, 2007, 11, 209-211.	16.8	6
285	Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell, 2007, 12, 81-93.	16.8	212
286	Drugging the Bad "AKT-TOR―to Overcome TKI-Resistant Lung Cancer. Cancer Cell, 2007, 12, 6-8.	16.8	12
287	2007 Highlights from: the 24th Annual Meeting of the American Association for Cancer Research Los Angeles, CA; April 14–18, 2007. Clinical Lung Cancer, 2007, 8, 359-363.	2.6	0
288	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Internal and Emergency Medicine, 2007, 2, 3-12.	2.0	12
289	Mechanisms of resistance to EGFR inhibitors. Targeted Oncology, 2007, 2, 31-37.	3.6	10
290	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targeted Oncology, 2007, 2, 145-151.	3.6	3
291	Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1089-1099.	6.4	104
292	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186.	3.6	3
293	Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Targeted Oncology, 2008, 3, 235-243.	3.6	3
294	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. Onkopipeline, 2008, 1, 101-108.	0.0	Ο

		CITATION REPORT	
#	Article	IF	CITATIONS
295	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General Thoracic and Cardiovascular Surgery, 2008, 56, 97-103.	0.9	38
296	Reversed mutation rates of <i>KRAS</i> and <i>EGFR</i> genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208.	4.1	84
297	EGFR inhibition in the treatment of nonâ€small cell lung cancer. Drug Development Research, 2008 359-372.	, 69, <u>2.9</u>	51
298	EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. International Journal of Cancer, 2008, 123, 2480-2486.	5.1	78
299	Expression and mutational analysis of <i>MET</i> in human solid cancers. Genes Chromosomes and Cancer, 2008, 47, 1025-1037.	1 2.8	282
300	Novel human antibody therapeutics: The age of the Umabs. Biotechnology Journal, 2008, 3, 1157-1	171. 3.5	49
301	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology, 2008, 21, S	16-S22. 5.5	313
302	The cancer biomarker problem. Nature, 2008, 452, 548-552.	27.8	848
303	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
304	EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene, 2008, 27, 957-965.	5.9	32
305	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27, 4702-4711.	5.9	1,272
306	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene, 20 27, 3944-3956.	008, 5.9	497
307	Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. British Journal of Cancer, 2008, 98, 749-755.	6.4	93
308	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer, 2008, 98, 907-914.	6.4	200
309	Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung ca British Journal of Cancer, 2008, 99, 911-922.	ancer. 6.4	170
310	Peptide nucleic acid–locked nucleic acid polymerase chain reaction clampâ€based detection test gefitinibâ€refractory T790M epidermal growth factor receptor mutation. Cancer Science, 2008, 99, 595-600.	for 3.9	75
311	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Science, 2008, 99, 929-935.	3.9	239
312	Induction of lung adenocarcinoma in transgenic mice expressing activated <i>EGFR</i> driven by th SPâ€C promoter. Cancer Science, 2008, 99, 1747-1753.	ie 3.9	27

#	Article	IF	Citations
313	Targeted Anticancer Therapies: Mouse Models Help Uncover the Mechanisms of Tumor Escape. Cancer Cell, 2008, 13, 5-7.	16.8	12
314	Drug-Resistant Phosphatidylinositol 3-Kinase: Guidance for the Preemptive Strike. Cancer Cell, 2008, 14, 107-108.	16.8	11
315	Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis. Cancer Cell, 2008, 14, 485-493.	16.8	226
316	A Trigger Squeezed. Structure, 2008, 16, 332-334.	3.3	0
317	Cancer Pharmacogenetics. Methods in Molecular Biology, 2008, 448, 437-446.	0.9	4
318	Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone. Clinical Colorectal Cancer, 2008, 7, 184-190.	2.3	147
319	siRNA Targeting against <i>EGFR,</i> a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma. Pathobiology, 2008, 75, 2-8.	3.8	20
320	Biochemical Assay-Based Selectivity Profiling of Clinically Relevant Kinase Inhibitors on Mutant Forms of EGF Receptor. Journal of Receptor and Signal Transduction Research, 2008, 28, 295-306.	2.5	5
321	Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells. New England Journal of Medicine, 2008, 359, 366-377.	27.0	1,602
322	Oncogene Addiction. Cancer Research, 2008, 68, 3077-3080.	0.9	801
323	Lung Cancer. New England Journal of Medicine, 2008, 359, 1367-1380.	27.0	2,271
324	Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters, 2008, 265, 307-317.	7.2	112
325	Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resistance Updates, 2008, 11, 51-60.	14.4	29
326	The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. European Journal of Surgical Oncology, 2008, 34, 89-93.	1.0	9
327	Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics and Development, 2008, 18, 73-79.	3.3	269
328	Pharmacogenetics: improving drug and dose selection. Current Opinion in Pharmacology, 2008, 8, 639-646.	3.5	20
329	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer, 2008, 60, S3-S9.	2.0	76
330	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer, 2008, 60, S10-S18.	2.0	21

ARTICLE IF CITATIONS The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR 331 2.0 18 mutations. Lung Cancer, 2008, 60, S19-S22. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer, 2008, 60, S23-S30. First-Line Gefitinib in Patients With Advanced Nonâ€"Small-Cell Lung Cancer Harboring 333 1.6 812 Somatic <i>EGFR </i>Mutations. Journal of Clinical Oncology, 2008, 26, 2442-2449. Heme Oxygenase-1 Prevents Airway Mucus Hypersecretion Induced by Cigarette Smoke in Rodents and 334 Humans. American Journal of Pathology, 2008, 173, 981-992. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted 335 agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and 10.7 709 metastatic colorectal cancer. Lancet Oncology, The, 2008, 9, 962-972. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 2895-2899. 649 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine, 2008, 337 12.2 152 59, 429-442. Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. Journal 338 1.6 267 of Clinical Oncology, 2008, 26, 1742-1751. Genetic Predictors of MEK Dependence in Nonâ€"Small Cell Lung Cancer. Cancer Research, 2008, 68, 339 0.9 235 9375-9383. Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of 340 Sciences of the United States of America, 2008, 105, 692-697. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by <i>Myc</i> and mutant <i>Kras</i>. Proceedings of the National Academy of Sciences of the 341 121 7.1United States of America, 2008, 105, 5242-5247. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a 342 1.2 phase II study. Annals of Oncology, 2008, 19, 1903-1909. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. 343 0.9 474 Cancer Research, 2008, 68, 4853-4861. Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma. Clinical Cancer Research, 344 267 2008, 14, 7519-7525. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. 345 3.7 46 Oncologist, 2008, 13, 1166-1176. Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. Oncologist, 2008, 346 13,933-944. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients 347 with non-small cell lung cancer utilising high-resolution melting amplicon analysis. Journal of 2.0 86 Clinical Pathology, 2008, 61, 487-493. <i>Epidermal Growth Factor Receptor</i> Gene Amplification Is Acquired in Association with Tumor 348 134 Progression of <i>EGFR</i>-Mutated Lung Cancer. Cancer Research, 2008, 68, 2106-2111.

#	Article	IF	CITATIONS
349	EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation. Clinical Cancer Research, 2008, 14, 2465-2475.	7.0	105
350	Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clinical Cancer Research, 2008, 14, 6867-6876.	7.0	51
351	Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance. Cancer Research, 2008, 68, 5827-5838.	0.9	141
352	Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on <i>EGFR</i> -Mutant Cells. Cancer Prevention Research, 2008, 1, 201-207.	1.5	59
353	Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern. Oncologist, 2008, 13, 1276-1284.	3.7	70
354	Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway. Journal of Thoracic Oncology, 2008, 3, 170-173.	1.1	13
355	An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2008, 3, 1096-1103.	1.1	43
356	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, S146-S149.	1.1	66
357	Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib. Cancer Research, 2008, 68, 571-579.	0.9	65
358	Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 361-370.	4.1	63
359	Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts. Clinical Cancer Research, 2008, 14, 4584-4592.	7.0	217
360	Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Molecular Cancer Therapeutics, 2008, 7, 1461-1471.	4.1	27
361	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 607-615.	4.1	50
362	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research, 2008, 68, 9479-9487.	0.9	574
363	Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations. Journal of Immunology, 2008, 180, 4338-4345.	0.8	21
364	EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents, 2008, 18, 889-901.	5.0	23
365	Epidermal growth factor receptor-targeted therapy. British Journal of Radiology, 2008, 81, S36-S44.	2.2	27
366	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. Clinical Cancer Research, 2008, 14, 6478-6486.	7.0	77

#	Article	IF	CITATIONS
367	SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology, 2008, 26, 2745-2753.	1.6	249
368	Gefitinib Induction of <i>In vivo</i> Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3. Clinical Cancer Research, 2008, 14, 5209-5219.	7.0	25
369	Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics, 2008, 7, 1880-1889.	4.1	204
370	Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Molecular Cancer Therapeutics, 2008, 7, 679-687.	4.1	52
371	EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. European Respiratory Journal, 2008, 33, 436-440.	6.7	39
372	Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12480-12484.	7.1	41
373	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel. Cancer Research, 2008, 68, 589-596.	0.9	172
374	Effects of Erlotinib in <i>EGFR</i> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clinical Cancer Research, 2008, 14, 7060-7067.	7.0	156
375	Newer opportunities in systemic therapy of lung cancer. Annals of Oncology, 2008, 19, vii31-vii37.	1.2	5
376	The T790M "gatekeeper―mutation in <i>EGFR</i> mediates resistance to low concentrations of an irreversible EGFR inhibitor. Molecular Cancer Therapeutics, 2008, 7, 874-879.	4.1	192
377	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2070-2075.	7.1	1,702
378	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	7.0	139
379	Somatic pharmacogenomics in cancer. Pharmacogenomics Journal, 2008, 8, 305-314.	2.0	22
380	Case 23-2008. New England Journal of Medicine, 2008, 359, 405-414.	27.0	2
381	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology, 2008, 19, 1605-1612.	1.2	81
382	Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation. Molecular Pharmacology, 2008, 74, 807-822.	2.3	54
383	Tumor Dependence on the EGFR Signaling Pathway Expressed by the p-EGFR:p-AKT Ratio Predicts Erlotinib Sensitivity in Human Non-small Cell Lung Cancer (NSCLC) Cells Expressing Wild-Type EGFR Gene. Journal of Thoracic Oncology, 2008, 3, 643-647.	1.1	19
384	Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer. Journal of Thoracic Openatory 2008, 3, 250-257	1.1	76

#	Article	IF	CITATIONS
385	First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2008, 3, S143-S145.	1.1	22
386	A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells. Journal of Thoracic Oncology, 2008, 3, 1224-1235.	1.1	106
387	Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 527-529.	1.1	63
388	Heat Shock Protein 90 Inhibition in Lung Cancer. Journal of Thoracic Oncology, 2008, 3, S152-S159.	1.1	70
389	Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. Journal of Thoracic Oncology, 2008, 3, 664-673.	1.1	35
390	Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study. Journal of Thoracic Oncology, 2008, 3, 1439-1445.	1.1	73
391	Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities. Current Pharmaceutical Design, 2008, 14, 2983-2998.	1.9	77
392	Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, ECFR Mutations and Gene Expression Analysis. American Journal of Surgical Pathology, 2008, 32, 810-827.	3.7	352
393	Stem Cell Biology in the Lung and Lung Cancers: Using Pulmonary Context and Classic Approaches. Cold Spring Harbor Symposia on Quantitative Biology, 2008, 73, 479-490.	1.1	10
394	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology, 2008, 20, 162-175.	2.4	46
395	EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC. Scientific World Journal, The, 2008, 8, 909-919.	2.1	25
396	Molecularly Targeted Therapy for Lung Cancer: Recent Topics. Journal of Lung Cancer, 2008, 7, 1.	0.2	2
397	Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer. International Journal of Medical Sciences, 2008, 5, 209-217.	2.5	67
398	Targeted therapies in non-small cell lung cancer. Cancer Imaging, 2008, 8, 199-205.	2.8	6
399	Molecular Mechanism of EGFR-TKI Resistance. Japanese Journal of Lung Cancer, 2009, 49, 939-943.	0.1	3
400	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Journal of Clinical Investigation, 2009, 119, 3000-10.	8.2	308
401	Mutation Detection by Real-Time PCR: A Simple, Robust and Highly Selective Method. PLoS ONE, 2009, 4, e4584.	2.5	90
402	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. Clinical Medicine Therapeutics, 2009, 1, CMT.S2122.	0.1	0

#	Article	IF	CITATIONS
403	Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs, 2009, 18, 1829-1842.	4.1	25
404	Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19503-19508.	7.1	286
405	Genetic Abnormalities of the <i>EGFR</i> Pathway in African American Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5620-5626.	1.6	85
406	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. European Respiratory Journal, 2009, 34, 489-506.	6.7	44
407	Erlotinib: applications in therapy and current status of research. Expert Review of Clinical Pharmacology, 2009, 2, 15-36.	3.1	1
408	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Molecular Cancer Therapeutics, 2009, 8, 2526-2536.	4.1	65
409	Noninvasive Detection of <i>EGFR</i> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 2630-2636.	7.0	229
410	Human cancers converge at the HIF-2α oncogenic axis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21306-21311.	7.1	118
411	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. Oncologist, 2009, 14, 399-411.	3.7	86
412	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research, 2009, 69, 3021-3031.	0.9	236
413	Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy. Clinical Cancer Research, 2009, 15, 460-467.	7.0	152
414	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1 Clinical Cancer Research, 2009, 15, 1133-1139.	7.0	120
415	Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 137-144.	3.2	21
416	Genetic Heterogeneity of EGFR Mutation in Pleomorphic Carcinoma of the Lung: Response to Gefitinib and Clinical Outcome. Japanese Journal of Clinical Oncology, 2009, 39, 267-270.	1.3	62
417	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18351-18356.	7.1	251
418	Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Research, 2009, 37, 4603-4612.	14.5	70
419	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>In vivo</i> . Cancer Research, 2009, 69, 5091-5098.	0.9	65
420	Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <i>MET</i> Amplification. Clinical Cancer Research, 2009, 15, 907-913.	7.0	47

#	Article	IF	Citations
421	<i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clinical Cancer Research, 2009, 15, 4554-4560.	7.0	258
422	Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 5040-5048.	7.0	26
423	Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocrine-Related Cancer, 2009, 16, 233-241.	3.1	37
424	EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?. Journal of Thoracic Oncology, 2009, 4, 1-4.	1.1	167
425	Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics. Molecular and Cellular Proteomics, 2009, 8, 2796-2808.	3.8	194
426	The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients. Journal of Thoracic Oncology, 2009, 4, 281-283.	1.1	192
427	Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clinical Cancer Research, 2009, 15, 1585-1592.	7.0	94
428	Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle, 2009, 8, 18-22.	2.6	72
429	RNAi-Induced synthetic lethality in cancer therapy. Cancer Biology and Therapy, 2009, 8, 2312-2314.	3.4	1
430	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. Journal of Thoracic Oncology, 2009, 4, 161-166.	1.1	59
431	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomarkers in Medicine, 2009, 3, 139-151.	1.4	4
432	Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells. Molecular Pharmacology, 2009, 75, 196-207.	2.3	211
433	Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy. Molecular Cancer Research, 2009, 7, 923-932.	3.4	43
434	Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Molecular Cancer Therapeutics, 2009, 8, 1536-1546.	4.1	24
435	A Systems Perspective of Ras Signaling in Cancer. Clinical Cancer Research, 2009, 15, 1510-1513.	7.0	42
436	Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer. Journal of Nuclear Medicine, 2009, 50, 1199-1202.	5.0	49
437	Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies. PLoS Computational Biology, 2009, 5, e1000557.	3.2	104
438	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130.	3.7	57

#	Article	lF	CITATIONS
439	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations. Cancer Research, 2009, 69, 7644-7652.	0.9	138
440	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 7502-7509.	7.0	136
441	Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance. Clinical Cancer Research, 2009, 15, 3484-3494.	7.0	297
442	Live-Cell Imaging of Caspase Activation for High-Content Screening. Journal of Biomolecular Screening, 2009, 14, 956-969.	2.6	47
443	The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Molecular Cancer Research, 2009, 7, 1736-1743.	3.4	69
444	Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. Journal of Clinical Oncology, 2009, 27, 5650-5659.	1.6	115
445	Double <i>EGFR</i> mutants containing rare <i>EGFR</i> mutant types show reduced <i>in vitro</i> response to gefitinib compared with common activating missense mutations. Molecular Cancer Therapeutics, 2009, 8, 2142-2151.	4.1	67
446	Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR. Clinical Chemistry, 2009, 55, 748-756.	3.2	55
447	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	1.2	37
448	Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells. Journal of Biomolecular Screening, 2009, 14, 1176-1184.	2.6	33
449	CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clinical Cancer Research, 2009, 15, 4046-4057.	7.0	108
450	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2009, 15, 6630-6638.	7.0	255
451	Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Molecular Cancer Therapeutics, 2009, 8, 1846-1855.	4.1	42
452	A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer, 2009, 9, 145.	2.6	26
453	Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling in Non–Small-Cell Lung Cancer Therapy. Clinical Lung Cancer, 2009, 10, S17-S23.	2.6	13
454	ErbBs in lung cancer. Experimental Cell Research, 2009, 315, 557-571.	2.6	61
455	The ErbB kinase domain: Structural perspectives into kinase activation and inhibition. Experimental Cell Research, 2009, 315, 649-658.	2.6	65
456	The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Experimental and Molecular Pathology, 2009, 87, 1-11.	2.1	90

	CITATION R	CITATION REPORT	
#	Article	IF	CITATIONS
457	Molecular perspectives on the non-responder phenomenon. Drug Discovery Today, 2009, 14, 373-379.	6.4	2
458	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharmacology, 2009, 78, 460-468.	4.4	71
459	The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Current Opinion in Cell Biology, 2009, 21, 288-295.	5.4	54
460	Linking somatic genetic alterations in cancer to therapeutics. Current Opinion in Cell Biology, 2009, 21, 304-310.	5.4	61
461	<i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer, 2009, 124, 1778-1784.	5.1	131
462	Modified PEGâ€anilinoquinazoline derivatives as potential EGFR PET agents. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 41-52.	1.0	14
463	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1137-1148.	2.5	39
464	Lung cancer biology: a genetic and genomic perspective. Clinical and Translational Oncology, 2009, 11, 263-269.	2.4	14
465	Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275.	2.4	19
466	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology, 2009, 11, 428-436.	2.4	4
467	Histoculture drug response assay for gefitinib in non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery, 2009, 57, 138-143.	0.9	13
468	Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer. Pathology and Oncology Research, 2009, 15, 651-658.	1.9	99
469	Basic Principles and Technologies for Deciphering the Genetic Map of Cancer. World Journal of Surgery, 2009, 33, 615-629.	1.6	13
470	Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MPâ€412 (AVâ€412) in mouse xenograft models. Cancer Science, 2009, 100, 1526-1531.	3.9	12
471	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.	27.8	886
472	Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genetics, 2009, 41, 1127-1132.	21.4	316
473	Attacking cancer at its foundation. Nature Medicine, 2009, 15, 1153-1157.	30.7	19
474	Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 2009, 9, 28-39.	28.4	2,278

#	Article	IF	CITATIONS
475	Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nature Reviews Cancer, 2009, 9, 321-326.	28.4	160
476	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Reviews Drug Discovery, 2009, 8, 709-723.	46.4	285
477	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 2009, 28, S14-S23.	5.9	179
478	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 2009, 28, S24-S31.	5.9	799
479	Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene, 2009, 28, S38-S45.	5.9	28
480	Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 2009, 28, 3801-3813.	5.9	280
481	The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene, 2009, 28, 1821-1832.	5.9	52
482	Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. Current Problems in Cancer, 2009, 33, 73-111.	2.0	17
483	Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Analytical Biochemistry, 2009, 393, 205-214.	2.4	14
484	Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies. Journal of Medicinal Chemistry, 2009, 52, 1493-1509.	6.4	152
485	Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL. Cancer Research, 2009, 69, 6871-6878.	0.9	427
486	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	7.7	52
487	Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: Applications of this method for the diagnosis of non-small-cell lung cancer. Clinica Chimica Acta, 2009, 401, 68-72.	1.1	13
488	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63, 219-226.	2.0	203
489	Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer, 2009, 63, 315-321.	2.0	107
490	Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer, 2009, 64, 314-318.	2.0	93
491	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer, 2009, 65, 80-84.	2.0	118
492	Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. Clinical Lung Cancer, 2009, 10, 281-289.	2.6	394

#	Article	IF	CITATIONS
493	Recent advances of novel targeted therapy in non-small cell lung cancer. Journal of Hematology and Oncology, 2009, 2, 2.	17.0	69
494	EGFR-directed therapies to treat non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 1133-1145.	4.1	12
495	Practical Use of Computational Chemistry in Kinase Drug Discovery. , 0, , 403-431.		0
496	Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. Neoplasia, 2009, 11, 1084-1092.	5.3	92
497	Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448.	2.5	64
498	Clinical Biomarkers in Oncology. Molecular Diagnosis and Therapy, 2009, 13, 103-114.	3.8	44
499	Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncology, The, 2009, 10, 992-1000.	10.7	496
500	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer: Table 1. Journal of Clinical Pathology, 2009, 62, 414-421.	2.0	25
501	Biomarker-Driven Early Clinical Trials in Oncology. Cancer Journal (Sudbury, Mass), 2009, 15, 406-420.	2.0	149
502	New targeted therapies for non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 335-350.	0.2	4
503	Non–Small Cell Lung Carcinoma. , 2009, 14, 199-205.		2
504	Targeted therapeutics-oriented tumor classification: a paradigm shift. Personalized Medicine, 2009, 6, 465-468.	1.5	7
505	Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 139-141.	1.1	41
506	Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib. Journal of Thoracic Oncology, 2009, 4, 1415-1419.	1.1	151
507	BRAF ^{V600E} mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	2.4	0
508	Clinical Development of MET Targeted Therapy For Human Cancer. Current Cancer Therapy Reviews, 2009, 5, 261-270.	0.3	1
509	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	1.1	273
510	Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy. Journal of Thoracic Oncology, 2010, 5, 765-777.	1.1	15

#	Article	IF	CITATIONS
511	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes and Cancer, 2010, 1, 1200-1210.	1.9	88
512	Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations. Journal of Thoracic Oncology, 2010, 5, 1048-1053.	1.1	76
513	Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1524-1528.	1.1	81
514	Molecular Diagnostics Testing for Lung Adenocarcinoma. , 2010, 15, 103-110.		1
515	Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 740-801.	4.9	606
516	1. Basic and Clinical Practice of Molecular Target Therapy for Lung Cancers The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2035-2051.	0.0	0
517	Downregulated ABCG2 Enhances Sensitivity to Topoisomerase I Inhibitor in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1726-1733.	1.1	10
518	Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503. Journal of Thoracic Oncology, 2010, 5, 169-178.	1.1	70
519	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 2010, 115, 4206-4216.	1.4	61
520	Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis. Internal Medicine, 2010, 49, 103-107.	0.7	36
523	Targeted Inhibition of Kinases in Cancer Therapy. Mount Sinai Journal of Medicine, 2010, 77, 573-586.	1.9	34
524	A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper―Mutant of Bcr-Abl. Journal of Medicinal Chemistry, 2010, 53, 5439-5448.	6.4	73
525	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies. Science Translational Medicine, 2010, 2, 35ra41.	12.4	142
526	Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 1023-1028.	2.3	25
527	Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemotherapy and Pharmacology, 2010, 66, 381-388.	2.3	55
529	Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. Biosensors and Bioelectronics, 2010, 26, 424-431.	10.1	18
530	Evolution of resistance to anti-cancer therapy during general dosing schedules. Journal of Theoretical Biology, 2010, 263, 179-188.	1.7	78
531	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1937-1944.	2.5	29

	CHAHON	REFORT	
#	Article	IF	CITATIONS
532	Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology, 2010, 5, 5-17.	3.6	17
533	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology, 2010, 5, 245-255.	3.6	56
534	In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based Drugs. Applied Biochemistry and Biotechnology, 2010, 160, 1723-1733.	2.9	12
535	Biomarkers in bronchopulmonary cancer. Clinical and Translational Oncology, 2010, 12, 92-99.	2.4	3
536	Biology and Therapy of Neoplastic Meningitis. Current Oncology Reports, 2010, 12, 41-49.	4.0	31
537	Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports, 2010, 12, 335-348.	4.0	22
538	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews, 2010, 29, 37-48.	5.9	81
539	EGFR mutations and the terminal respiratory unit. Cancer and Metastasis Reviews, 2010, 29, 23-36.	5.9	109
540	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Journal of Neuro-Oncology, 2010, 99, 283-286.	2.9	198
541	Genetic Evolution of Epidermal Growth Factor Receptor in Adenocarcinoma With a Bronchioloalveolar Carcinoma Component. Clinical Lung Cancer, 2010, 11, 160-168.	2.6	6
542	Validating cancer drug targets through chemical genetics. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 251-257.	7.4	6
543	Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochemical Pharmacology, 2010, 80, 613-623.	4.4	83
544	Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genetics and Cytogenetics, 2010, 203, 7-15.	1.0	40
545	Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell, 2010, 17, 77-88.	16.8	956
546	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.	16.8	1,139
547	Oncogenic mutant forms of ECFR: Lessons in signal transduction and targets for cancer therapy. FEBS Letters, 2010, 584, 2699-2706.	2.8	141
548	Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Journal of Cellular and Molecular Medicine, 2010, 14, 504-527.	3.6	57
549	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine, 2010, 2, 146-158.	6.9	370

#	Article	IF	CITATIONS
550	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. Human Mutation, 2010, 31, 264-271.	2.5	48
551	Integrin beta1 overâ€expression associates with resistance to tyrosine kinase inhibitor gefitinib in nonâ€small cell lung cancer. Journal of Cellular Biochemistry, 2010, 111, 1565-1574.	2.6	67
552	Unnatural Polyketide Analogues Selectively Target the HER Signaling Pathway in Human Breast Cancer Cells. ChemBioChem, 2010, 11, 573-580.	2.6	10
553	<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Molecular Carcinogenesis, 2010, 49, 353-362.	2.7	116
554	Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase–quantitative polymerase chain reaction. Analytical Biochemistry, 2010, 398, 266-268.	2.4	23
555	Targeted covalent drugs of the kinase family. Current Opinion in Chemical Biology, 2010, 14, 475-480.	6.1	158
556	A Structure-Guided Approach to Creating Covalent FGFR Inhibitors. Chemistry and Biology, 2010, 17, 285-295.	6.0	127
557	Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorganic and Medicinal Chemistry, 2010, 18, 2317-2326.	3.0	25
558	Synthesis and biological activity of N4-phenylsubstituted-6-(2,4-dichloro) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorganic and Medicinal Chemistry, 2010, 18, 3575-3587.	32 Td (ph 3.0	enylmethyl)-7 30
559	Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology, 2010, 75, 94-109.	4.4	38
560	Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. Journal of Biomedical Science, 2010, 17, 37.	7.0	9
561	ECF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to ECFRâ€ŧargeting tyrosine kinase inhibitors. FEBS Journal, 2010, 277, 316-326.	4.7	89
562	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinibâ€resistant nonâ€small cell lung cancer cells with acquired <i>MET</i> amplification. Cancer Science, 2010, 101, 167-172.	3.9	58
563	Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature, 2010, 464, 436-440.	27.8	245
564	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas. Nature Biotechnology, 2010, 28, 71-78.	17.5	71
565	Turning the tide in lung cancer. Nature Biotechnology, 2010, 28, 999-1002.	17.5	6
566	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chemical Biology, 2010, 6, 291-299.	8.0	254
567	Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer, 2010, 10, 130-137.	28.4	618

ARTICLE IF CITATIONS # Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews 28.4 943 568 Cancer, 2010, 10, 760-774. The current status of targeted therapy for nonâ€small cell lung cancer. Internal Medicine Journal, 2010, 0.8 40, 611-618. 570 Gene Expression Analysis for Tumor Profiling., 2010, , 225-241. 0 Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database. 571 Molecules, 2010, 15, 4041-4054. Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling. PLoS ONE, 572 2.5 33 2010, 5, e13470. Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341. 0.1 574 EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514. 1.8 159 Immunohistochemical Detection of <i>EGFR</i> Mutation Using Mutation-Specific Antibodies in Lung 108 Cancer. Clinical Cancer Research, 2010, 16, 3349-3355. 576 Models of carcinogenesis: an overview. Carcinogenesis, 2010, 31, 1703-1709. 2.8 133 Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic 2.8 158 577 ERK signaling in lung cancer cells. Carcinogenesis, 2010, 31, 577-586. Predictive and prognostic molecular markers for cancer medicine. Therapeutic Advances in Medical 578 3.2 178 Oncology, 2010, 2, 125-148. Consequences of targeted treatments for second-line therapy. Annals of Oncology, 2010, 21, 579 1.2 vii234-vii240. Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape. Molecular Cancer 580 4.1 74 Therapeutics, 2010, 9, 1931-1944. Reply to A. Ocana et al. Journal of Clinical Oncology, 2010, 28, e422-e423. 1.6 Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations. 583 0.9 55 Cancer Research, 2010, 70, 3843-3850. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable 584 313 Oncogenic Mutant Kinases. Journal of Clinical Oncology, 2010, 28, 4616-4620. Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in 585 Patients With Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 1.6 402 3076-3083. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer 209 Research, 2010, 16, 5873-5882.

#	Article	IF	CITATIONS
587	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. Cancer Research, 2010, 70, 8036-8044.	0.9	25
588	Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 1938-1949.	7.0	112
589	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics, 2010, 9, 1647-1656.	4.1	66
590	Reciprocal and Complementary Role of <i>MET</i> Amplification and <i>EGFR </i> T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clinical Cancer Research, 2010, 16, 5489-5498.	7.0	200
591	TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation. Molecular Cancer Therapeutics, 2010, 9, 2785-2792.	4.1	75
592	Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 357-360.	1.6	735
593	<i>EGFR</i> Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. American Journal of Clinical Pathology, 2010, 133, 922-934.	0.7	110
594	Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 101-106.	1.3	73
595	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	21
596	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy, 2010, 10, 955-965.	2.4	14
597	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	27.6	593
598	Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets, 2010, 14, 1073-1090.	3.4	140
599	Quantifying EGFR Alterations in the Lung Cancer Genome with Nanofluidic Digital PCR Arrays. Clinical Chemistry, 2010, 56, 623-632.	3.2	92
600	Molecular Testing in Lung Carcinoma. American Journal of Clinical Pathology, 2010, 134, 7-9.	0.7	5
601	An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. Cancer Research, 2010, 70, 2485-2494.	0.9	250
602	Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency. Cancer Research, 2010, 70, 1625-1634.	0.9	146
603	A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP. Molecular Cancer Therapeutics, 2010, 9, 3322-3329.	4.1	33
604	The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition. Molecular Cancer Research, 2010, 8, 1142-1151.	3.4	24

#	Article	IF	Citations
605	Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer. Clinical Cancer Research, 2010, 16, 5371-5373.	7.0	4
606	Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. DMM Disease Models and Mechanisms, 2010, 3, 111-119.	2.4	77
607	Potential of ErbB4 antibodies for cancer therapy. Future Oncology, 2010, 6, 37-53.	2.4	31
608	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research, 2010, 16, 755-763.	7.0	82
609	Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research, 2010, 70, 8715-8725.	0.9	142
610	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	35
611	Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers, 2010, 2, 2153-2170.	3.7	34
612	Application of second-generation sequencing to cancer genomics. Briefings in Bioinformatics, 2010, 11, 524-534.	6.5	42
613	Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research. Journal of the National Cancer Institute, 2010, 102, 1310-1321.	6.3	182
614	HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation. Cancer Research, 2010, 70, 1989-1999.	0.9	63
615	A growing family: Adding mutated Erbb4 as a novel cancer target. Cell Cycle, 2010, 9, 1487-1503.	2.6	34
616	Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle, 2010, 9, 4098-4105.	2.6	19
617	Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib. Oncology, 2010, 79, 423-429.	1.9	43
618	Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biology and Therapy, 2010, 9, 572-582.	3.4	59
619	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	2.4	47
620	Core Needle Lung Biopsy Specimens: Adequacy for <i>EGFR</i> and <i>KRAS</i> Mutational Analysis. American Journal of Roentgenology, 2010, 194, 266-269.	2.2	110
621	Predictive Genomic Biomarkers. Current Topics in Microbiology and Immunology, 2010, 355, 173-188.	1.1	1
622	Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway. Current Cancer Drug Targets, 2010, 10, 824-833.	1.6	28

#	ARTICLE	IF	CITATIONS
623	Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. American Journal of Roentgenology, 2010, 195, W221-W228.	2.2	182
624	Favorable Response to Gefitinib Treatment of Lung Adenocarcinoma With Coexisting Germline and Somatic Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology, 2010, 28, e701-e703.	1.6	8
625	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 2363-2389.	1.8	19
626	Drug Efficacy Testing in Mice. Current Topics in Microbiology and Immunology, 2010, 355, 19-38.	1.1	14
628	Targeted Therapies in Lung Cancer. Surgical Pathology Clinics, 2010, 3, 71-82.	1.7	33
629	Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2010, 53, 2892-2901.	6.4	54
630	A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opinion on Pharmacotherapy, 2010, 11, 311-320.	1.8	35
631	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer, 2010, 67, 86-92.	2.0	23
632	Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68, 198-203.	2.0	105
633	Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer, 2010, 68, 269-272.	2.0	57
634	Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?. Lung Cancer, 2010, 68, 309-318.	2.0	109
635	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 2010, 69, 1-12.	2.0	59
636	Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors. Journal of Proteome Research, 2010, 9, 6033-6043.	3.7	27
637	Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer, 2010, 9, 75.	19.2	197
638	Response to Pemetrexed Chemotherapy in Lung Adenocarcinoma-Bronchioloalveolar Carcinoma Insensitive to Erlotinib. Clinical Lung Cancer, 2010, 11, 57-60.	2.6	8
639	Supersensitive Mutation: Two Case Reports of Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2010, 11, E5-E8.	2.6	3
640	Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons. Journal of Molecular Diagnostics, 2010, 12, 644-652.	2.8	14
641	<i>Drosophila</i> as a Novel Therapeutic Discovery Tool for Thyroid Cancer. Thyroid, 2010, 20, 689-695.	4.5	33
#	Article		CITATIONS
-----	--	------	-----------
642	Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)- <i>N</i> -hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2010, 53, 2000-2009.		229
643	Scaffold-based design of kinase inhibitors for cancer therapy. Current Opinion in Genetics and Development, 2010, 20, 79-86.		16
644	Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer Letters, 2010, 289, 228-236.	7.2	21
645	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. European Journal of Cancer, 2010, 46, 625-635.	2.8	25
646	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177.	2.8	71
647	Fusion protein based on Grb2-SH2 domain for cancer therapy. Biochemical and Biophysical Research Communications, 2010, 399, 262-267.	2.1	8
648	The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer the temperature of the the temperature of temperature of the temperature of temperature	5.0	131
649	Targeting erbB receptors. Seminars in Cell and Developmental Biology, 2010, 21, 961-966.	5.0	26
650	<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation. Science Signaling, 2010, 3, ra84.		314
651	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet, The, 2010, 375, 1437-1446.	13.7	972
652	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews, 2010, 36, S21-S29.	7.7	128
653	Clinical Applications of Kinase Inhibitors in Solid Tumors. , 2010, , 615-631.		1
654	Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis. American Journal of Pathology, 2010, 177, 415-423.	3.8	167
655	Molecularly targeted therapy: when to stop and when to continue?. Lancet Oncology, The, 2010, 11, 709-711.	10.7	5
658	EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine, 2010, 363, 1734-1739.	27.0	1,124
659	Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors. ACS Chemical Biology, 2010, 5, 121-138.	3.4	55
660	Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 3965-3972.	1.6	332
661	Using iTRAQ Combined with Tandem Affinity Purification to Enhance Low-Abundance Proteins Associated with Somatically Mutated EGFR Core Complexes in Lung Cancer. Journal of Proteome Research, 2011, 10, 182-190.	3.7	29

ARTICLE IF CITATIONS P2Y6 Receptors and ADAM17 Mediate Low-Dose Gamma-Ray-Induced Focus Formation (Activation) of EGF 1.5 23 662 Receptor. Radiation Research, 2011, 175, 193-200. Caspase 9b: a new target for therapy in non-small-cell lung cancer. Expert Review of Anticancer 2.4 Therapy, 2011, 11, 499-502. 664 Erlotinib. BioDrugs, 2011, 25, 139-146. 4.6 3 Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma. Molecular Diagnosis and Therapy, 2011, 15, 347-352. A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy 666 2.8 160 in Nonâ€"Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2011, 13, 74-84. Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1071-1079. 5.6 ¹⁸F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor 668 5.0 94 Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences of the United States 7.1 515 of America, 2011, 108, 7535-7540. Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine 670 4.6 55 Kinase Inhibitors in Non-Small Cell Lung Cancer. Molecular Pharmaceutics, 2011, 8, 2069-2079. A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest 671 2.1 Medicine, 2011, 32, 839-851. Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740. 672 2.1 194 Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine, 2011, 364, 947-955. Genomics and the Continuum of Cancer Care. New England Journal of Medicine, 2011, 364, 340-350. 674 27.0 282 Exploring Aigialomycin D and Its Analogues as Protein Kinase Inhibitors for Cancer Targets. ACS 2.8 Medicinal Chemistry Letters, 2011, 2, 662-666. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to 676 2.0 152 EGFR-TKIs. Lung Cancer, 2011, 73, 176-182. Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with 678 2.0 24 advanced non-small cell lung cancer. Lung Cancer, 2011, 74, 293-299. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal 679 patient selection. Lung Cancer, 2011, 74, 268-273.

#	Article		CITATIONS
680	High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer, 2011, 74, 384-391.		10
681	Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology, 2011, 8, 661-668.	27.6	145
682	Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. Drugs, 2011, 71, 79-88.	10.9	6
683	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	10.9	23
684	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. Cancers, 2011, 3, 1195-1231.	3.7	21
685	Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines. Advances in Medical Sciences, 2011, 56, 275-284.	2.1	82
686	Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome. Translational Oncology, 2011, 4, 59-70.	3.7	11
687	Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	12.4	457
688	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	2.4	47
689	RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. Journal of Clinical Bioinformatics, 2011, 1, 6.	1.2	16
690	The Evolving War on Cancer. Cell, 2011, 145, 19-24.	28.9	197
691	A Blueprint for Advancing Genetics-Based Cancer Therapy. Cell, 2011, 147, 26-31.	28.9	64
692	Use of molecular markers for predicting therapy response in cancer patients. Cancer Treatment Reviews, 2011, 37, 151-159.	7.7	94
693	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. European Journal of Cancer, 2011, 47, 1231-1243.	2.8	127
694	Next-generation sequencing applied to molecular diagnostics. Expert Review of Molecular Diagnostics, 2011, 11, 425-444.	3.1	33
695	Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncology, The, 2011, 12, 1169-1174.	10.7	165
696	Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436.	2.5	37
697	Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Research, 2011, 13, R35.	5.0	121

#	Article		CITATIONS
698	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 673-682.		44
699	Unraveling the Genetics of Cancer: Genome Sequencing and Beyond. Annual Review of Genomics and Human Genetics, 2011, 12, 407-430.	6.2	85
700	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	9.4	455
701	Parsing out the complexity of RAF inhibitor resistance. Pigment Cell and Melanoma Research, 2011, 24, 361-365.	3.3	6
702	Epidermal growth factor receptor mutationâ€guided treatment for lung cancers: Where are we now?. Thoracic Cancer, 2011, 2, 1-6.		5
703	Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nature Reviews Clinical Oncology, 2011, 8, 142-150.	27.6	277
704	Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR–TKI for adenocarcinoma of the lung. Lung Cancer, 2011, 71, 350-355.	2.0	39
705	Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer, 2011, 74, 35-40.	2.0	64
706	Personalized Therapy for Non-Small Cell Lung Cancer: Which Drug for Which Patient?. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 281-290.		11
707	Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates, 2011, 14, 260-279.	14.4	30
708	Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Frontiers in Bioscience - Landmark, 2011, 16, 116.	3.0	8
709	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2011, Volume 4, 1-9.	0.7	4
710	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. Journal of Lung Cancer, 2011, 10, 1.	0.2	2
711	EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience - Landmark, 2011, 16, 1811.	3.0	15
712	Trastuzumab-Resistance and Breast Cancer. , 2011, , .		3
713	Afatinib treatment in advanced non-small cell lung cancer. Lung Cancer: Targets and Therapy, 2011, 2, 47.	2.7	3
714	EGFR genomic alterations in cancer prognostic and predictive values. Frontiers in Bioscience - Elite, 2011, E3, 879-887.	1.8	29
715	Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics, 2011, 2011, 1-13.	2.0	21

#	Article	IF	CITATIONS
716	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
717	AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo. PLoS ONE, 2011, 6, e21487.		40
718	IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Research, 2011, 21, 44-56.	1.2	18
719	A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA. Journal of Thoracic Oncology, 2011, 6, 1639-1648.	1.1	71
720	Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1152-1161.	1.1	233
721	Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models. Journal of Thoracic Oncology, 2011, 6, 699-706.	1.1	52
722	Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. Journal of Thoracic Oncology, 2011, 6, 1128-1131.	1.1	83
724	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	4.9	227
725	Detection of low-level EGFR T790M mutation in lung cancer tissues. Apmis, 2011, 119, 403-411.	2.0	27
726	Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Reviews Drug Discovery, 2011, 10, 179-187.	46.4	131
727	The resurgence of covalent drugs. Nature Reviews Drug Discovery, 2011, 10, 307-317.	46.4	1,384
728	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471, 523-526.	27.8	374
729	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer, 2011, 11, 93.	2.6	16
730	Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagnostic Pathology, 2011, 6, 118.	2.0	33
731	Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer, 2011, 12, 360-368.	2.6	28
732	The challenge of developing robust drugs to overcome resistance. Drug Discovery Today, 2011, 16, 755-61.	6.4	21
733	Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment. European Journal of Pharmacology, 2011, 667, 56-65.	3.5	30
734	Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036. Cancer Cell, 2011, 19, 556-568.	16.8	172

#	Article		CITATIONS
735	CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant. Cancer Cell, 2011, 19, 679-690.		560
736	Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer. Cancer Cell, 2011, 20, 755-767.	16.8	40
737	A General Framework for Inhibitor Resistance in Protein Kinases. Chemistry and Biology, 2011, 18, 966-975.	6.0	49
738	Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 295-309.	5.2	13
739	New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?. Clinical Cancer Research, 2011, 17, 6-11.	7.0	24
740	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	2.5	24
741	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of Clinical Oncology, 2011, 29, 3085-3096.	1.6	890
742	Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges. Cancer Discovery, 2011, 1, 297-311.	9.4	47
743	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69.	22.4	644
744	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 2011, 3, 75ra26.	12.4	2,938
745	The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma. Surgery Today, 2011, 41, 818-823.	1.5	4
746	Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clinical Cancer Research, 2011, 17, 7808-7815.	7.0	301
7 4 7			
/4/	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408.	2.5	17
747	 Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Medical Oncology, 2011, 28, 572-577. 	2.5 2.5	17 14
747 750 751	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human nonâ€"small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408.BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Medical Oncology, 2011, 28, 572-577.Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical and Translational Oncology, 2011, 13, 812-818.	2.5 2.5 2.4	17 14 7
750 751 752	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human nonâ€"small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408.BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Medical Oncology, 2011, 28, 572-577.Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical and Translational Oncology, 2011, 13, 812-818.Targetable "Driverâ€-Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology, 2011, 2, 178-188.	2.5 2.5 2.4 0.7	17 14 7 22
747 750 751 752 753	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Medical Oncology, 2011, 28, 572-577. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical and Translational Oncology, 2011, 13, 812-818. Targetable "Driverâ€-Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology, 2011, 2, 178-188. Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	2.5 2.5 2.4 0.7 0.9	17 14 7 22 60

#	Article	IF	CITATIONS
755	Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: A novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer, 2011, 11, 172.	2.6	27
756	Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Systems Biology, 2011, 5, 29.	3.0	8
757	Genetically informed lung cancer medicine. Journal of Pathology, 2011, 223, 231-241.	4.5	59
758	Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology, 2011, 103, 574-586.	1.7	21
759	<i>EGFR</i> gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathology, 2011, 119, 80-91.	2.4	107
760	<i>EGFR</i> and <i>KRAS</i> mutations in lung carcinoma. Cancer Cytopathology, 2011, 119, 111-117.	2.4	213
761	Reaction of plasma hepatocyte growth factor levels in nonâ€small cell lung cancer patients treated with EGFRâ€TKIs. International Journal of Cancer, 2011, 129, 1410-1416.	5.1	22
762	Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors. Cancer Research, 2011, 71, 1081-1091.	0.9	194
763	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Annals of Pharmacotherapy, 2011, 45, 263-275.	1.9	0
764	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 2011, 12, 922-933.		25
765	Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy. Journal of the National Cancer Institute Monographs, 2011, 2011, 91-94.	2.1	2
766	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology and Therapy, 2011, 11, 777-792.	3.4	209
767	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations. Clinical Cancer Research, 2011, 17, 1160-1168.	7.0	292
768	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clinical Cancer Research, 2011, 17, 1169-1180.	7.0	539
769	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	2.0	91
770	EGFR Mutant Lung Cancer. Current Topics in Microbiology and Immunology, 2011, 355, 59-81.	1.1	8
771	p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation. Cancer Research, 2011, 71, 7071-7079.	0.9	105
772	Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy, 2011, 3, 107-116.	2.0	13

#	Article	IF	Citations
773	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 2011, 6, 2011-2017.	1.1	196
774	New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. Clinical Cancer Research, 2011, 17, 5530-5537.		326
775	Genotype-driven therapies for non-small cell lung cancer: focus on <i>EGFR</i> , <i>KRAS</i> and <i>ALK</i> gene abnormalities. Therapeutic Advances in Medical Oncology, 2011, 3, 113-125.	3.2	96
776	A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research, 2011, 71, 6051-6060.	0.9	560
777	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology, 2011, 13, 1364-1369.	1.2	309
778	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. Clinical Cancer Research, 2011, 17, 1616-1622.	7.0	556
779	Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology and Therapy, 2011, 12, 436-446.	3.4	15
780	BEAMing Sheds Light on Drug Resistance. Clinical Cancer Research, 2011, 17, 7508-7510.	7.0	5
781	JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling. Molecular Cancer Therapeutics, 2011, 10, 481-494.	4.1	147
782	Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma. Clinical Cancer Research, 2011, 17, 5901-5912.		38
783	MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	12
784	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <i>EGFR</i> Mutant Lung Cancer. Clinical Cancer Research, 2011, 17, 2260-2269.	7.0	101
785	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. Clinical Cancer Research, 2011, 17, 2521-2527.	7.0	116
786	Genetic and epigenetic changes in lung carcinoma and their clinical implications. Modern Pathology, 2011, 24, 932-943.	5.5	64
787	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the United States of America, 2011, 108, 17432-17437.	7.1	38
788	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i> -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clinical Cancer Research, 2011, 17, 6322-6328.	7.0	57
789	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	12.4	543
790	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	1.1	4,127

#	Article	IF	Citations
791	Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2011, 8, 15-22		6
792	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes and Cancer, 2011, 2, 335-343.	1.9	28
793	Does the Addition of Vascular Endothelial Growth Factor Inhibitors to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Overcome T790M Acquired Resistance?. Journal of Thoracic Oncology, 2011, 6, 404.	1.1	0
794	Resistance to HER2-directed antibodies and tyrosine kinase inhibitors. Cancer Biology and Therapy, 2011, 11, 793-800.	3.4	156
795	The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer Journal, 2011, 1, e15-e15.	6.2	22
796	Usp18 Regulates Epidermal Growth Factor (EGF) Receptor Expression and Cancer Cell Survival via MicroRNA-7. Journal of Biological Chemistry, 2011, 286, 25377-25386.	3.4	60
797	Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1603-1608.	7.1	89
798	Heterogeneous Distribution of <i>EGFR</i> Mutations Is Extremely Rare in Lung Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2972-2977.	1.6	218
799	Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells. Journal of Biological Chemistry, 2011, 286, 20558-20568.	3.4	154
800	Biotinylated Probe Isolation of Targeted Gene Region Improves Detection of T790M Epidermal Growth Factor Receptor Mutation via Peptide Nucleic Acid–Enriched Real-Time PCR. Clinical Chemistry, 2011, 57, 770-773.		13
801	Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer, 2011, 105, 1131-1136.	6.4	10
802	Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1720-1727.	4.1	128
803	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 2011, 105, 1554-1562.	6.4	62
804	MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents. Cancer Research, 2011, 71, 4494-4505.	0.9	72
807	How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers. Journal of Clinical Oncology, 2011, 29, 2273-2281.	1.6	107
808	Mechanisms of Resistance to ECFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	108
809	Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon―Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 3812-3821.	7.0	413
810	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Current Oncology, 2012, 19, 73-85.	2.2	9

#	Article		CITATIONS
811	Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers. Cancer Discovery, 2012, 2, 450-457.		53
812	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future. Current Oncology, 2012, 19, 24-32.	2.2	25
813	Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7340.	1.3	32
814	Personalized Targeted Therapy for Lung Cancer. International Journal of Molecular Sciences, 2012, 13, 11471-11496.	4.1	61
815	Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer. Archives of Pathology and Laboratory Medicine, 2012, 136, 1205-1209.	2.5	18
816	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <i>EGFR</i> -Mutant Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 2149-2157.	4.1	81
817	Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 1472-1482.	7.0	1,018
818	Personalized Therapy of Lung Cancer. Onkologie, 2012, 35, 14-19.	0.8	5
819	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7.	2.0	34
820	Intratumor Heterogeneity: Seeing the Wood for the Trees. Science Translational Medicine, 2012, 4, 127ps10.	12.4	443
821	SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2012, 11, 952-962.	4.1	21
822	Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. Genes and Cancer, 2012, 3, 467-480.	1.9	116
823	Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. Journal of Clinical Pathology, 2012, 65, 522-527.	2.0	26
824	Synthesis and Anti-proliferative Activity of Substituted-Anilinoquinazolines and Its Relation to EGFR Inhibition. Arzneimittelforschung, 2012, 62, 360-366.	0.4	1
825	Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer. Current Cancer Drug Targets, 2012, 12, 107-123.	1.6	47
826	Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3417-3420.	1.6	61
827	OutFOXing tumors. Science-Business EXchange, 2012, 5, 719-719.	0.0	0
828	SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-l inhibitors via induction of ISC15. Oncogene, 2012, 31, 4107-4116.	5.9	44

#	Article		CITATIONS
829	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i> Mutant Lung Cancer. Clinical Cancer Research, 2012, 18, 1663-1671.		81
830	3′-Deoxy-3′- ¹⁸ F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-x _L Inhibitors in Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 443-450.		28
831	Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Research, 2012, 22, 1197-1211.		461
832	The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2012, 11, 730-739.		70
833	Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice, 2012, 2012, 1-9.	1.6	59
834	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. Biochemistry Research International, 2012, 2012, 1-18.	3.3	42
835	Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC. Japanese Journal of Clinical Oncology, 2012, 42, 528-533.	1.3	28
836	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.9	48
837	Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA. Molecular Pharmacology, 2012, 81, 527-540.		53
838	Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance. Science Translational Medicine, 2012, 4, 120ps2.	12.4	91
839	Studying a Complex Tumor. Cancer Journal (Sudbury, Mass), 2012, 18, 107-114.	2.0	26
840	An Exploratory Analysis of Pharmaceutical Drugs as Basic Research Tools. Drug Information Journal, 2012, 46, 192-196.	0.5	1
841	Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 856-865.	1.1	39
842	Kinase Inhibitor Conjugates. Current Pharmaceutical Design, 2012, 18, 2891-2900.	1.9	7
843	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	1.1	585
844	Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology Reports, 2012, 27, 923-928.	2.6	11
845	Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 272-280.	1.1	37
846	Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 118-131.	1.6	29

#	Article		CITATIONS
847	Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy. Letters in Drug Design and Discovery, 2012, 9, 84-125.		4
848	Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study. Journal of Thoracic Oncology, 2012, 7, 348-354.	1.1	197
849	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. Journal of Thoracic Oncology, 2012, 7, 1078-1085.	1.1	34
850	Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomarkers, 2012, 10, 63-69.	1.7	41
851	A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 419-426.	1.1	48
852	Applying biomarker testing to clinical practice in lung cancer. Lung Cancer Management, 2012, 1, 145-154.	1.5	0
853	Targeted therapy for lung cancer. Anti-Cancer Drugs, 2012, 23, 1016-1021.	1.4	27
854	Treatment of nonsmall cell lung cancer. Current Opinion in Oncology, 2012, 24, 123-129.	2.4	25
855	Protein Expression Signatures for Inhibition of Epidermal Growth Factor Receptor-mediated Signaling. Molecular and Cellular Proteomics, 2012, 11, M111.015222.	3.8	18
856	Update on HER1–3 in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, S369-S371.	1.1	4
857	Ellagic Acid – Chemopreventive Role in Oral Cancer. Journal of Cancer Science & Therapy, 2012, 04, .	1.7	11
858	Network systems biology for targeted cancer therapies. Chinese Journal of Cancer, 2012, 31, 134-141.	4.9	24
859	Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. International Journal of Oncology, 2012, 41, 147-52.	3.3	15
860	MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity. Journal of Thoracic Oncology, 2012, 7, 1337-1344.	1.1	21
861	A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. Oncology Reports, 2012, 28, 1225-1230.	2.6	5
862	Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2012, 7, 40-48.	1.1	40
863	Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. Chest, 2012, 141, 420-428.	0.8	42
864	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 1513-1521.	1.1	46

		CITATION RE	PORT	
#	Article		IF	CITATIONS
865	EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Subsequently Retain Moderate Sensitivity to Erlotinib. Journal of Thoracic Oncology, 2012, 7,	Can 434-442.	1.1	17
866	Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer. Color Cancer, 2012, 1, 491-502.	rectal	0.8	1
867	Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung with Epidermal Growth Factor Receptor-Gene Mutation. Journal of Thoracic Oncology, 2012,	Cancer 7, 49-56.	1.1	38
868	A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping. Journ Thoracic Oncology, 2012, 7, 1755-1766.	nal of	1.1	28
869	Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mu in Plasma DNA. Journal of Thoracic Oncology, 2012, 7, 1369-1381.	tations	1.1	68
870	Rare and Novel Epidermal Growth Factor Receptor Mutations in Non—Small-Cell Lung Canc of Clinical Response to Gefitinib in Two Cases. Journal of Thoracic Oncology, 2012, 7, 941-94	er and Lack 2.	1.1	11
871	Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acqui Resistance to Erlotinib in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1	red 583-1593.	1.1	74
872	XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects wi Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib o Erlotinib. Journal of Thoracic Oncology, 2012, 7, 219-226.	th Non-small br	1.1	51
873	Mechanisms of intrinsic and acquired resistance to kinaseâ€ŧargeted therapies. Pigment Cell and Melanoma Research, 2012, 25, 819-831.		3.3	43
874	The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung C 2012, 76, 131-137.	lancer,	2.0	26
875	Winning the Arms Race by Improving Drug Discovery against Mutating Targets. ACS Chemica 2012, 7, 278-288.	ıl Biology,	3.4	14
876	Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 934-947.	2012, 2,	9.4	255
877	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biology, 2012, 33, 2061-2068.		1.8	30
878	Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer. International Journal of Molecular Sciences, 2012, 13, 3959-3978.		4.1	87
879	Local phosphocycling mediated by LOK/SLK restricts ezrin function to the apical aspect of ep cells. Journal of Cell Biology, 2012, 199, 969-984.	thelial	5.2	96
880	EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implication treatment. Lung Cancer, 2012, 77, 2-8.	s for future	2.0	62
881	The <i>EGFR</i> T790M Mutation in Acquired Resistance to an Irreversible Second-Generation Inhibitor. Molecular Cancer Therapeutics, 2012, 11, 784-791.	EGFR	4.1	159
882	Advances in Treatment of Lung Cancer With Targeted Therapy. Archives of Pathology and Lat Medicine, 2012, 136, 504-509.	ooratory	2.5	75

#	Article	IF	CITATIONS
883	It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Molecular Cancer Therapeutics, 2012, 11, 2549-2555.	4.1	48
884	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Investigational New Drugs, 2012, 30, 2148-2160.	2.6	15
885	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 2352-2363.	2.6	62
886	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology, The, 2012, 13, 539-548.	10.7	390
887	Correlation of immunohistochemical staining p63 and TTF-1 with ECFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 629-638.	2.8	32
888	Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2069-2077.	2.5	31
889	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da Associação Médica Brasileira, 2012, 58, 263-268.	0.7	6
890	Lung Cancer. Radiologic Clinics of North America, 2012, 50, 951-960.	1.8	3
891	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da Associação Médica Brasileira (English Edition), 2012, 58, 263-268.	0.1	0
892	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. American Journal of Pathology, 2012, 181, 1034-1043.	3.8	55
893	Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer. , 2012, , .		0
895	Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance. MedChemComm, 2012, 3, 780.	3.4	19
896	Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opinion on Therapeutic Targets, 2012, 16, 313-324.	3.4	22
897	Vandetanib for the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1211-1221.	4.1	6
898	Targeted therapy of non-small-cell lung carcinoma. Therapeutic Advances in Respiratory Disease, 2012, 6, 41-56.	2.6	4
899	A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases. Biochemistry, 2012, 51, 2390-2406.	2.5	23
900	Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Research, 2012, 22, 2101-2108.	5.5	74
901	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clinical and Experimental Metastasis, 2012, 29, 841-846.	3.3	14

#	Article	IF	CITATIONS
902	Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respiratory Medicine, 2012, 106, 173-183.	2.9	67
903	Impact of Genomics on Personalized Cancer Medicine. Clinical Cancer Research, 2012, 18, 612-618.	7.0	52
904	<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation. Cancer Discovery, 2012, 2, 922-933.	9.4	613
905	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	3.1	13
906	Two Sides of the Same Coin: <i>EGFR</i> Exon 19 Deletions and Insertions in Lung Cancer. Clinical Cancer Research, 2012, 18, 1490-1492.	7.0	14
907	Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion. American Journal of Pathology, 2012, 181, 111-120.	3.8	52
908	Dynamics of targeted cancer therapy. Trends in Molecular Medicine, 2012, 18, 311-316.	6.7	78
909	Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures. Bioorganic and Medicinal Chemistry, 2012, 20, 3756-3767.	3.0	11
910	Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters, 2012, 318, 124-134.	7.2	205
911	Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews, 2012, 38, 36-53.	7.7	57
912	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2012, 38, 173-184.	7.7	31
913	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews, 2012, 38, 416-430.	7.7	114
914	Converting Cancer Therapies into Cures: Lessons from Infectious Diseases. Cell, 2012, 148, 1089-1098.	28.9	159
915	A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924. Cell Reports, 2012, 1, 309-316.	6.4	75
916	Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action. Annual Review of Pharmacology and Toxicology, 2012, 52, 505-521.	9.4	288
917	Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Molecular Cancer Therapeutics, 2012, 11, 1071-1081.	4.1	6
918	Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer, 2012, 12, 95.	2.6	36
919	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Medi <u>cine, 2012, 10, 28.</u>	5.5	109

#	Article	IF	CITATIONS
920	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA Journal, 2012, 3, 6.	6.1	2
921	A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry. PLoS ONE, 2012, 7, e43842.	2.5	88
922	Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology, 2012, 9, 542-548.	27.6	115
923	Molecular Pathology of Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2012, 138, 332-346.	0.7	115
924	Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 15-31.	3.4	688
925	Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Medicinal Chemistry, 2012, 4, 87-105.	2.3	19
926	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics: Targets and Therapy, 2012, 6, 337.	3.2	46
927	Vemurafenib. Drugs, 2012, 72, 2207-2222.	10.9	89
928	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 771-781.	3.4	28
929	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics Journal, 2012, 12, 277-286.	2.0	32
930	Functional drug–gene interactions in lung cancer. Expert Review of Molecular Diagnostics, 2012, 12, 291-302.	3.1	7
931	Structural Optimization and Structure–Activity Relationships of <i>N</i> ² -(4-(4-Methylpiperazin-1-yl)phenyl)- <i>N</i> ⁸ -phenyl-9 <i>H</i> -purine-2,8-dia Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations, Journal of Medicinal Chemistry, 2012, 55, 10685-10699	mine 6.4	50
932	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. European Respiratory Journal, 2012, 39, 677-684.	6.7	45
933	Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors. Methods in Molecular Biology, 2012, 795, 1-34.	0.9	117
934	Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomedicine and Pharmacotherapy, 2012, 66, 384-389.	5.6	30
935	Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non–Small-Cell Lung Cancers. Clinical Lung Cancer, 2012, 13, 488-493.	2.6	12
936	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology, 2012, 83, 407-421.	4.4	151
937	Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer, 2012, 75, 30-37.	2.0	61

#	Article	IF	CITATIONS
938	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer, 2012, 76, 26-31.	2.0	42
939	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	2.0	206
940	Conversion from the "oncogene addiction―to "drug addiction―by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 2012, 76, 292-299.	2.0	56
941	Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer, 2012, 77, 134-139.	2.0	102
942	EGFR and myosin II inhibitors cooperate to suppress EGFRâ€T790Mâ€mutant NSCLC cells. Molecular Oncology, 2012, 6, 299-310.	4.6	12
943	Cytopathology of lung cancer: moving from morphology to molecular. Diagnostic Histopathology, 2012, 18, 313-320.	0.4	6
944	Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs, 2012, 72, 28-36.	10.9	61
945	Treating ALK-positive lung cancer—early successes and future challenges. Nature Reviews Clinical Oncology, 2012, 9, 268-277.	27.6	224
946	Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia, 2012, 26, 708-715.	7.2	92
947	Circulating Tumor Cells in Lung Cancer. Acta Cytologica, 2012, 56, 655-660.	1.3	65
948	Modeling Oncogenic Signaling Networks from Gene Expression Dynamics. , 2012, , 69-81.		0
949	Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC. Current Treatment Options in Oncology, 2012, 13, 516-526.	3.0	12
950	Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma. Cell Biochemistry and Biophysics, 2012, 64, 155-160.	1.8	52
951	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. Medical Oncology, 2012, 29, 3198-3201.	2.5	4
952	Molecular Diagnosis of Lung Cancer. Molecular Pathology Library, 2012, , 87-97.	0.1	0
953	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant. MedChemComm, 2012, 3, 1155.	3.4	16
954	Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 433-440.	1.6	471
955	BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death and Differentiation, 2012, 19, 2029-2039.	11.2	61

#	Article	IF	CITATIONS
956	Tyrosine Kinase Inhibitors in Lung Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 589-605.	2.2	32
957	Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain. PLoS ONE, 2012, 7, e29828.	2.5	117
958	A Novel Classification of Lung Cancer into Molecular Subtypes. PLoS ONE, 2012, 7, e31906.	2.5	99
959	Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells. PLoS ONE, 2012, 7, e41017.	2.5	62
960	Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells. PLoS ONE, 2012, 7, e42264.	2.5	41
961	An In Vivo C. elegans Model System for Screening EGFR-Inhibiting Anti-Cancer Drugs. PLoS ONE, 2012, 7, e42441.	2.5	24
962	Gefitinib Analogue V1801 Induces Apoptosis of T790M EGFR-Harboring Lung Cancer Cells by Up-Regulation of the BH-3 Only Protein Noxa. PLoS ONE, 2012, 7, e48748.	2.5	12
963	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2012, 2, 35-49.	2.5	6
964	Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. Frontiers in Oncology, 2012, 2, 12.	2.8	46
965	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. , 2012, , .		2
966	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
967	Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 685-689.	3.8	2
968	Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. Critical Reviews in Oncogenesis, 2012, 17, 1-16.	0.4	277
969	Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkologia, 2012, 5, 401-406.	1.4	5
970	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Inhibitors and Overcoming Strategies in Lung Cancer. Journal of Lung Cancer, 2012, 11, 59.	0.2	2
971	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	5.5	215
972	Acquired resistance to drugs targeting receptor tyrosine kinases. Biochemical Pharmacology, 2012, 83, 1041-1048.	4.4	104
973	Discovery of HDAC-Inhibiting Multi-Target Inhibitors. RSC Drug Discovery Series, 2012, , 221-242.	0.3	1

#	Article	IF	CITATIONS
974	Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 2012, 489, 155-159.	27.8	320
975	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 2012, 44, 852-860.	21.4	1,049
976	The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer, 2012, 12, 553-563.	28.4	766
977	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
978	Antitumor activity of HM781â€36B, a highly effective panâ€HER inhibitor in erlotinibâ€resistant NSCLC and other EGFRâ€dependent cancer models. International Journal of Cancer, 2012, 130, 2445-2454.	5.1	67
979	Epidermal growth factor receptor and <i>Kâ€Ras</i> mutations and resistance of lung cancer to insulinâ€like growth factor 1 receptor tyrosine kinase inhibitors. Cancer, 2012, 118, 3993-4003.	4.1	39
980	Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes and Development, 2012, 26, 641-650.	5.9	214
981	Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012, 30, 433-446.	1.3	58
982	Pharmacogenetics of <i>EGFR</i> in lung cancer: perspectives and clinical applications. Pharmacogenomics, 2012, 13, 789-802.	1.3	38
983	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 2012, 485, 260-263.	27.8	641
984	Driver mutations as predictive biomarkers in lung cancer. Current Respiratory Care Reports, 2012, 1, 21-29.	0.6	0
985	NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma. Cancer Cell, 2012, 21, 348-361.	16.8	207
986	Treatment-Emergent Mutations in NAEÎ ² Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Cell, 2012, 21, 388-401.	16.8	98
987	The role of pseudokinases in cancer. Cellular Signalling, 2012, 24, 1173-1184.	3.6	32
988	Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clinical Lung Cancer, 2012, 13, 107-114.	2.6	122
989	Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2012, 13, 267-279.	2.6	21
990	The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases. Clinical Lung Cancer, 2012, 13, 288-296.	2.6	45
991	Discovery of novel selective inhibitors for EGFR-T790M/L858R. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1365-1370.	2.2	24

# 992	ARTICLE Ligandâ€ŧriggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Science, 2012, 103, 1189-1194.	IF 3.9	CITATIONS
993	Molecular biology of chronic myeloid leukemia. Cancer Science, 2012, 103, 1601-1610.	3.9	46
994	Biomarkers and transcriptome profiling of lung cancer. Respirology, 2012, 17, 620-626.	2.3	20
995	The rise and fall of gatekeeper mutations? The <i>BCRâ€ABL1</i> T315I paradigm. Cancer, 2012, 118, 293-299.	4.1	73
996	Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 289-299.	2.3	50
997	Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Molecular Biology Reports, 2012, 39, 4971-4979.	2.3	36
999	Volumetric tumor growth in advanced nonâ€small cell lung cancer patients with <i>EGFR</i> mutations during EGFRâ€ŧyrosine kinase inhibitor therapy. Cancer, 2013, 119, 3761-3768.	4.1	40
1000	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	11.4	408
1001	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 991-1003.	2.4	8
1002	In silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. Journal of Molecular Graphics and Modelling, 2013, 44, 220-231.	2.4	26
1003	Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 2013, 10, 472-484.	27.6	1,482
1004	Hsp90, an unlikely ally in the war on cancer. FEBS Journal, 2013, 280, 1381-1396.	4.7	171
1005	Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer. BMC Cancer, 2013, 13, 210.	2.6	39
1006	Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer. Cancer Cell International, 2013, 13, 38.	4.1	22
1007	Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell International, 2013, 13, 15.	4.1	29
1008	Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Molecular Cancer, 2013, 12, 76.	19.2	36
1009	Cisplatin influences acquisition of resistance to molecularâ€ŧargeted agents through epithelial–mesenchymal transitionâ€like changes. Cancer Science, 2013, 104, 904-911.	3.9	48
1010	Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer. Molecular Biotechnology, 2013, 54, 913-919.	2.4	33

_
RТ

#	Article	IF	CITATIONS
1011	Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer. Pathology and Oncology Research, 2013, 19, 833-838.	1.9	27
1012	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Experimental Cell Research, 2013, 319, 417-423.	2.6	25
1013	Melanoma genotypes and phenotypes get personal. Laboratory Investigation, 2013, 93, 858-867.	3.7	23
1014	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Molecular Oncology, 2013, 7, 112-120.	4.6	70
1015	Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nature Communications, 2013, 4, 1701.	12.8	42
1016	Genetics and biomarkers in personalisation of lung cancer treatment. Lancet, The, 2013, 382, 720-731.	13.7	266
1017	Phosphoproteomic analysis of anaplastic lymphoma kinase (<scp>ALK</scp>) downstream signaling pathways identifies signal transducer and activator of transcriptionÂ3 as a functional target of activated <scp>ALK</scp> in neuroblastoma cells. FEBS Journal, 2013, 280, 5269-5282.	4.7	35
1018	The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers. Annals of Thoracic Surgery, 2013, 96, 962-968.	1.3	90
1019	Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. MedChemComm, 2013, 4, 1202.	3.4	16
1020	Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months. Respiratory Medicine Case Reports, 2013, 10, 10-12.	0.4	1
1021	A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer, 2013, 82, 299-304.	2.0	28
1022	Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene, 2013, 32, 27-38.	5.9	114
1023	Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M. Cancer Discovery, 2013, 3, 168-181.	9.4	87
1024	The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19, 1389-1400.	30.7	883
1025	Role of TRPM2 and TRPV1 cation channels in cellular responses to radiation-induced DNA damage. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3382-3390.	2.4	32
1026	Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition. Structure, 2013, 21, 209-219.	3.3	152
1027	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218.	2.4	13
1028	A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. European Journal of Cancer, 2013, 49, 2345-2355.	2.8	12

#	Article	IF	CITATIONS
1029	Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1449-1459.	2.3	51
1030	Clinical Analysis and Interpretation of Cancer Genome Data. Journal of Clinical Oncology, 2013, 31, 1825-1833.	1.6	123
1031	What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway. Cancer Discovery, 2013, 3, 1345-1354.	9.4	131
1032	Nanomedicine therapeutic approaches to overcome cancer drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1866-1879.	13.7	598
1033	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers. Clinical Cancer Research, 2013, 19, 2240-2247.	7.0	2,097
1034	Next-generation sequencing for lung cancer. Future Oncology, 2013, 9, 1323-1336.	2.4	38
1035	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	2.0	29
1036	Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Clinica Chimica Acta, 2013, 425, 119-124.	1.1	20
1038	Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. Multidisciplinary Respiratory Medicine, 2013, 8, 47.	1.5	14
1039	A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F]fluorothymidine-positron emission tomography. Investigational New Drugs, 2013, 31, 506-515.	2.6	8
1040	Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer, 2013, 13, 606.	2.6	66
1041	Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33, 845-851.	1.0	4
1042	Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2013, 72, 1299-1304.	2.3	12
1043	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene, 2013, 32, 4427-4435.	5.9	23
1044	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis, 2013, 5, 369-391.	1.5	52
1045	Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 2013, 13, 714-726.	28.4	3,667
1046	The novel phosphoinositide 3â€kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of <i>epidermal growth factor receptor</i> mutant lung cancer cells triggered by hepatocyte growth factor. International Journal of Cancer, 2013, 133, 505-513.	5.1	28
1047	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease. Journal of Clinical Oncology, 2013, 31, 1070-1080.	1.6	425

#	Article	IF	CITATIONS
1048	Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. Cancer Research, 2013, 73, 6770-6779.	0.9	87
1049	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3595-604.	7.1	116
1050	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	1.6	2,854
1051	The role of afatinib in the management of non-small cell lung carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1529-1539.	3.3	4
1052	Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 145-164.	1.6	7
1053	<scp>HCRP</scp> 1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. Oral Diseases, 2013, 19, 206-211.	3.0	19
1054	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer, 2013, 79, 8-13.	2.0	102
1055	Survival of lung adenocarcinoma patients with malignant pleural effusion. European Respiratory Journal, 2013, 41, 1409-1418.	6.7	83
1056	EGFR mutation status in brain metastases of non-small cell lung carcinoma. Journal of Neuro-Oncology, 2013, 111, 1-10.	2.9	62
1057	<i>ALK</i> in Lung Cancer: Past, Present, and Future. Journal of Clinical Oncology, 2013, 31, 1105-1111.	1.6	387
1058	Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. Neoplasia, 2013, 15, 61-IN18.	5.3	13
1059	Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples. Translational Oncology, 2013, 6, 504-510.	3.7	9
1060	The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non–Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clinical Lung Cancer, 2013, 14, 311-321.	2.6	11
1061	Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study. Cancer Treatment Communications, 2013, 1, 1-5.	0.4	1
1062	α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Letters, 2013, 335, 472-478.	7.2	29
1063	Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer, 2013, 80, 235-241.	2.0	96
1064	Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of the Chinese Medical Association, 2013, 76, 249-257.	1.4	42
1065	Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 82, 294-298.	2.0	101

#	Article	IF	CITATIONS
1066	Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Journal of Clinical Oncology, 2013, 31, 3987-3996.	1.6	299
1067	Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. Journal of Clinical Pathology, 2013, 66, 870-874.	2.0	36
1068	Comparison Study of the Performance of the QIAGEN EGFR RGQ and EGFR Pyro Assays for Mutation Analysis in Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 7-19.	0.7	12
1069	Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. Oncologist, 2013, 18, 717-725.	3.7	72
1070	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer, 2013, 81, 328-336.	2.0	49
1071	Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochemical and Biophysical Research Communications, 2013, 439, 586-590.	2.1	33
1072	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 79, 283-288.	2.0	68
1073	Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Human Pathology, 2013, 44, 1286-1292.	2.0	19
1074	Concurrent Molecular Alterations in Tumors With Germ Line Epidermal Growth Factor Receptor T790M Mutations. Clinical Lung Cancer, 2013, 14, 452-456.	2.6	20
1075	A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2013, 79, 270-275.	2.0	17
1076	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Seminars in Diagnostic Pathology, 2013, 30, 298-312.	1.5	13
1077	EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study. Lung Cancer, 2013, 82, 38-43.	2.0	32
1078	Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 264-270.	2.5	26
1079	Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 247-253.	1.8	37
1080	EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomarker Research, 2013, 1, 2.	6.8	33
1081	Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemotherapy and Pharmacology, 2013, 71, 829-842.	2.3	367
1082	Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. Pharmacological Research, 2013, 68, 68-94.	7.1	238
1083	Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1325-1334.	2.3	24

#	Article	IF	CITATIONS
1084	Exploring a New Frontier in Cancer Treatment: Targeting the Ubiquitin and Ubiquitin-like Activating Enzymes. Journal of Medicinal Chemistry, 2013, 56, 2165-2177.	6.4	27
1085	The Human Kinome and Kinase Inhibition. Current Protocols in Pharmacology, 2013, 60, Unit2.9.	4.0	63
1086	Surgery for NSCLC in the era of personalized medicine. Nature Reviews Clinical Oncology, 2013, 10, 235-244.	27.6	85
1087	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	7.7	68
1088	Resistance to BRAF-targeted therapy in melanoma. European Journal of Cancer, 2013, 49, 1297-1304.	2.8	311
1089	PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis. Science Signaling, 2013, 6, ra20.	3.6	107
1090	Existing and Emerging Technologies for Tumor Genomic Profiling. Journal of Clinical Oncology, 2013, 31, 1815-1824.	1.6	129
1091	Cancer stem cells in lung cancer: Evidence and controversies. Respirology, 2013, 18, 757-764.	2.3	120
1092	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013, 497, 108-112.	27.8	1,443
1093	Genomic Dysregulation in gastric tumors. Journal of Surgical Oncology, 2013, 107, 237-242.	1.7	24
1094	Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology, 2013, 13, 394-401.	3.5	70
1095	Identification of driver mutations in lung cancer: first step in personalized cancer. Targeted Oncology, 2013, 8, 3-14.	3.6	26
1096	Evaluating the Predictivity of Virtual Screening for A bl Kinase Inhibitors to Hinder Drug Resistance. Chemical Biology and Drug Design, 2013, 82, 506-519.	3.2	6
1097	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 277-288.	4.4	80
1098	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. Cancer Treatment Reviews, 2013, 39, 489-497.	7.7	26
1099	Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 115-123.	1.0	24
1100	Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer, 2013, 79, 276-282.	2.0	38
1101	The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. Clinical Investigation 2013 3 369-383	0.0	3

#	Article	IF	CITATIONS
1102	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2013, 56, 4738-4748.	6.4	67
1103	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmacogenomics and Personalized Medicine, 2013, 6, 25.	0.7	30
1104	EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance. Current Oncology Reports, 2013, 15, 396-404.	4.0	25
1105	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	2.8	397
1106	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters, 2013, 328, 144-151.	7.2	135
1107	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 2013, 79, 33-39.	2.0	156
1108	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	2.5	415
1109	Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment. Annals of Surgical Oncology, 2013, 20, 545-552.	1.5	16
1110	Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells. ACS Medicinal Chemistry Letters, 2013, 4, 921-926.	2.8	34
1111	Prediction of anti-EGFR drug resistance base on binding free energy and hydrogen bond analysis. , 2013, , .		5
1112	Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.	1.6	101
1113	Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment. Journal of Clinical Oncology, 2013, 31, 1858-1865.	1.6	116
1114	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1691-1700.	2.5	29
1115	Targeting tyrosine kinases in cancer. Cancer Cytopathology, 2013, 121, 61-71.	2.4	12
1116	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene, 2013, 32, 3846-3856.	5.9	104
1117	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8. 823-859.	1.1	792
1118	A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. Oncology Reports, 2013, 30, 863-869.	2.6	39
1119	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer, Current Pharmaceutical Design, 2013, 19, 818-832.	1.9	24

		CITATION REPORT		
# 1120	ARTICLE The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGI Non-Small-Cell Lung Cancer Cells to Erlotinib. Journal of Thoracic Oncology, 2013, 8, 693	-R 3-702.	IF 1.1	Citations
1121	Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in t cancer cell line harboring T790M mutation. International Journal of Oncology, 2013, 42,	ne H1975 lung 2094-2102.	3.3	27
1122	Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes and Cancer, 2013, 4, 82-90.		1.9	69
1123	Advances in personalized therapy for lung cancer. Expert Opinion on Medical Diagnostic 475-485.	s, 2013, 7,	1.6	9
1124	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Comparison With RECIST 1.0. American Journal of Roentgenology, 2013, 201, W64-W7	Inhibitors: 1.	2.2	39
1125	Fer Protein-Tyrosine Kinase Promotes Lung Adenocarcinoma Cell Invasion and Tumor Me Molecular Cancer Research, 2013, 11, 952-963.	tastasis.	3.4	44
1126	Beyond genetics in personalized cancer treatment: assessing dynamics and heterogenei responses. Personalized Medicine, 2013, 10, 221-225.	ty of tumor	1.5	5
1127	Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kin Proceedings of the National Academy of Sciences of the United States of America, 2013	nase. , 110, 10616-10621.	7.1	143
1128	EGFR lung cancer mutants get specialized. Proceedings of the National Academy of Scie United States of America, 2013, 110, 15169-15170.	nces of the	7.1	12
1129	EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Non-Small Cell Lung Cancer and Their Relationships with Clinical Features. International Molecular Sciences, 2013, 14, 24549-24559.	Patients with Iournal of	4.1	40
1130	Lung Cancer in the Era of Targeted Therapy: A Cytologist's Perspective. Archives of Patho Laboratory Medicine, 2013, 137, 1816-1821.	ology and	2.5	10
1131	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular charac Molecular and Clinical Oncology, 2013, 1, 575-581.	terisation.	1.0	42
1132	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistar Non–Small Cell Lung Cancer. Cancer Discovery, 2013, 3, 430-443.	nce in	9.4	203
1133	Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kir with [¹²⁴ 1]-Morpholino-IPQA. BioMed Research International, 2013, 2013,	nase Using PET 1-10.	1.9	9
1134	Impact of the College of American Pathologists, the International Association for the Stu Cancer, and the Association for Molecular Pathology Clinical Practice Guidelines for Egfr Testing in Lung Cancer in Canada. Current Oncology, 2013, 20, 220-226.	idy of Lung and Alk	2.2	12
1135	Combination of Pyrosequencing [®] and Sanger sequencing reveals alleged in exon 18 of <i>EGFR</i> . Personalized Medicine, 2013, 10, 201-209.	novel mutation	1.5	4
1136	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resist Gefitinib in NSCLC. Molecular Cancer Research, 2013, 11, 759-767.	ance to	3.4	179
1137	PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 636-642.		1.5	13

#	Article	IF	CITATIONS
1138	Membrane Phospholipids, EML4-ALK, and Hsp90 as Novel Targets in Lung Cancer Treatment. Cancer Journal (Sudbury, Mass), 2013, 19, 238-246.	2.0	11
1139	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 263-271.	2.0	4
1140	Antitumor Impact of <i>p14ARF</i> on Gefitinib-Resistant Non–Small Cell Lung Cancers. Molecular Cancer Therapeutics, 2013, 12, 1616-1628.	4.1	13
1141	Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. Cancer Discovery, 2013, 3, 1404-1415.	9.4	564
1142	Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling. Cancer Research, 2013, 73, 6243-6253.	0.9	125
1143	Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2013, 12, 2200-2212.	4.1	137
1144	USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research, 2013, 19, 3894-3904.	7.0	112
1145	Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and Therapy, 2013, 6, 135.	2.0	66
1146	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells. Cancer Research, 2013, 73, 3051-3061.	0.9	241
1147	Disease diversity and FLT3 mutations. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20860-20861.	7.1	5
1148	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research, 2013, 23, 1434-1445.	5.5	48
1149	Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. Clinical Cancer Research, 2013, 19, 6967-6975.	7.0	57
1150	Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology and Therapy, 2013, 14, 481-491.	3.4	43
1151	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	3.3	74
1152	Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer. Science Signaling, 2013, 6, re6.	3.6	208
1153	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptorâ€mutated lung cancer model. Cancer Science, 2013, 104, 1440-1446.	3.9	34
1154	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. Clinical Pharmacology and Therapeutics, 2013, 95, 24-31.	4.7	75
1155	Detection of epidermal growth factor receptor T790M mutation in plasma <scp>DNA</scp> from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Science, 2013, 104, 1198-1204.	3.9	75

#	Article	IF	CITATIONS
1156	Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptorâ€ŧyrosine kinase inhibitor. Cancer, 2013, 119, 4325-4332.	4.1	169
1157	Enhanced antitumor activity of erlotinib in combination with the <scp>H</scp> sp90 inhibitor <scp>CH</scp> 5164840 against nonâ€smallâ€cell lung cancer. Cancer Science, 2013, 104, 1346-1352.	3.9	33
1158	Restriction endonucleaseâ€mediated realâ€time digestionâ€PCR for somatic mutation detection. International Journal of Cancer, 2013, 132, 2858-2866.	5.1	4
1159	Heregulin induces resistance to lapatinibâ€mediated growth inhibition of <scp>HER</scp> 2â€amplified cancer cells. Cancer Science, 2013, 104, 1618-1625.	3.9	32
1160	Sensitivity and kinase activity of epidermal growth factor receptor (<scp>EGFR</scp>) exon 19 and others to <scp>EGFR</scp> â€ŧyrosine kinase inhibitors. Cancer Science, 2013, 104, 584-589.	3.9	51
1161	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology, 2013, 9, 705.	7.2	42
1162	Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMSâ€690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologicallyâ€Based Pharmacokinetic Simulations. Journal of Clinical Pharmacology, 2013, 53, 217-227.	2.0	11
1163	Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Physical Biology, 2013, 10, 026004.	1.8	3
1164	Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation. Molecular Cancer Therapeutics, 2013, 12, 2145-2156.	4.1	80
1165	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. Journal of Clinical Oncology, 2013, 31, 1874-1884.	1.6	101
1166	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death and Disease, 2013, 4, e810-e810.	6.3	67
1167	Rare mutations in non-small-cell lung cancer. Future Oncology, 2013, 9, 699-711.	2.4	23
1168	Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2. Clinical Cancer Research, 2013, 19, 5390-5401.	7.0	67
1169	Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. Molecular Cancer Therapeutics, 2013, 12, 2167-2175.	4.1	33
1170	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Molecular Cancer Therapeutics, 2013, 12, 589-597.	4.1	62
1171	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	6.3	51
1172	Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Scientific Reports, 2013, 3, 2855.	3.3	34
1173	New treatment strategy for patients withEGFR-mutant lung cancer. Lung Cancer Management, 2013, 2, 505-516.	1.5	ο

#	Article	IF	CITATIONS
1174	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. Lung Cancer Management, 2013, 2, 381-390.	1.5	0
1175	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Research, 2013, 15, R85.	5.0	120
1176	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood, 2013, 121, 3165-3171.	1.4	110
1177	Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer. , 2013, , 155-182.		0
1178	Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations. Journal of Thoracic Oncology, 2013, 8, e59-e60.	1.1	15
1179	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI. Journal of Thoracic Oncology, 2013, 8, 1059-1068.	1.1	48
1180	High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?. Journal of Thoracic Oncology, 2013, 8, 1118-1120.	1.1	66
1181	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	1.1	113
1182	Afatinib after Disease Progression with Gefitinib in Advanced Adenocarcinoma of the Lung. Journal of Pharmacy Practice and Research, 2013, 43, 137-139.	0.8	1
1183	BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations. Journal of Thoracic Oncology, 2013, 8, 295-300.	1.1	17
1184	Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology, 2013, 4, 28.	3.5	503
1185	Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncology Reports, 2013, 29, 1975-1982.	2.6	38
1187	Lungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. Journal of Thoracic Oncology, 2013, 8, 123-125.	1.1	33
1188	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 161-169.	4.9	64
1189	Dose Reduction or Intermittent Administration of Erlotinib: Which Is Better for Patients Suffering from Intolerable Toxicities?. Internal Medicine, 2013, 52, 599-603.	0.7	6
1190	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Management and Research, 2013, 5, 15.	1.9	4
1191	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Management and Research, 2013, 5, 91.	1.9	15
1193	Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics: Targets and Therapy, 2013, 7, 91.	3.2	24

#	Article	IF	Citations
1194	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets and Therapy, 2013, 4, 43.	2.7	3
1195	Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Tuberculosis and Respiratory Diseases, 2013, 75, 95.	1.8	16
1196	Targeting the EGFR family of receptor tyrosine kinases. , 0, , 843-853.		0
1197	Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e51021.	2.5	7
1198	N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines. PLoS ONE, 2013, 8, e57692.	2.5	104
1199	mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF. PLoS ONE, 2013, 8, e62104.	2.5	32
1200	DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation. PLoS ONE, 2013, 8, e67782.	2.5	34
1201	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	2.5	31
1202	Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo. PLoS ONE, 2013, 8, e77411.	2.5	42
1203	Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors. PLoS ONE, 2013, 8, e81393.	2.5	9
1204	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. PLoS ONE, 2013, 8, e84700.	2.5	41
1205	A view on EGFR-targeted therapies from the oncogene-addiction perspective. Frontiers in Pharmacology, 2013, 4, 53.	3.5	41
1206	Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations. PLoS ONE, 2013, 8, e78500.	2.5	15
1207	Biomarkers in Lung Cancer: Integration with Radiogenomics Data. , 2013, , .		1
1208	HER. , 0, , 85-109.		0
1209	Tyrosine-kinase inhibitors in oncology. , 0, , 872-883.		0
1210	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
1211	Molecular Pathology of Lung Cancer: Current Status and Future Directions. Tuberculosis and Respiratory Diseases, 2014, 77, 49.	1.8	12

ARTICLE IF CITATIONS Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. 1212 1.5 94 Brazilian Journal of Medical and Biological Research, 2014, 47, 929-939. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. OncoTargets and Therapy, 2014, 7, 1689. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics: Targets and 1214 3.2 25 Therapy, 2014, 8, 183. Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of 2.5 34 EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M. PLoS ONE, 2014, 9, e114000. In-Depth Analysis Shows Synergy between Erlotinib and miR-34a. PLoS ONE, 2014, 9, e89105. 1216 2.5 62 Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. PLoS ONE, 2014, 9, e110780. 2.5 Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. Journal of 1218 2.5 16 Personalized Medicine, 2014, 4, 297-310. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. 1210 2.5 Journal of Personalized Medicine, 2014, 4, 386-401. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer 1220 2.0 32 patients. OncoTargets and Therapy, 2014, 7, 513. Molecular pathways and therapeutic targets in lung cancer. Oncotarget, 2014, 5, 1392-1433. 1.8 171 EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Design, 1222 4.336 Development and Therapy, 2014, 8, 1595. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a 2.0 24 meta-analysis. OncoTargets and Therapy, 2014, 7, 387. A Case of Lung Adenocarcinoma with Postoperative Recurrence of Multiple Bone Metastases that Showed a Gradual Complete Response to Combined Administration of Erlotinib and Zoledronic Acid. 1224 1.1 0 Tumori, 2014, 100, e45-e48. Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e353-e365. 3.8 The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer 1226 2.2 8 cell line NCI-H1975 in vitro. Journal of Molecular Histology, 2014, 45, 641-652. Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC. Lung Cancer 1227 Management, 2014, 3, 459-476. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <i>EGFR</i>-Mutant 1228 9.4 348 Lung Cancer with and without T790M Mutations. Cancer Discovery, 2014, 4, 1036-1045. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. 1229 7.1 Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3316-24.

#	Article	IF	CITATIONS
1230	Translational Therapeutics in Genetically Engineered Mouse Models of Cancer. Cold Spring Harbor Protocols, 2014, 2014, pdb.top069997.	0.3	10
1231	Mechanisms Behind the Inhibition of Lung Adenocarcinoma Cell by Shikonin. Cell Biochemistry and Biophysics, 2014, 70, 1459-1467.	1.8	18
1232	Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History. Journal of the National Cancer Institute, 2014, 106, djt361-djt361.	6.3	13
1233	Cell-to-cell variability in cell death: can systems biology help us make sense of it all?. Cell Death and Disease, 2014, 5, e1261-e1261.	6.3	34
1234	Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death and Disease, 2014, 5, e1227-e1227.	6.3	68
1235	Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo. Cell Death and Disease, 2014, 5, e1138-e1138.	6.3	16
1236	lsoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR. Journal of Biological Chemistry, 2014, 289, 35839-35848.	3.4	88
1237	Targeting Oncogenic Drivers. Progress in Tumor Research, 2014, 41, 1-14.	0.1	7
1238	The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. CNS Oncology, 2014, 3, 209-217.	3.0	2
1239	Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme. Molecular Therapy - Nucleic Acids, 2014, 3, e150.	5.1	7
1240	Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. Lung Cancer: Targets and Therapy, 2014, 5, 1.	2.7	44
1241	The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice. Molecular Cancer Therapeutics, 2014, 13, 329-340.	4.1	58
1242	Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine. PLoS Computational Biology, 2014, 10, e1003554.	3.2	61
1243	Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models. Frontiers in Oncology, 2014, 4, 344.	2.8	15
1244	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non–Small Cell Carcinoma of the Lung. Archives of Pathology and Laboratory Medicine, 2014, 138, 171-174.	2.5	20
1245	Abnormal activation of the ECFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer. Oncology Reports, 2014, 31, 1940-1946.	2.6	25
1246	Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Veterinary Research, 2014, 10, 105.	1.9	27
1247	Reversion of erlotinib-acquired resistance twice by chemotherapy. Cancer Biology and Therapy, 2014, 15, 172-177.	3.4	1

ARTICLE IF CITATIONS Management of <i>EGFR</i>-mutant non-small-cell lung cancer patients afterÂfirst-line reversible EGF 1248 0 1.5 receptor-tyrosine kinaseÂinhibitors. Lung Cancer Management, 2014, 3, 77-84. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related 1249 ÉGFR-TKI Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Řesearch, 2014, 20, 4059-4074. An activation of <scp>LC3A</scp>â€mediated autophagy contributes to <i>de novo</i> and acquired 1250 resistance to <scp>EGFR</scp> tyrosine kinase inhibitors in lung adenocarcinoma. Journal of 4.5 44 Pathology, 2014, 234, 277-288. Molecular diagnostic testing of cytology specimens: current applications and future considerations. 0.5 Journal of the American Society of Cytopathology, 2014, 3, 280-294. ERK1/2 Blockade Prevents Epithelial–Mesenchymal Transition in Lung Cancer Cells and Promotes Their 1252 0.9 145 Sensitivity to EGFR Inhibition. Cancer Research, 2014, 74, 309-319. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitorâ€sensitizing and resistance mutations in the plasma DNA of patients with advanced nonâ€"small cell lung cancer during treatment 4.1 180 with erlotinib. Cancer, 2014, 120, 3896-3901. Luteolin is effective in the nonâ€small cell lung cancer model with <scp>L</scp>858<scp>R</scp>/<scp>T</scp>790<scp>M EGF</scp> receptor mutation and erlotinib resistance. British Journal of Pharmacology, 2014, 171, 2842-2853. 1254 5.4 51 AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung 9.4 1,655 Cancer. Cancer Discovery, 2014, 4, 1046-1061. Molecular alterations in nonâ€smallâ€cell lung cancer: Perspective for targeted therapy and specimen 1256 2.3 15 management for the bronchoscopist. Respirology, 2014, 19, 1117-1125. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and 1.8 resistance. Respiratory Investigation, 2014, 52, 348-356. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor 1258 4.1 57 mutations. Cancer, 2014, 120, 2090-2098. The evolving genomic classification of lung cancer. Journal of Pathology, 2014, 232, 121-133. 4.5 Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR 1260 2.1 25 récycling. Biochemical and Biophysical Research Communications, 2014, 455, 269-276. Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 1.8 16 2293-2305. Antiâ€tumor activity of <scp>WK</scp>88â€1, a novel geldanamycin derivative, in gefitinibâ€resistant 1262 22 3.9 nonâ€small cell lung cancers with Met amplification. Cancer Science, 2014, 105, 1245-1253. Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3â€²-Deoxy-3â€²-[18F]-Fluorothymidine Positron Emission Tomography. Clinical Cancer 24 Research, 2014, 20, 4806-4815. Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor 1264 6.4 28 Lung Tumors with the Acquired Resistance Mutation T790M. Cell Reports, 2014, 7, 1824-1832. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. Journal of Experimental and Clinical Cancer 8.6 Research, 2014, 33, 52.

#	Article	IF	CITATIONS
1266	Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biology, 2014, 15, 461.	8.8	23
1267	Molecular Testing of Lung Carcinomas. , 2014, 19, 36-39.		0
1268	Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. Journal of Thoracic Oncology, 2014, 9, 456-463.	1.1	112
1269	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Research, 2014, 42, 13557-13572.	14.5	102
1270	Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology, 2014, 9, 1523-1531.	1.1	19
1271	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228
1272	Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects. Advances in Experimental Medicine and Biology, 2014, 804, 47-66.	1.6	26
1273	Deploying Ibrutinib to Lung Cancer: Another Step in the Quest Towards Drug Repurposing. Journal of the National Cancer Institute, 2014, 106, dju250-dju250.	6.3	8
1274	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clinical Epidemiology, 2014, 6, 423.	3.0	139
1275	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. European Respiratory Review, 2014, 23, 356-366.	7.1	139
1276	<i>nab</i> -paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 129-141.	2.4	14
1277	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. Journal of Hematology and Oncology, 2014, 7, 22.	17.0	29
1278	Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib. Cellular Physiology and Biochemistry, 2014, 34, 865-872.	1.6	42
1279	3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer. Journal of Biological Chemistry, 2014, 289, 28192-28201.	3.4	17
1280	Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. Journal of Thoracic Oncology, 2014, 9, 483-487.	1.1	67
1281	Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation. Journal of Thoracic Oncology, 2014, 9, 775-783.	1.1	34
1283	Acquired resistance to EGFRâ€ŧargeted therapies inÂcolorectal cancer. Molecular Oncology, 2014, 8, 1084-1094.	4.6	121
1284	Glioblastoma: From Molecular Pathology to Targeted Treatment. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1-25.	22.4	427

ARTICLE IF CITATIONS Cheminformatics at the interface of medicinal chemistry and proteomics. Biochimica Et Biophysica 1285 2.3 20 Acta - Proteins and Proteomics, 2014, 1844, 156-161. Diacylglycerol kinase $\hat{I}\cdot$ modulates on cogenic properties of lung cancer cells. Clinical and Translational On cology, 2014, 16, 29-35. 1286 2.4 19 1287 Personalized Health Care (PHC) in Cancer., 2014, , 23-49. 0 Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic 1288 149 sifters and biochips. Lab on A Chip, 2014, 14, 78-88. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung 1289 3.8 23 cancer. Translational Respiratory Medicine, 2014, 2, 2. Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. Molecular Diagnosis and 1290 3.8 Therapy, 2014, 18, 273-284. Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma derived meningeal carcinomatosis. International Cancer 1291 0.5 3 Conference Journal, 2014, 3, 211-214. Evolution of acquired resistance to anti-cancer therapy. Journal of Theoretical Biology, 2014, 355, 1292 1.7 10-20. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in 1293 2.0 81 advanced NSCLC patients. Lung Cancer, 2014, 84, 295-300. 1294 The impact of germline mutations on targeted therapy. Journal of Pathology, 2014, 232, 230-243. 4.5 Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase 1295 17 4.7inhibition: new strategy against cancer. FEBS Journal, 2014, 281, 2172-2189. Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. Experimental and 1296 2.1 Molecular Pathology, 2014, 96, 85-91. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Experimental Cell 1297 2.6 43 Research, 2014, 322, 168-177. Lung Cancer Stem Cells and Implications for Future Therapeutics. Cell Biochemistry and Biophysics, 2014, 69, 389-398. 1298 1.8 Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer 1299 183 9.4 Discovery, 2014, 4, 606-619. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase 2.0 86 inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer, 2014, 83, 37-43. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of 1301 7.2 22 angiogenesis by telomere overhang oligonucleotides. Cancer Letters, 2014, 343, 14-23. Ceritinib in <i>ALK</i>-Rearranged Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 1,367 2014, 370, 1189-1197.
# 1303	ARTICLE Epistatic interactions and drug response. Journal of Pathology, 2014, 232, 255-263.	IF 4.5	Citations 24
1304	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced nonâ€small cell lung cancer. Cancer, 2014, 120, 2289-2298.	4.1	30
1305	ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell, 2014, 25, 282-303.	16.8	817
1306	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. Clinical Cancer Research, 2014, 20, 2264-2275.	7.0	60
1307	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. Journal of Pathology, 2014, 232, 274-282.	4.5	48
1308	Liquid Biopsies: Genotyping Circulating Tumor DNA. Journal of Clinical Oncology, 2014, 32, 579-586.	1.6	1,811
1309	Molecular analysis of circulating tumour cells—biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	27.6	535
1310	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research, 2014, 20, 2001-2010.	7.0	215
1311	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	8.7	255
1312	Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma. Journal of Immunoassay and Immunochemistry, 2014, 35, 256-268.	1.1	11
1313	New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background. Pathology and Oncology Research, 2014, 20, 11-25.	1.9	44
1314	Section IV: Non–small cell lung cancer and malignant melanoma. Current Problems in Cancer, 2014, 38, 180-198.	2.0	2
1315	Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. Biochemical Society Transactions, 2014, 42, 758-764.	3.4	5
1317	Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation. Journal of Medicinal Chemistry, 2014, 57, 10176-10191.	6.4	53
1318	Aspects biologiques des cancers bronchiques. Revue Des Maladies Respiratoires Actualites, 2014, 6, 311-319.	0.0	0
1319	Thérapies ciblées : comment déterminer la cible ?. Revue Des Maladies Respiratoires Actualites, 2014, 6, 453-458.	0.0	0
1320	Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochemical and Biophysical Research Communications, 2014, 453, 681-685.	2.1	57
1321	Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance. Respiratory Investigation, 2014, 52, 330-338.	1.8	18

#	Article	IF	CITATIONS
1322	Enhanced antiâ€angiogenic effect of <scp>E</scp> 7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitorâ€resistant nonâ€smallâ€cell lung cancer xenograft models. Cancer Science, 2014, 105, 1023-1031.	3.9	21
1323	Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15964-15968.	7.1	100
1324	Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by <i>DDR2</i> Gatekeeper Mutation and <i>NF1</i> Loss. Molecular Cancer Therapeutics, 2014, 13, 475-482.	4.1	51
1325	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 2547-2558.	4.1	106
1326	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). Lung Cancer, 2014, 86, 158-163.	2.0	47
1327	Personalized medicine: Special treatment. Nature, 2014, 513, S8-S9.	27.8	17
1328	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4.	2.6	32
1329	A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 1226-1235.	2.6	9
1330	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2014, 14, 453-468.	3.1	17
1331	EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11721-11726.	7.1	43
1332	Advancing clinical oncology through genome biology and technology. Genome Biology, 2014, 15, 427.	8.8	9
1333	Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Research, 2014, 74, 7181-7184.	0.9	53
1334	In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. Medicinal Chemistry Research, 2014, 23, 5074-5085.	2.4	49
1335	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	6.3	88
1336	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1333-1348.	4.1	48
1337	Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase. Journal of Medicinal Chemistry, 2014, 57, 6594-6609.	6.4	127
1338	Upconversion nanoparticle-based ligase-assisted method for specific and sensitive detection of T790M mutation in epidermal growth factor receptor. Biosensors and Bioelectronics, 2014, 62, 120-126.	10.1	17
1339	Somatic alterations as the basis for resistance to targeted therapies. Journal of Pathology, 2014, 232, 244-254.	4.5	31

#	Article	IF	CITATIONS
1340	MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation. Cancer Research, 2014, 74, 253-262.	0.9	125
1341	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	1.6	121
1342	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
1343	Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non–Small Cell Lung Cancer Cells. Clinical Cancer Research, 2014, 20, 5423-5434.	7.0	60
1344	Discoidin domain receptors: a proteomic portrait. Cellular and Molecular Life Sciences, 2014, 71, 3269-3279.	5.4	28
1345	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. Journal of Molecular Medicine, 2014, 92, 697-707.	3.9	58
1346	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 505-521.	3.0	97
1347	ls there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. Cancer Chemotherapy and Pharmacology, 2014, 73, 1063-1070.	2.3	18
1348	The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors. Molecular and Cellular Biochemistry, 2014, 392, 239-247.	3.1	7
1349	Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies. Clinical Cancer Research, 2014, 20, 2249-2256.	7.0	230
1350	Integrin β3 links therapy resistance and cancer stem cell properties. Nature Cell Biology, 2014, 16, 397-399.	10.3	20
1351	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. New England Journal of Medicine, 2014, 370, 2286-2294.	27.0	1,042
1352	Ibrutinib Treatment of CLL: The Cancer Fights Back. Cancer Cell, 2014, 26, 11-13.	16.8	28
1353	EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. Targeted Oncology, 2014, 9, 389-394.	3.6	3
1354	Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. BMC Cancer, 2014, 14, 369.	2.6	33
1355	Inhibition of human lung cancer cell proliferation and survival by wine. Cancer Cell International, 2014, 14, 6.	4.1	27
1356	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Molecular Cancer, 2014, 13, 143.	19.2	55
1357	Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. Journal of Medical Case Reports, 2014, 8, 64.	0.8	7

#	Article	IF	CITATIONS
1358	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2014, 23, 809-821.	4.1	29
1359	Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews Clinical Oncology, 2014, 11, 473-481.	27.6	740
1360	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 1382-1389.	4.1	104
1361	Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement. Clinical Lung Cancer, 2014, 15, 398-404.	2.6	8
1362	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. Cancer Treatment Reviews, 2014, 40, 1192-1198.	7.7	51
1363	Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. Cancer Discovery, 2014, 4, 650-661.	9.4	594
1364	Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer, 2014, 83, 44-50.	2.0	23
1365	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. Clinical Lung Cancer, 2014, 15, 1-6.	2.6	79
1366	Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Experimental Cell Research, 2014, 323, 288-296.	2.6	44
1367	Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. Journal of Ethnopharmacology, 2014, 151, 210-217.	4.1	36
1368	SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer, 2014, 85, 1-6.	2.0	28
1369	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer, 2014, 84, 161-167.	2.0	81
1370	Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 298-303.	2.8	11
1371	Metformin Sensitizes EGFR-TKl–Resistant Human Lung Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> through Inhibition of IL-6 Signaling and EMT Reversal. Clinical Cancer Research, 2014, 20, 2714-2726.	7.0	212
1372	New approach to cancer therapy based on a molecularly defined cancer classification. Ca-A Cancer Journal for Clinicians, 2014, 64, 70-74.	329.8	22
1373	The <scp>MAPK</scp> pathway across different malignancies: A new perspective. Cancer, 2014, 120, 3446-3456.	4.1	752
1374	ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non–Small-Cell Lung Cancer?. Clinical Lung Cancer, 2014, 15, 313-319.	2.6	26
1375	CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Lung Cancer, 2014, 85, 147-151.	2.0	13

#	Article	IF	CITATIONS
1376	Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 576.	2.3	59
1377	A Patient With Metastatic Lung Adenocarcinoma Harboring Concurrent <i>EGFR</i> L858R, <i>EGFR</i> Germline T790M, and <i>PIK3CA</i> Mutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer. Journal of the National Comprehensive Cancer Network: INCCN. 2014. 12. 6-11.	4.9	13
1381	SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncology Reports, 2014, 32, 2612-2618.	2.6	10
1382	Assessing adaptation of the cancer kinome in response to targeted therapies. Biochemical Society Transactions, 2014, 42, 765-769.	3.4	11
1383	Afatinib: rationale for use in non-small-cell lung cancer based on clinical trial data. Clinical Investigation, 2014, 4, 55-61.	0.0	1
1384	Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood, 2014, 124, 3924-3931.	1.4	44
1385	Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood, 2014, 123, 2075-2083.	1.4	99
1386	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. Journal of Thoracic Oncology, 2014, 9, 892-896.	1.1	106
1387	Curcumin Lowers Erlotinib Resistance in Non-Small Cell Lung Carcinoma Cells With Mutated EGF Receptor. Oncology Research, 2014, 21, 137-144.	1.5	42
1388	Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. Oncology Reports, 2014, 31, 2619-2624.	2.6	12
1389	Advanced EGFR Mutation-Positive Non–Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations. Cancer Control, 2014, 21, 67-73.	1.8	16
1390	Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort. Journal of Thoracic Oncology, 2014, 9, 554-558.	1.1	63
1391	Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncology Reports, 2014, 32, 145-152.	2.6	18
1392	Synthesizing combination therapies for evolutionary dynamics of disease for nonlinear pharmacodynamics. , 2014, , .		2
1393	Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma. International Journal of Oncology, 2014, 44, 1118-1130.	3.3	69
1394	Zielgerichtetes Vorgehen gegen onkogene Faktoren. Karger Kompass Onkologie, 2015, 2, 61-70.	0.0	0
1395	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 738-746.	1.1	70

#	Article		CITATIONS
1397	Activity of secondâ€generation ALK inhibitors against crizotinibâ€resistant mutants in an NPMâ€ALK model compared to EML4â€ALK. Cancer Medicine, 2015, 4, 953-965.	2.8	72
1398	Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells. Oncology Letters, 2015, 10, 2652-2656.	1.8	16
1399	(Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. Scientific Reports, 2015, 5, 16348.	3.3	38
1400	Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Molecular Medicine Reports, 2015, 11, 2767-2774.	2.4	22
1401	Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Scientific Reports, 2015, 5, 17730.	3.3	73
1402	Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports, 2015, 5, 13076.	3.3	40
1404	EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. Scientific Reports, 2015, 5, 13959.	3.3	34
1409	Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood, 2015, 126, 471-477.	1.4	112
1410	An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation. Internal Medicine, 2015, 54, 2491-2496.	0.7	22
1411	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. International Journal of Oncology, 2015, 46, 497-504.	3.3	29
1412	ERÎ ² localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Scientific Reports, 2015, 5, 11392.	3.3	19
1413	Non–Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 515-524.	4.9	323
1414	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics, 2015, 14s4, CIN.S19338.	1.9	59
1415	Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy. Neoplasia, 2015, 17, 697-703.	5.3	16
1416	Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. Journal of Thoracic Oncology, 2015, 10, 1553-1559.	1.1	137
1417	Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations. Diagnostic Pathology, 2015, 10, 57.	2.0	6
1418	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. Cancer Control, 2015, 22, 193-199.	1.8	23
1419	Long Progression-free Survival with Afatinib in a Patient with EGFR-unknown Lung Adenocarcinoma after Erlotinib Failure: A Case Report. Tumori, 2015, 101, e64-e66.	1.1	2

#	Article	IF	CITATIONS
1420	Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 431-436.	1.3	19
1422	The Pharmaceutical Applications of Next Generation Sequencing in Oncology Drug Designing and Development. Journal of Next Generation Sequencing & Applications, 2015, 02, .	0.3	1
1423	New and emerging factors in tumorigenesis: an overview. Cancer Management and Research, 2015, 7, 225.	1.9	27
1424	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	2.0	16
1425	Molecular analysis of EGFR gene in different types of tumor material from NSCLC patients. Neoplasma, 2015, 62, 439-448.	1.6	3
1426	Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. OncoTargets and Therapy, 2015, 8, 3665.	2.0	54
1427	Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. Journal of Cancer, 2015, 6, 1214-1221.	2.5	10
1428	TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. Oncotarget, 2015, 6, 25726-25740.	1.8	13
1429	Advanced Human In vitro Models for the Discovery and Development of Lung Cancer Therapies. , 2015, , \cdot		3
1430	Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Medical Journal, 2015, 56, 1186.	2.2	14
1431	Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e165-e173.	3.8	16
1432	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers, 2015, 7, 763-783.	3.7	59
1433	Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer. Journal of Cancer, 2015, 6, 568-574.	2.5	18
1434	Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues. BioMed Research International, 2015, 2015, 1-7.	1.9	10
1435	Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0119135.	2.5	38
1436	AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells. PLoS ONE, 2015, 10, e0119832.	2.5	28
1437	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS ONE, 2015, 10, e0129123.	2.5	17
1438	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0129838.	2.5	9

#	Article	IF	CITATIONS
1439	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS ONE, 2015, 10, e0134346.	2.5	72
1440	Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?. Diagnostic and Interventional Radiology, 2015, 21, 78-84.	1.5	16
1441	Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. OncoTargets and Therapy, 2015, 8, 905.	2.0	14
1442	Article Commentary: Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. Cancer Informatics, 2015, 14s4, CIN.S19330.	1.9	11
1443	The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. BioMed Research International, 2015, 2015, 1-10.	1.9	13
1444	EGFR Signaling and its inhibition by EGFR inhibitors in NSCLC. International Journal of Applied Sciences and Biotechnology, 2015, 2, 375-388.	0.8	1
1445	Mutation of cysteine 46 in IKK-beta increases inflammatory responses. Oncotarget, 2015, 6, 31805-31819.	1.8	26
1446	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clinical Cancer Research, 2015, 21, 2221-2226.	7.0	72
1447	Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma. Cancer Discovery, 2015, 5, 534-549.	9.4	57
1448	Amplification of Chromosome 8 Genes in Lung Cancer. Journal of Cancer, 2015, 6, 270-275.	2.5	34
1449	Molecular Interaction of a Kinase Inhibitor Midostaurin with Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics. PLoS ONE, 2015, 10, e0119765.	2.5	20
1450	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research, 2015, 21, 3924-3933.	7.0	459
1451	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, The, 2015, 16, 830-838.	10.7	786
1452	<i>EGFR</i> mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncology, 2015, 11, 1611-1623.	2.4	82
1453	Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment. Clinical Science, 2015, 128, 619-634.	4.3	67
1454	High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemotherapy and Pharmacology, 2015, 75, 1261-1266.	2.3	64
1455	New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. , 2015, , 129-154.		0
1456	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling, 2015, 8, ra53.	3.6	33

#	Article	IF	CITATIONS
1457	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Archives of Toxicology, 2015, 89, 1227-1240.	4.2	42
1458	Lung Cancer in the Era of Precision Medicine. Clinical Cancer Research, 2015, 21, 2213-2220.	7.0	148
1459	Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 1107-1116.	4.1	43
1460	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i> -Mutant Lung Cancer. Cancer Discovery, 2015, 5, 960-971.	9.4	211
1461	Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73.	6.4	42
1462	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	2.4	5
1463	Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper―F691L Mutation with PLX3397. Cancer Discovery, 2015, 5, 668-679.	9.4	145
1464	Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research, 2015, 21, 3377-3383.	7.0	34
1465	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. Journal of Thoracic Oncology, 2015, 10, 1049-1057.	1.1	85
1466	Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncology Reports, 2015, 34, 2864-2870.	2.6	17
1467	Acquisition of cancer stem cellâ€like properties in nonâ€small cell lung cancer with acquired resistance to afatinib. Cancer Science, 2015, 106, 1377-1384.	3.9	62
1468	Synthesis, characterization and biological activity of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as epidermal growth factor receptor inhibitors. Chemical Research in Chinese Universities, 2015, 31, 936-941.	2.6	4
1469	Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Molecular Biology of the Cell, 2015, 26, 4087-4099.	2.1	79
1471	Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncology Letters, 2015, 10, 2063-2066.	1.8	18
1472	Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3. Oncology Reports, 2015, 34, 1875-1882.	2.6	6
1473	Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncology Reports, 2015, 33, 1499-1504.	2.6	17
1474	ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. Molecular Cancer Therapeutics, 2015, 14, 2831-2839.	4.1	23
1475	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. Oncology Research and Treatment, 2015, 38, 291-298.	1.2	82

#	Article	IF	CITATIONS
1476	Sitting above the maze: recent model discoveries in molecular science. Molecular Simulation, 2015, 41, 205-229.	2.0	4
1478	EGFR T790M resistance mutation in non small-cell lung carcinoma. Clinica Chimica Acta, 2015, 444, 81-85.	1.1	61
1479	Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study. Clinical Lung Cancer, 2015, 16, 121-127.	2.6	12
1480	The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study. EBioMedicine, 2015, 2, 194-204.	6.1	60
1481	Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. Journal of Molecular Graphics and Modelling, 2015, 57, 36-48.	2.4	9
1482	Novel curcumin analogs to overcome EGFR–TKI lung adenocarcinoma drug resistance and reduce EGFR–TKI-induced GI adverse effects. Bioorganic and Medicinal Chemistry, 2015, 23, 1507-1514.	3.0	28
1483	Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient. Clinical Lung Cancer, 2015, 16, e1-e3.	2.6	8
1484	The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treatment Reviews, 2015, 41, 160-169.	7.7	83
1485	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	4.5	200
1486	Insight into the Role of Wnt5a-Induced Signaling in Normal and Cancer Cells. International Review of Cell and Molecular Biology, 2015, 314, 117-148.	3.2	75
1487	The role of BIM-EL and BCL2- $\hat{l}\pm$ on the efficacy of erlotinib and gefitinib in lung cancer. Respiratory Physiology and Neurobiology, 2015, 209, 64-68.	1.6	6
1488	25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations. Molecular Pharmacology, 2015, 87, 766-775.	2.3	130
1489	Ten things you should know about protein kinases: <scp>IUPHAR R</scp> eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	5.4	270
1490	Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors. ACS Chemical Biology, 2015, 10, 234-245.	3.4	52
1491	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer, 2015, 121, E1-6.	4.1	55
1492	The Design of Covalent Allosteric Drugs. Annual Review of Pharmacology and Toxicology, 2015, 55, 249-267.	9.4	96
1493	TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models. Molecular Cancer Therapeutics, 2015, 14, 14-22.	4.1	95
1494	Combinatorial Action of MicroRNAs <i>let-7</i> and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle, 2015, 14, 2171-2180.	2.6	131

		CITATION RE	EPORT	
#	Article		IF	CITATIONS
1495	Adaptive stress signaling in targeted cancer therapy resistance. Oncogene, 2015, 34, 5	5599-5606.	5.9	57
1496	Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma mediated by c-Kit pathway transduction. Tumor Biology, 2015, 36, 2993-2999.	a xenografts is	1.8	7
1497	Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Rev 361-375.	views, 2015, 41,	7.7	142
1498	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate S Potential Biomarker. Clinical Lung Cancer, 2015, 16, 348-357.	or Metastatic Synthase RNA as a	2.6	14
1499	Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Can Activating <i>EGFR</i> Mutations and HGF Overexpression. Molecular Cancer Therape 533-541.	cer with utics, 2015, 14,	4.1	25
1500	Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Mouse Lung Cancer Model. Cell Reports, 2015, 10, 1187-1201.	Crosstalk in	6.4	137
1501	Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung ca Journal of Cancer Research and Clinical Oncology, 2015, 141, 615-626.	ncer cell lines.	2.5	17
1502	Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung ca Journal of Pharmacology, 2015, 754, 82-91.	incer. European	3.5	31
1503	The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kir mutant and wild-type non-small cell lung cancer. Targeted Oncology, 2015, 10, 235-24	nase inhibition in 15.	3.6	32
1504	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung ca Review of Clinical Pharmacology, 2015, 8, 461-477.	ancer. Expert	3.1	31
1505	Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors. ACS Me Chemistry Letters, 2015, 6, 782-786.	dicinal	2.8	43
1506	EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug schedu selection. , 2015, 154, 67-77.	uling and patient		41
1507	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivi Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research, 2 5305-5313.	ty to Afatinib or 015, 21,	7.0	164
1508	2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFRL858R/T7 and Medicinal Chemistry Letters, 2015, 25, 4277-4281.	90M. Bioorganic	2.2	19
1509	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in <i>RET Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2015, 14, 2238-2248.</i>	۲-Rearranged	4.1	19
1510	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by De Plasma Cell-Free DNA. Clinical Chemistry, 2015, 61, 1191-1196.	eep Sequencing of	3.2	99
1511	Nonenriched PCR Versus Mutant-Enriched PCR in Detecting Selected Epidermal Growt Receptor Gene Mutations Among Nonsmall-Cell Lung Cancer Patients. Genetic Testing Biomarkers, 2015, 19, 444-449.	h Factor ; and Molecular	0.7	5
1512	Anchor-based classification and type-C inhibitors for tyrosine kinases. Scientific Report 10938.	is, 2015, 5,	3.3	11

#	Article	IF	CITATIONS
1513	MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. Cytogenetic and Genome Research, 2015, 146, 1-8.	1.1	58
1514	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Molecular Aspects of Medicine, 2015, 45, 55-66.	6.4	26
1515	Inflammation and Lung Cancer: The Link to Angiogenesis. , 2015, , 137-159.		0
1516	Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs, 2015, 29, 167-183.	4.6	59
1517	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 990-998.	10.7	353
1518	CpC hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. Lung Cancer, 2015, 87, 265-271.	2.0	33
1519	Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2015, 21, 3818-3820.	7.0	35
1520	Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress and Chaperones, 2015, 20, 729-741.	2.9	19
1521	SELPHI: correlation-based identification of kinase-associated networks from global phospho-proteomics data sets. Nucleic Acids Research, 2015, 43, W276-W282.	14.5	24
1522	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Research, 2015, 75, 2489-2500.	0.9	266
1523	Biomarkers in Lung Adenocarcinoma: A Decade of Progress. Archives of Pathology and Laboratory Medicine, 2015, 139, 469-480.	2.5	66
1524	RE: A Cancer Theory Kerfuffle Can Lead to New Lines of Research. Journal of the National Cancer Institute, 2015, 107, djv060-djv060.	6.3	2
1525	NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation. OncoTargets and Therapy, 2015, 8, 269.	2.0	22
1526	Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 2015, 125, 1780-1789.	8.2	364
1527	Trends in the early investigational drug development and areas for improvement. Expert Opinion on Investigational Drugs, 2015, 24, 845-850.	4.1	1
1528	Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells. Cancer Biology and Therapy, 2015, 16, 549-557.	3.4	14
1529	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for <i>EGFR</i> -Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2015, 33, 1666-1673.	1.6	99
1530	Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis. Seminars in Diagnostic Pathology, 2015, 32, 325-333.	1.5	9

#	Article	IF	Citations
1531	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Annals of Oncology, 2015, 26, 1363-1371.	1.2	37
1532	Overcoming Resistance to Targeted Therapy for Lung Cancer. New England Journal of Medicine, 2015, 372, 1760-1761.	27.0	24
1533	Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Phytomedicine, 2015, 22, 560-567.	5.3	32
1534	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients WithÂEpidermal Growth Factor Receptor MutantÂLung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorÂTherapy. Clinical Lung Cancer, 2015, 16, 228-236.	2.6	23
1535	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non–small-cell lung cancer. Cancer Genetics, 2015, 208, 271-278.	0.4	12
1536	A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice. EJNMMI Research, 2015, 5, 14.	2.5	38
1537	Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond. Chinese Journal of Cancer, 2015, 34, 149-60.	4.9	20
1538	Application of biomarkers in oncology clinical trials. Clinical Investigation, 2015, 5, 61-74.	0.0	1
1539	Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinibâ€resistant lung cancer growth. Molecular Carcinogenesis, 2015, 54, 322-331.	2.7	47
1540	Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells. Journal of Biological Chemistry, 2015, 290, 9101-9110.	3.4	80
1541	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Expert Opinion on Drug Safety, 2015, 14, 97-110.	2.4	7
1542	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer, 2015, 16, 358-365.	2.6	14
1543	Refining the treatment of NSCLC according to histological and molecular subtypes. Nature Reviews Clinical Oncology, 2015, 12, 511-526.	27.6	247
1544	Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. Journal of Proteome Research, 2015, 14, 2617-2625.	3.7	48
1545	Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. Cancer and Metastasis Reviews, 2015, 34, 173-182.	5.9	6
1546	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Annals of Oncology, 2015, 26, 1830-1837.	1.2	43
1547	Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6955-6960.	7.1	102
1548	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer, 2015, 16, e25-e35.	2.6	100

#	Article	IF	CITATIONS
1549	Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation. Molecular and Clinical Oncology, 2015, 3, 329-333.	1.0	10
1550	Digital PCR analysis of circulating nucleic acids. Clinical Biochemistry, 2015, 48, 948-956.	1.9	159
1551	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 94-101.	2.4	126
1552	Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. Proteomics, 2015, 15, 340-355.	2.2	42
1553	Molecular targeted therapy in the treatment of advanced stage nonâ€small cell lung cancer (<scp>NSCLC</scp>). Respirology, 2015, 20, 370-378.	2.3	119
1554	ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas. Cancer Research, 2015, 75, 1035-1045.	0.9	26
1555	Emerging platforms using liquid biopsy to detect <i>EGFR</i> mutations in lung cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1427-1440.	3.1	36
1556	DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2722-2730.	4.1	33
1557	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106.	7.1	4
1558	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
1559	Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties. Computers in Biology and Medicine, 2015, 63, 293-300.	7.0	11
1560	HSP90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact. Heat Shock Proteins, 2015, , 289-322.	0.2	2
1561	How to develop novel treatments for EGFR-mutant lung cancer. Future Oncology, 2015, 11, 2375-2378.	2.4	6
1562	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Therapeutic Advances in Medical Oncology, 2015, 7, 263-273.	3.2	47
1563	Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology, 2015, 42, 896-908.	2.2	36
1564	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 2015, 192, 539-544.	2.8	106
1565	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. Science Translational Medicine, 2015, 7, 312re10.	12.4	366
1566	Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer. Cancer Research, 2015, 75, 4937-4948.	0.9	59

#	Article	IF	CITATIONS
1567	Minimal residual disease in cancer therapy – Small things make all the difference. Drug Resistance Updates, 2015, 21-22, 1-10.	14.4	34
1568	Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 5110-5120.	7.0	113
1569	Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells. Toxicology and Applied Pharmacology, 2015, 287, 17-25.	2.8	8
1570	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. Journal of Hematology and Oncology, 2015, 8, 95.	17.0	81
1571	Radiotherapy of non-small-cell lung cancer in the era of <i>EGFR</i> gene mutations and EGF receptor tyrosine kinase inhibitors. Future Oncology, 2015, 11, 2329-2342.	2.4	15
1572	Targeting Signaling Transduction Pathways in Bladder Cancer. Current Oncology Reports, 2015, 17, 58.	4.0	37
1573	Agents in the preclinical development stage for non-small cell lung cancer. Expert Review of Anticancer Therapy, 2015, 15, 1361-1366.	2.4	0
1574	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications, 2015, 6, 8305.	12.8	97
1575	Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. Journal of Medicinal Chemistry, 2015, 58, 8877-8895.	6.4	43
1576	Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor. Molecular Cancer Research, 2015, 13, 1238-1247.	3.4	47
1577	Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Current Treatment Options in Oncology, 2015, 16, 51.	3.0	9
1578	Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Research, 2015, 75, 4728-4741.	0.9	49
1579	Genetic instability in the tumor microenvironment: a new look at an old neighbor. Molecular Cancer, 2015, 14, 145.	19.2	48
1580	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radical Biology and Medicine, 2015, 89, 287-299.	2.9	73
1581	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry, 2015, 58, 6844-6863.	6.4	92
1582	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. AAPS Journal, 2015, 17, 1483-1491.	4.4	7
1583	Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer, 2015, 89, 287-293.	2.0	29
1584	Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. Lung Cancer, 2015, 90, 167-174.	2.0	10

#	Article	IF	CITATIONS
1585	EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 835-841.	2.3	40
1586	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2015, 16, 49.	3.0	28
1587	Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers. Biochemistry, 2015, 54, 7212-7221.	2.5	7
1588	PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16, 1843-1862.	1.3	180
1589	Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer With T790M Mutations. Clinical Lung Cancer, 2015, 16, e97-e99.	2.6	3
1590	Canertinib induces ototoxicity in three preclinical models. Hearing Research, 2015, 328, 59-66.	2.0	8
1591	Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. Cell Reports, 2015, 11, 446-459.	6.4	18
1592	Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell, 2015, 163, 1059-1063.	28.9	115
1593	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. Prostate, 2015, 75, 175-182.	2.3	11
1594	The combination of irreversible <scp>EGFR TKI</scp> s and <scp>SAHA</scp> induces apoptosis and autophagyâ€mediated cell death to overcome acquired resistance in <scp>EGFR</scp> <scp>T</scp> 790 <scp>M</scp> â€mutated lung cancer. International Journal of Cancer, 2015, 136, 2717-2729.	5.1	55
1595	Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 542-552.	4.1	28
1596	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. , 2015, , .		7
1597	Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumor Biology, 2015, 36, 7-19.	1.8	50
1599	Design, microwave-mediated synthesis and biological evaluation of novel 4-aryl(alkyl)amino-3-nitroquinoline and 2,4-diaryl(dialkyl)amino-3-nitroquinolines as anticancer agents. Bioorganic Chemistry, 2015, 58, 1-10.	4.1	22
1600	MUC1 Promoter–Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.4	18
1601	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015, 34, 3617-3626.	5.9	211
1602	Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective. Current Pharmaceutical Design, 2016, 22, 3171-3181.	1.9	77
1603	The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedicalscience, 2016, 10, 638.	1.1	6

#	Article	IF	Citations
1604	EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment. Oncotarget, 2016, 7, 3367-3378.	1.8	9
1605	Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget, 2016, 7, 9707-9717.	1.8	123
1606	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget, 2016, 7, 6984-6993.	1.8	134
1607	Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. Oncotarget, 2016, 7, 86313-86325.	1.8	34
1608	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e141-e149.	3.8	63
1609	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. Oncotarget, 2016, 7, 45237-45248.	1.8	25
1610	Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e585-e593.	3.8	30
1611	Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type <i>EGFR</i> . Oncotarget, 2016, 7, 16273-16281.	1.8	9
1612	ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget, 2016, 7, 12289-12304.	1.8	22
1613	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 172-182.	2.8	80
1614	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology. Oncotarget, 2016, 7, 50477-50489.	1.8	12
1615	Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget, 2016, 7, 28748-28760.	1.8	95
1616	Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling. Oncotarget, 2016, 7, 9462-9476.	1.8	41
1617	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Disease Markers, 2016, 2016, 1-14.	1.3	13
1618	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. International Journal of Molecular Sciences, 2016, 17, 1186.	4.1	20
1619	Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget, 2016, 7, 71013-71035.	1.8	69
1620	Inducible Mouse Models for Cancer Drug Target Validation. Journal of Cancer Prevention, 2016, 21, 243-248.	2.0	10
1621	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. OncoTargets and Therapy, 2016. Volume 9, 5461-5473.	2.0	41

#	Article	IF	CITATIONS
1622	Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses. OncoTargets and Therapy, 2016, 9, 2961.	2.0	4
1623	MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines. Frontiers in Genetics, 2016, 7, 197.	2.3	74
1624	Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2016, 17, 237.	4.1	42
1625	Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine, 2016, 6, 3.	2.5	9
1626	Pingyangmycin and Bleomycin Share the Same Cytotoxicity Pathway. Molecules, 2016, 21, 862.	3.8	18
1627	Novel Selective and Potent ECFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Molecules, 2016, 21, 1462.	3.8	12
1628	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150567.	2.5	32
1629	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics, 2016, 6, 1232-1243.	10.0	42
1630	Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 6137-6145.	2.0	36
1631	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget, 2016, 7, 51922-51933.	1.8	94
1632	Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Medical Science Monitor, 2016, 22, 1435-1441.	1.1	53
1633	Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chemical Society Reviews, 2016, 45, 4929-4952.	38.1	150
1634	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	2.0	31
1635	Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR. ChemBioChem, 2016, 17, 990-994.	2.6	1
1636	Targeted therapies for treatment of nonâ€small cell lung cancer—Recent advances and future perspectives. International Journal of Cancer, 2016, 138, 2549-2561.	5.1	155
1637	Novel Quinazoline Derivatives Bearing Various 4â€Aniline Moieties as Potent <scp>EGFR</scp> Inhibitors with Enhanced Activity Against <scp>NSCLC</scp> Cell Lines. Chemical Biology and Drug Design, 2016, 87, 635-643.	3.2	10
1638	Precision Oncology Medicine: The Clinical Relevance of Patientâ€ 6 pecific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology, 2016, 56, 1484-1499.	2.0	75
1639	Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report. Oncology Letters, 2016, 12, 356-360.	1.8	2

#	Article	IF	CITATIONS
1640	Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. Archiv Der Pharmazie, 2016, 349, 573-593.	4.1	29
1641	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non–Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer, 2016, 17, 466-469.	2.6	16
1642	Biomarker development in the precision medicine era: lung cancer as a case study. Nature Reviews Cancer, 2016, 16, 525-537.	28.4	406
1643	Polypharmacology in Drug Development: A Minireview of Current Technologies. ChemMedChem, 2016, 11, 1211-1218.	3.2	39
1644	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports, 2016, 6, 37997.	3.3	31
1645	Adenoid Cystic Carcinoma of the Lung with an <i>EGFR</i> Mutation. Internal Medicine, 2016, 55, 1621-1624.	0.7	13
1646	AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. BMC Cancer, 2016, 16, 491.	2.6	10
1648	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. Angewandte Chemie, 2016, 128, 11069-11073.	2.0	4
1649	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
1650	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science, 2016, 23, 86.	7.0	41
1651	Inhibition of the growth of human melanoma cells by methionine enkephalin. Molecular Medicine Reports, 2016, 14, 5521-5527.	2.4	15
1652	Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncology Letters, 2016, 12, 4598-4604.	1.8	49
1653	Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. Targeted Oncology, 2016, 11, 619-629.	3.6	15
1654	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e5-e11.	2.6	39
1655	New Pharmaceutical Agents in Oncology. Physician Assistant Clinics, 2016, 1, 435-463.	0.1	0
1657	Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. Oncology Letters, 2016, 11, 535-542.	1.8	19
1658	Treatment of <i>EGFR</i> -Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors. JAMA Oncology, 2016, 2, 948.	7.1	30
1659	Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. Molecular Pharmaceutics, 2016, 13, 2117-2125.	4.6	42

#	Article	IF	CITATIONS
1660	miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers. Cancer Research, 2016, 76, 4160-4169.	0.9	56
1661	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. Future Medicinal Chemistry, 2016, 8, 853-878.	2.3	15
1662	Genetic traits for hematogeneous tumor cell dissemination in cancer patients. Cancer and Metastasis Reviews, 2016, 35, 41-48.	5.9	20
1663	AZD9291 overcomes T790ÂM-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells. Investigational New Drugs, 2016, 34, 407-415.	2.6	13
1664	Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. Oncolmmunology, 2016, 5, e1168549.	4.6	15
1665	Emerging treatment for ALK-positive lung cancer. Expert Opinion on Emerging Drugs, 2016, 21, 147-155.	2.4	4
1666	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	28.8	49
1667	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. Drugs, 2016, 76, 831-840.	10.9	13
1668	The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. Pathology and Oncology Research, 2016, 22, 755-761.	1.9	3
1669	PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Reports, 2016, 15, 843-856.	6.4	46
1670	Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 5505-5512.	3.0	24
1671	Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. Journal of Nanobiotechnology, 2016, 14, 47.	9.1	68
1672	Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. British Journal of Cancer, 2016, 115, 1069-1077.	6.4	26
1673	Acquired <i>MET</i> D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery, 2016, 6, 1334-1341.	9.4	133
1674	Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells. Oncology Research, 2016, 24, 295-303.	1.5	49
1675	Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment. Biochemical and Biophysical Research Communications, 2016, 479, 393-397.	2.1	3
1676	Sporoderm-Broken Spores of <i>Ganoderma lucidum</i> Inhibit the Growth of Lung Cancer: Involvement of the Akt/mTOR Signaling Pathway. Nutrition and Cancer, 2016, 68, 1151-1160.	2.0	21
1677	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4- <i>d</i>]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of Medicinal Chemistry, 2016, 59, 8103-8124.	6.4	52

ARTICLE IF CITATIONS Insight into the Inhibition of Drugâ€Resistant Mutants of the Receptor Tyrosine Kinase EGFR. 13.8 1678 54 Angewandte Chemie - International Edition, 2016, 55, 10909-10912. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. 1679 3.1 Endocrine-Related Cancer, 2016, 23, R337-R352. Evaluation of a novel salivaâ€based epidermal growth factor receptor mutation detection for lung 1680 1.9 64 cancer: A pilot study. Thoracic Cancer, 2016, 7, 428-436. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ cancer antibodies: 1681 IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424. Combined inhibition of <scp>EZH</scp>2 and histone deacetylases as a potential epigenetic therapy for 1682 3.9 45 nonâ€smallâ€cell lung cancer cells. Cancer Science, 2016, 107, 955-962. Rebiopsy for patients with nonâ€smallâ€cell lung cancer after epidermal growth factor receptorâ€tyrosine kinase inhibitor failure. Cancer Science, 2016, 107, 1001-1005. An HPLC method for the determination of a novel antiâ€hypertension agent 6,7â€dimethoxyâ€3â€[4â€(4â€fluorobenzyloxy)â€3â€methoxyphenylmethyl]quinazolinâ€4(3<i>H</i>)â€one in rat.⊅lasma: 2 1684 application to pharmacokinetic study. Biomedical Chromatography, 2016, 30, 1118-1123. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Molecular Cancer Therapeutics, 1685 4.1 2016, 15, 2586-2597. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, 1686 13.7 132 The, 2016, 388, 1002-1011. Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. Journal of 6.4 Medicinal Chemistry, 2016, 59, 9080-9093. Resistance to Therapy. Cancer Treatment and Research, 2016, 170, 183-202. 1688 0.5 10 Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt 1689 2.6 signaling pathway. Experimental Cell Research, 2016, 349, 320-327. Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung 1690 2.0 35 adenocarcinoma patients signifies a poor response to EGFR-TKIs. Lung Cancer, 2016, 102, 101-107. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. International Journal of Oncology, 2016, 49, 1576-1588. 3.3 38 Discovery of $(\langle i \rangle R \langle i \rangle, \langle i \rangle E \langle i \rangle) - \langle i \rangle N \langle i \rangle - (7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 \langle i \rangle H \langle i \rangle - (7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 \langle i \rangle H \langle i \rangle - (7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 \langle i \rangle - (7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1 \langle i \rangle - (7-Chloro-1-(1-[4-(dimethylamino)but-2-(i)(1-[4-(dimethylamino)but-2-(i)($ 1693 (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and 6.4 80 Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. Journal of Medicinal Chemistry, 2016, 59, 6671-6689 Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) \tilde{A} - c-MET 1694 Antibodies and Antibody-Drug Conjugates. Journal of Biological Chemistry, 2016, 291, 25106-25119. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open, 2016, 1, 1696 4.5 38 e000078. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15â€...years of clinical evidence. ESMO Open, 2016, 1, 4.5 e000088.

#	Article	IF	CITATIONS
1698	Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Cell Discovery, 2016, 2, 16031.	6.7	26
1699	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer, 2016, 16, 864.	2.6	41
1700	The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1337-1351.	3.1	18
1701	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. Scientific Reports, 2016, 6, 35249.	3.3	33
1702	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2016, 2, 16018.	30.5	1,863
1703	Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer. Scientific Reports, 2016, 6, 27514.	3.3	8
1704	Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Scientific Reports, 2016, 6, 29093.	3.3	16
1705	Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics. Proteome Science, 2016, 14, 12.	1.7	13
1706	Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncology Letters, 2016, 12, 4009-4012.	1.8	15
1707	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	12.8	520
1708	An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Scientific Reports, 2016, 6, 22120.	3.3	11
1709	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Scientific Reports, 2016, 6, 20913.	3.3	197
1710	Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays. Integrative Biology (United Kingdom), 2016, 8, 1221-1231.	1.3	10
1711	Comparative chemical array screening for p38γ/l̃´ MAPK inhibitors using a single gatekeeper residue difference between p38α/l̃² and p38l³/l̃´. Scientific Reports, 2016, 6, 29881.	3.3	8
1712	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v1-v27.	1.2	1,351
1713	Integrating cancer genomic data into electronic health records. Genome Medicine, 2016, 8, 113.	8.2	57
1714	Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest. Molecular Medicine Reports, 2016, 13, 2878-2884.	2.4	34
1715	ls it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?. Medicine (United States), 2016, 95, e5115.	1.0	6

#	Article	IF	CITATIONS
1716	Impact of bevacizumab in combination with erlotinib on <scp><i>EGFR</i></scp> â€mutated non–small cell lung cancer xenograft models with <scp>T790M</scp> mutation or <scp><i>MET</i></scp> amplification. International Journal of Cancer, 2016, 138, 1024-1032.	5.1	35
1717	Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics, 2016, 15, 743-752.	4.1	144
1718	Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Cancer Letters, 2016, 379, 124-133.	7.2	51
1719	Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. SpringerPlus, 2016, 5, 531.	1.2	27
1720	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. Cancer Research, 2016, 76, 3942-3953.	0.9	165
1721	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
1722	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	3.2	25
1723	Emerging Role of mTOR in the Response to Cancer Therapeutics. Trends in Cancer, 2016, 2, 241-251.	7.4	95
1724	Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. BMC Cancer, 2016, 16, 147.	2.6	12
	Protein-structure-guided discovery of functional mutations across 19 cancer types. Nature Constice		
1725	2016, 48, 827-837.	21.4	128
1725 1726	2016, 48, 827-837. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429.	21.4 0.9	128 29
1725 1726 1727	 IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374. 	21.4 0.9 1.5	128 29 49
1725 1726 1727 1728	INDERFORMET Structure guided discovery of functional inductions across 19 cancer types. Nature Oeneucs, 2016, 48, 827-837. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Nonâ€"Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition, 2016, 44, 1201-1212.	21.4 0.9 1.5 3.3	128 29 49 94
1725 1726 1727 1728 1729	Note: Proteinstructure guided discovery of functional inductions across 15 cancer types. Nature Genetics, 2016, 48, 827-837. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Nonâ€"Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition, 2016, 44, 1201-1212. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Reports, 2016, 14, 772-781.	21.4 0.9 1.5 3.3 6.4	128 29 49 94 40
1725 1726 1727 1728 1729 1730	2016, 48, 827-837. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Nonâ€"Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition, 2016, 44, 1201-1212. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Reports, 2016, 14, 772-781. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2016, 24, 2871-2881.	21.4 0.9 1.5 3.3 6.4 3.0	128 29 49 94 40 25
1725 1726 1727 1728 1729 1730	INDEFINITION Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinase Cell Reports, 2016, 14, 772-781. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of ECFR including the T790M/L858R Circulating Tumor DNAâ€" the Potential of Liquid Biopsies. Current Breast Cancer Reports, 2016, 8, 14-21.	21.4 0.9 1.5 3.3 6.4 3.0 1.0	128 29 49 94 40 25 2
1725 1726 1727 1728 1729 1730 1731	Note: Structure galaced discovery of numerous across 15 cancer types: Nature Generics, 2016, 48, 827-837. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non〓Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Research, 2016, 76, 4418-4429. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition, 2016, 44, 1201-1212. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Reports, 2016, 14, 772-781. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2016, 24, 2871-2881. Circulating Tumor DNA— the Potential of Liquid Biopsies. Current Breast Cancer Reports, 2016, 8, 14-21. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research, 2016, 76, 305-318.	 21.4 0.9 1.5 3.3 6.4 3.0 1.0 0.9 	128 29 49 94 40 25 2 2 98

	CHATION	REFORT	
#	Article	IF	CITATIONS
1734	Target Therapy in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 127-136.	1.6	18
1735	Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. European Journal of Clinical Pharmacology, 2016, 72, 1-11.	1.9	72
1736	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2016, 17, 452-463.	10.7	418
1737	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	1.3	54
1738	Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis. JAMA - Journal of the American Medical Association, 2016, 315, 1266.	7.4	113
1739	Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation. Journal of Thoracic Oncology, 2016, 11, 1051-1063.	1.1	58
1740	Dynamics of circulating tumor <scp>DNA</scp> represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. Cancer Science, 2016, 107, 353-358.	3.9	28
1741	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	17.5	837
1742	Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2016, 59, 6580-6594.	6.4	84
1743	Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1571-1575.	2.2	29
1744	Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 112, 298-346.	5.5	55
1745	Treatment modalities for advanced <i>ALK</i> -rearranged non-small-cell lung cancer. Future Oncology, 2016, 12, 945-961.	2.4	17
1746	Activating Mutations in <i>PIK3CB</i> Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. Cancer Research, 2016, 76, 1193-1203.	0.9	52
1747	Molecular Imaging of Biomarkers in Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 53S-59S.	5.0	56
1748	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine, 2016, 8, 324ra14.	12.4	81
1749	Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. European Journal of Medicinal Chemistry, 2016, 110, 195-203.	5.5	24
1750	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 2016, 22, 262-269.	30.7	768
1751	EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Research, 2016, 76, 1591-1602.	0.9	103

#	Article	IF	CITATIONS
1752	Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy, 2016, 61, 223-235.	1.6	57
1753	Molecular pathology in real time. Cancer and Metastasis Reviews, 2016, 35, 129-140.	5.9	26
1754	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. British Journal of Cancer, 2016, 114, 616-622.	6.4	17
1755	The Pitfalls of Companion Diagnostics. Journal of Molecular Diagnostics, 2016, 18, 331-335.	2.8	1
1756	Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 547-556.	2.5	9
1757	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	3.2	40
1758	The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opinion on Therapeutic Targets, 2016, 20, 737-753.	3.4	82
1759	The Microenvironment of Lung Cancer and Therapeutic Implications. Advances in Experimental Medicine and Biology, 2016, 890, 75-110.	1.6	96
1760	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
1761	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Review of Anticancer Therapy, 2016, 16, 147-157.	2.4	33
1762	Opportunities and challenges in combination gene cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 35-40.	13.7	64
1763	Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Advances in Experimental Medicine and Biology, 2016, 890, 37-56.	1.6	66
1764	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research, 2016, 22, 2139-2145.	7.0	30
1765	4-Aminoindazolyl-dihydrofuro[3,4- d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 534-539.	2.2	42
1766	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene, 2016, 35, 2949-2960.	5.9	60
1767	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	5.0	31
1768	Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90–EGFR association. Oncogene, 2016, 35, 3387-3398.	5.9	42
1769	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting, 2016, 24, 373-385.	4.4	21

#	Article	IF	CITATIONS
1770	Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-NaÃ⁻ve EGFR L858R-Induced Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 426-435.	7.0	46
1771	Detection of T790M, the Acquired Resistance <i>EGFR</i> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 2016, 22, 1103-1110.	7.0	326
1772	Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Oncogene, 2016, 35, 621-630.	5.9	37
1773	Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. International Journal of Cancer, 2016, 138, 525-532.	5.1	53
1774	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
1775	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66, 530-540.	12.1	161
1776	In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: from mutational analysis to drug designing. Journal of Biomolecular Structure and Dynamics, 2017, 35, 427-434.	3.5	19
1777	Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model. Molecular Carcinogenesis, 2017, 56, 94-105.	2.7	24
1778	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Clinical Cancer Research, 2017, 23, 677-686.	7.0	58
1779	An Eigen-Binding Site Based Method for the Analysis of Anti-EGFR Drug Resistance in Lung Cancer Treatment. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2017, 14, 1187-1194.	3.0	10
1780	Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nature Reviews Clinical Oncology, 2017, 14, 57-66.	27.6	239
1781	The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer. Science Signaling, 2017, 10, .	3.6	41
1782	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	3.2	49
1783	Epidermal growth factor receptor (EGFR)—MAPK—nuclear factor(NF)â€̂ºB—IL8: A possible mechanism of particulate matter(PM) 2.5â€induced lung toxicity. Environmental Toxicology, 2017, 32, 1628-1636.	4.0	37
1784	<i>SOX2</i> promotes lineage plasticity and antiandrogen resistance in <i>TP53</i> - and <i>RB1</i> -deficient prostate cancer. Science, 2017, 355, 84-88.	12.6	759
1785	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 281-285.	2.6	35
1786	A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 340-343.	2.6	19
1787	Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival. Clinical Lung Cancer, 2017, 18, 421-431.e3.	2.6	12

#	Article	IF	CITATIONS
1788	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
1789	Role of Imaging in the Era of Precision Medicine. Academic Radiology, 2017, 24, 639-649.	2.5	52
1790	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opinion on Pharmacotherapy, 2017, 18, 295-304.	1.8	12
1791	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21.		123
1792	Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. Chemistry and Biodiversity, 2017, 14, e1600372.	2.1	15
1793	Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncology, 2017, 13, 787-797.	2.4	31
1794	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacological Research, 2017, 117, 406-415.	7.1	55
1795	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Scientific Reports, 2017, 7, 40847.	3.3	54
1796	The feasibility of using mutation detection in ctDNA to assess tumor dynamics. International Journal of Cancer, 2017, 140, 2642-2647.	5.1	82
1797	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 2361-2372.	6.4	43
1798	Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer. International Journal of Cancer, 2017, 140, 2596-2607.	5.1	35
1799	Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2017, 77, 2078-2089.	0.9	126
1800	A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood Cancer Journal, 2017, 7, e529-e529.	6.2	11
1801	Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies. Cancer Treatment Reviews, 2017, 54, 122-131.	7.7	46
1802	Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer. Lung Cancer, 2017, 108, 96-102.	2.0	29
1803	Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Science Translational Medicine, 2017, 9, .	12.4	62
1804	An Acquired <i>HER2</i> â€^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	9.4	85
1805	Discovery of (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidin-1-y (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. lournal of Medicinal Chemistry, 2017, 60, 2944-2962.	l)piperidin 6.4	-1-yl)prop-2

#	Article	IF	CITATIONS
1807	Molecular mechanisms of therapy resistance in solid tumors: chasing "moving―targets. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 155-164.	2.8	12
1808	Identification of spirobisnaphthalene derivatives with anti-tumor activities from the endophytic fungus Rhytidhysteron rufulum AS21B. Bioorganic and Medicinal Chemistry, 2017, 25, 2878-2882.	3.0	41
1809	Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1784-1788.	2.2	11
1810	A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends in Pharmacological Sciences, 2017, 38, 427-437.	8.7	68
1811	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer. Lung Cancer, 2017, 108, 75-82.	2.0	37
1812	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Targeted Oncology, 2017, 12, 153-161.	3.6	31
1813	Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non–small Cell Lung Cancer. Clinical Therapeutics, 2017, 39, 610-619.	2.5	2
1814	Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. Oncogene, 2017, 36, 3661-3672.	5.9	34
1815	Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 1366-1376.	4.1	23
1817	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist, 2017, 22, 576-584.	3.7	39
1818	EGFR T790M mutation testing within the osimertinib AURA Phase I study. Lung Cancer, 2017, 109, 9-13.	2.0	20
1819	Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. European Journal of Medicinal Chemistry, 2017, 142, 32-47.	5.5	119
1820	Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients. Clinical and Translational Oncology, 2017, 19, 1283-1291.	2.4	30
1821	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping. Journal of Medicinal Chemistry, 2017, 60, 4636-4656.	6.4	56
1822	Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 147-154.	2.8	41
1823	Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer, 2017, 109, 137-144.	2.0	120
1824	Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 101-111.	2.2	32
1825	The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations. Oncogene, 2017, 36, 2824-2834.	5.9	39

#	Article	IF	CITATIONS
1826	Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC. Scientific Reports, 2017, 7, 3121.	3.3	22
1827	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. Npj Precision Oncology, 2017, 1, .	5.4	70
1828	Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer. Cancer Research, 2017, 77, 3527-3539.	0.9	42
1829	Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1288-1295.	2.5	7
1830	Plasma genotyping in patients with non-small-cell lung cancer: simplifying or confusing the diagnosis?. Lung Cancer Management, 2017, 6, 29-37.	1.5	0
1831	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2017, 23, 5101-5111.	7.0	126
1832	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Medical Oncology, 2017, 34, 121.	2.5	12
1833	Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Research, 2017, 77, 3908-3921.	0.9	56
1834	JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2017, 16, 1645-1657.	4.1	18
1835	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. Journal of Medicinal Chemistry, 2017, 60, 5613-5637.	6.4	77
1836	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	3.2	30
1837	Drug-biomarker co-development in oncology – 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	14.4	48
1838	MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells. Oncogenesis, 2017, 6, e307-e307.	4.9	42
1839	An LC–MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 141, 9-18.	2.8	4
1840	A large, singleâ€center, realâ€world study of clinicopathological characteristics and treatment in advanced <scp>ALK</scp> â€positive nonâ€smallâ€cell lung cancer. Cancer Medicine, 2017, 6, 953-961.	2.8	15
1841	Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. Bioorganic and Medicinal Chemistry, 2017, 25, 2713-2723.	3.0	32
1842	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer, 2017, 108, 109-114.	2.0	36
1843	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer, 2017, 108, 154-160.	2.0	18

#	Article	IF	CITATIONS
1844	Integrative analysis of multi-omics data reveals distinct impacts of DDB1-CUL4 associated factors in human lung adenocarcinomas. Scientific Reports, 2017, 7, 333.	3.3	15
1845	Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular and Cellular Proteomics, 2017, 16, 891-910.	3.8	42
1846	Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model. Anti-Cancer Drugs, 2017, 28, 480-488.	1.4	3
1847	Drug Resistance in Cancer. , 2017, , 449-473.		2
1848	HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER. , 2017, 22, 414-425.		1
1849	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 201-216.	3.2	30
1850	Non-reproducible sequence artifacts in FFPE tissue: an experience report. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1199-1207.	2.5	10
1851	Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy. Cancer Drug Discovery and Development, 2017, , 105-118.	0.4	0
1852	SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer, 2017, 106, 50-57.	2.0	49
1853	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports, 2017, 7, 44206.	3.3	28
1854	Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular Cancer Research, 2017, 15, 915-928.	3.4	37
1855	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026617.	6.2	59
1856	Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine and Pharmacotherapy, 2017, 90, 24-37.	5.6	45
1858	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 612-623.	1.1	203
1859	Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 159-165.	3.4	28
1860	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029587.	6.2	15
1861	Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clinical Lung Cancer, 2017, 18, e233-e241.	2.6	30
1862	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. Journal of Clinical Oncology, 2017, 35, 243-252.	1.6	19

#	Article	IF	CITATIONS
1863	The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR. Biochemical Pharmacology, 2017, 126, 51-68.	4.4	18
1864	Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism–Mediated Osimertinib Resistance in <i>EGFR-</i> Mutant Lung Cancer. Clinical Cancer Research, 2017, 23, 3139-3149.	7.0	69
1865	Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658.	28.4	679
1866	Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicology and Applied Pharmacology, 2017, 335, 16-27.	2.8	17
1867	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clinical Cancer Research, 2017, 23, 7467-7473.	7.0	26
1868	Gefitinib: an "orphan―drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.8	2
1869	Genomics alterations of metastatic and primary tissues across 15 cancer types. Scientific Reports, 2017, 7, 13262.	3.3	20
1870	Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM). Cancer Biomarkers, 2017, 20, 581-588.	1.7	4
1871	Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Molecular Cancer Therapeutics, 2017, 16, 2572-2585.	4.1	26
1872	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 7725-7744.	6.4	24
1873	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	2.8	29
1874	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. Oncology Letters, 2017, 14, 3559-3565.	1.8	10
1875	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer, 2017, 113, 51-58.	2.0	16
1876	Synthesis, biological evaluation and mechanism studies of matrine derivatives as anticancer agents. Oncology Letters, 2017, 14, 3057-3064.	1.8	9
1877	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical Oncology, 2017, 34, 175.	2.5	5
1878	Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. Journal of Molecular Diagnostics, 2017, 19, 801-804.	2.8	64
1879	A case of resistance to tyrosine kinase inhibitor therapy. Anti-Cancer Drugs, 2017, 28, 1056-1061.	1.4	10
1880	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	9.4	158

#	Article	IF	CITATIONS
1881	Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer, 2017, 111, 182-189.	2.0	30
1882	Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. Critical Reviews in Oncology/Hematology, 2017, 117, 38-47.	4.4	85
1883	Sigma1 Pharmacology in the Context of Cancer. Handbook of Experimental Pharmacology, 2017, 244, 237-308.	1.8	54
1884	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas ® EGFR mutation test. Lung Cancer, 2017, 111, 190-194.	2.0	13
1885	Cancer Clonal Evolution and Intra-tumor Heterogeneity. Current Clinical Pathology, 2017, , 27-39.	0.0	1
1886	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	1.1	21
1887	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical Cancer Research, 2017, 23, 6661-6672.	7.0	110
1888	Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non-small cell lung carcinoma. Oncology Letters, 2017, 14, 2249-2253.	1.8	11
1889	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Scientific Reports, 2017, 7, 6595.	3.3	29
1890	Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors. Oncology Letters, 2017, 14, 2191-2197.	1.8	16
1891	Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. European Journal of Medicinal Chemistry, 2017, 142, 271-289.	5.5	167
1892	Chemotherapeutics-resistance "arms―race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer. Life Sciences, 2017, 186, 25-32.	4.3	17
1893	A method of high-throughput functional evaluation of <i>EGFR</i> gene variants of unknown significance in cancer. Science Translational Medicine, 2017, 9, .	12.4	168
1894	Personalised medicine for nonsmall cell lung cancer. European Respiratory Review, 2017, 26, 170066.	7.1	37
1895	Proteasome-associated deubiquitinases and cancer. Cancer and Metastasis Reviews, 2017, 36, 635-653.	5.9	78
1896	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia, 2017, 19, 1012-1021.	5.3	77
1897	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Science Translational Medicine, 2017, 9, .	12.4	96
1898	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194.	7.2	27

		CITATION REPORT		
#	Article		IF	Citations
1899	From academia to industry: a road more travelled. Annals of Oncology, 2017, 28, 2312	2-2314.	1.2	4
1900	Evaluation of gefitinib efficacy according to body mass index, body surface area, and b patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemothera Pharmacology, 2017, 79, 497-505.	ody weight in py and	2.3	16
1901	Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging therapeutic targets. MAbs, 2017, 9, 1118-1128.	multiple	5.2	32
1902	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-c overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 2017, 28	ell lung cancer: , 270-277.	1.2	425
1903	Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated model. International Journal of Oncology, 2017, 51, 425-434.	NSCLC xenograft	3.3	68
1904	Application of nonsense-mediated primer exclusion (NOPE) for preparation of unique barcoded libraries. BMC Genomics, 2017, 18, 440.	molecular	2.8	2
1905	Strategies for monitoring and combating resistance to combination kinase inhibitors f therapy. Genome Medicine, 2017, 9, 37.	or cancer	8.2	52
1906	Osimertinib-related skin and mucosal adverse events. Cancer Treatment and Research Communications, 2017, 12, 53-55.		1.7	1
1907	Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killin cells. MAbs, 2017, 9, 114-126.	g of lung cancer	5.2	58
1908	Imaging biobanks in oncology: European perspective. Future Oncology, 2017, 13, 433	-441.	2.4	25
1909	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Lung Cancer and the Role of Biopsy at Progression. Oncologist, 2017, 22, 3-11.	Non-Small Cell	3.7	34
1910	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Annua Cancer Biology, 2017, 1, 257-274.	l Review of	4.5	4
1911	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer Journal of Cancer, 2017, 70, 12-21.	r. European	2.8	36
1912	Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heteroger resistance. Protein and Cell, 2017, 8, 178-190.	eity, and drug	11.0	22
1913	Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC with EGFR-TKIs. Clinical and Translational Oncology, 2017, 19, 332-340.	patients treated	2.4	72
1914	Pathology and Molecular Pathology of Lung Cancer. , 2017, , 367-390.			1
1915	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adend with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2017, 12, 102-104	ocarcinomas 9.	1.1	40
1916	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Per Non–Small Cell Lung Cancer Cells Following EGFR Inhibition. Clinical Cancer Researc 1531-1541.	sistence of h, 2017, 23,	7.0	46

#	Article	IF	CITATIONS
1917	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 31-38.	3.1	23
1918	Targeting <i>EGFR</i> mutation in non-small-cell lung cancer: challenges and future perspectives. Future Oncology, 2017, 13, 201-204.	2.4	3
1919	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: ProposalÂfrom the Bench. Journal of Thoracic Oncology, 2017, 12, 27-35.	1.1	24
1920	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. Oncology Letters, 2017, 14, 5947-5951.	1.8	16
1921	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Reports, 2017, 21, 3298-3309.	6.4	157
1922	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
1923	Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells <i>via</i> IL-6/STAT3 Pathway Inhibition. Biological and Pharmaceutical Bulletin, 2017, 40, 1306-1313.	1.4	47
1924	Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles. Cancer Nanotechnology, 2017, 8, 7.	3.7	39
1925	Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR†́TKI. Oncology Letters, 2017, 15, 901-907.	1.8	13
1926	Lentivirus-mediated silencing of HOTAIR IncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma. Oncology Letters, 2018, 15, 2829-2838.	1.8	23
1927	Tissue-Agnostic Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 222-230.	3.8	25
1928	Concurrent T790M and L858R mutations in treatment-naÃ⁻ve metastatic non-small-cell lung cancer: A therapeutic challenge – Current treatment strategies and promising therapies of the future in a nutshell. Asian Journal of Oncology, 0, 03, 087-091.	0.2	Ο
1929	Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. Chinese Medical Journal, 2017, 130, 1446-1453.	2.3	1
1930	The Importance of EGFR Mutation Detection Method for the Correct Clinical Management of Patients with Non-Small Cell Lung Cancer: A Case Report. , 2017, 07, .		Ο
1931	The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. Journal of Cancer, 2017, 8, 1865-1871.	2.5	8
1933	Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology, 2017, 24, 111-119.	2.2	19
1934	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. International Journal of Molecular Sciences, 2017, 18, 1374.	4.1	47
1935	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology, 2017, 7, 97.	2.8	12

#	Article	IF	CITATIONS
1936	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. ELife, 2017, 6, .	6.0	154
1937	Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 1527-1533.	2.0	13
1938	Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 2017, 8, 16052-16074.	1.8	245
1939	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125.	2.7	49
1940	The resistance mechanisms and treatment strategies for <i>EGFR</i> -mutant advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 71358-71370.	1.8	51
1941	M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. PLoS ONE, 2017, 12, e0175514.	2.5	12
1942	Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI. PLoS ONE, 2017, 12, e0187824.	2.5	8
1944	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	12.8	117
1945	AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways. Journal of Hematology and Oncology, 2017, 10, 172.	17.0	11
1946	PKPD modeling of acquired resistance to anti-cancer drug treatment. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 617-630.	1.8	12
1947	BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget, 2017, 8, 39945-39962.	1.8	29
1948	EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets and Therapy, 2017, Volume 8, 147-159.	2.7	23
1949	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers, 2017, 9, 35.	3.7	85
1950	Managing Resistance to EFGR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 607-618.	3.8	16
1951	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. Journal of Clinical Oncology, 2017, 35, 3065-3074.	1.6	349
1952	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?. Journal of Clinical Oncology, 2017, 35, 692-693.	1.6	1
1953	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget, 2017, 8, 75712-75726.	1.8	119
1954	Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget, 2017, 8, 114371-114392.	1.8	96

#	Article	IF	CITATIONS
1955	The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis. Journal of Thoracic Disease, 2017, 9, 1980-1987.	1.4	7
1956	The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR. Journal of Thoracic Disease, 2017, 9, 2397-2403.	1.4	13
1957	Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1323-S1331.	1.4	19
1958	Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Translational Lung Cancer Research, 2017, 6, S21-S34.	2.8	9
1959	Raising the bar: the future of EGFR inhibition in non-small lung cancer. Translational Lung Cancer Research, 2017, 6, S58-S61.	2.8	0
1960	Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Annals of Oncology, 2018, 29, i28-i37.	1.2	95
1961	Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. ESMO Open, 2018, 3, e000292.	4.5	15
1962	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 740-750.	4.1	27
1963	Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts. Oncology Letters, 2018, 15, 4676-4682.	1.8	2
1964	Insights from Large-Scale Cancer Genome Sequencing. Annual Review of Cancer Biology, 2018, 2, 429-444.	4.5	5
1965	EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790â€ [−] M resistant mutation in lung cancer cells. Cancer Letters, 2018, 424, 84-96.	7.2	14
1966	Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Scientific Reports, 2018, 8, 3482.	3.3	19
1967	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. Clinical Cancer Research, 2018, 24, 2138-2147.	7.0	21
1968	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	7.0	357
1969	Combination TSâ€1 plus EGFRâ€tyrosine kinase inhibitors (TKIs) for the treatment of nonâ€small cell lung cancer after progression on firstâ€line or further EGFRâ€TKIs: A phase II, singleâ€arm trial. Thoracic Cancer, 2018, 9, 693-698.	1.9	3
1970	Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 152, 327-337.	4.4	27
1971	Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine and Growth Factor Reviews, 2018, 41, 18-27.	7.2	22
1972	Ramanâ€mikrospektroskopischer Nachweis für den Metabolismus eines Tyrosinkinaseâ€Inhibitors, Neratinib, in Krebszellen. Angewandte Chemie, 2018, 130, 7370-7374.	2.0	9
#	Article	IF	CITATIONS
------	---	------	-----------
1973	Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 29-49.	0.1	0
1974	Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. Angewandte Chemie - International Edition, 2018, 57, 7250-7254.	13.8	67
1975	Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib. Journal of Physical Chemistry B, 2018, 122, 4680-4692.	2.6	12
1976	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1740-1750.	3.0	17
1978	Computational Analysis of Epidermal Growth FactorÂReceptor Mutations Predicts Differential DrugÂSensitivity Profiles toward Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 721-726.	1.1	11
1979	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology, 2018, 29, i10-i19.	1.2	449
1980	Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor. Journal of Receptor and Signal Transduction Research, 2018, 38, 48-60.	2.5	10
1981	Targeting EGFR ^{L858R/T790M} and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	10.5	113
1982	Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775333.	3.2	41
1983	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. Oncology Letters, 2018, 15, 3726-3734.	1.8	6
1984	lmpact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181.	46.4	294
1985	Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical Pharmacology in Drug Development, 2018, 7, 532-542.	1.6	17
1986	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	4.5	15
1987	Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis. JAMA Oncology, 2018, 4, 671.	7.1	61
1989	Prediction of response to targeted and immune checkpoint therapies. Personalized Medicine, 2018, 15, 45-56.	1.5	0
1990	Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. Critical Reviews in Oncology/Hematology, 2018, 122, 150-156.	4.4	36
1991	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer, 2018, 124, 1008-1015.	4.1	42
1992	High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Scientific Reports, 2018, 8, 418.	3.3	88

#	Article	IF	CITATIONS
1993	Size-based separation methods of circulating tumor cells. Advanced Drug Delivery Reviews, 2018, 125, 3-20.	13.7	163
1994	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. Cancer Chemotherapy and Pharmacology, 2018, 81, 443-453.	2.3	10
1995	MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription. Tumori, 2018, 104, 221-231.	1.1	10
1996	A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers, 2018, 22, 333-344.	1.7	3
1997	Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics, 2018, 19, 88.	2.6	20
1998	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC Cancer, 2018, 18, 191.	2.6	14
1999	Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma. Journal of Proteomics, 2018, 189, 48-59.	2.4	8
2000	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Lung Cancer, 2018, 121, 12-17.	2.0	23
2001	Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiotherapy and Oncology, 2018, 129, 52-60.	0.6	32
2002	Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering, 2018, 2, 239-253.	22.5	18
2003	AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis. Radiation Research, 2018, 189, 283-291.	1.5	10
2004	In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition. Computational Biology and Chemistry, 2018, 74, 167-189.	2.3	19
2005	Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 3267-3279.	0.9	31
2006	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	4.9	476
2007	Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clinical Lung Cancer, 2018, 19, e431-e438.	2.6	14
2008	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab on A Chip, 2018, 18, 1174-1196.	6.0	234
2009	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. Clinical Lung Cancer, 2018, 19, 93-104.	2.6	41
2010	Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clinical Lung Cancer, 2018, 19, 35-41.	2.6	9

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2011	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice challenges, and insights. Medicinal Research Reviews, 2018, 38, 325-376.	gaps,	10.5	50
2012	Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit E0 activation. Bioorganic and Medicinal Chemistry, 2018, 26, 1167-1173.	JFR	3.0	14
2013	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.			0
2014	Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An up of recent medicinal chemistry efforts. European Journal of Medicinal Chemistry, 2018, 143, 449	odate 463.	5.5	46
2015	<i>In silico</i> evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib. Journal of Biomolecular Structure and Dynamics, 2018, 4209-4219.	36,	3.5	11
2016	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applicati 2018, , 1-32.	ons,	0.1	0
2017	An oligoclonal antibody durably overcomes resistance of lung cancer to thirdâ€generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.		6.9	46
2018	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. Curr Cancer Research, 2018, , 243-280.	ent	0.2	0
2019	Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Upt Lung Cancer. Journal of Proteome Research, 2018, 17, 63-75.	ake in	3.7	18
2020	EGFR Mutational Profiling in Non–Small Cell Lung Cancer: The Clinical Performance of a Sensi Reverse-Hybridization Assay. Applied Immunohistochemistry and Molecular Morphology, 2018, 388-392.	ive 26,	1.2	0
2021	Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790 inhibitors. Journal of Receptor and Signal Transduction Research, 2018, 38, 393-412.	M EGFR	2.5	21
2022	Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. Oncotarget, 2018, 9, 37520-37533.		1.8	7
2023	Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 act and EGFR downregulation. BMB Reports, 2018, 51, 27-32.	ivation	2.4	9
2024	Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i> -Mutant Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-29.		3.0	49
2025	Characterization of the Epidermal Growth Factor Receptor T790M Mutation in Colorectal Cance Precision Oncology, 2018, 2, 1-7.	r. JCO	3.0	1
2026	Selective gene amplification to detect the T790M mutation in plasma from patients with advan- non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyros kinase inhibitor (EGFR-TKI) resistance. Journal of Thoracic Disease, 2018, 10, 1431-1439.	red ine	1.4	9
2027	Inherited lung cancer syndromes targeting never smokers. Translational Lung Cancer Research, 7, 498-504.	2018,	2.8	31
2028	Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of ep growth factor receptor explored by molecular dynamics simulations. RSC Advances, 2018, 8, 39797-39810.	dermal	3.6	13

#	Article	IF	CITATIONS
2029	Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells. JCI Insight, 2018, 3, .	5.0	26
2030	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	3.0	2
2031	Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. BMC Complementary and Alternative Medicine, 2018, 18, 293.	3.7	37
2032	Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. PLoS ONE, 2018, 13, e0207001.	2.5	17
2033	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells, 2018, 7, 212.	4.1	190
2034	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE, 2018, 13, e0208097.	2.5	17
2035	A digital PCR assay development to detect EGFR T790M mutation in NSCLC patients. Frontiers in Laboratory Medicine, 2018, 2, 89-96.	1.7	9
2036	BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B. BMC Biology, 2018, 16, 150.	3.8	43
2037	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. Marine Drugs, 2018, 16, 506.	4.6	17
2038	CAGE Binds to Beclin1, Regulates Autophagic Flux and CAGE-Derived Peptide Confers Sensitivity to Anti-cancer Drugs in Non-small Cell Lung Cancer Cells. Frontiers in Oncology, 2018, 8, 599.	2.8	24
2039	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers, 2018, 10, 503.	3.7	44
2040	Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Analytical Cellular Pathology, 2018, 2018, 1-9.	1.4	35
2041	Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. Oncotarget, 2018, 9, 15418-15434.	1.8	21
2042	Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. Cancers, 2018, 10, 483.	3.7	120
2043	EGFR Role in Cancer: A Potential Therapeutic Target. , 2018, , 225-234.		1
2044	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	1.8	6
2045	Glycoproteomic Alterations in Drug-Resistant Nonsmall Cell Lung Cancer Cells Revealed by Lectin Magnetic Nanoprobe-Based Mass Spectrometry. Journal of Proteome Research, 2018, 17, 3761-3773.	3.7	26
2046	Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2018, 19, 58.	3.0	41

#	Article	IF	CITATIONS
2047	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2457-2463.	2.5	8
2048	Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. European Journal of Cancer, 2018, 103, 165-175.	2.8	40
2049	Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and Cell Biology, 2018, 37, 903-908.	1.9	2
2050	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	9.4	71
2051	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer, 2018, 126, 112-118.	2.0	14
2052	Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget, 2018, 9, 13652-13665.	1.8	31
2053	Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. Scientific Reports, 2018, 8, 15278.	3.3	26
2054	Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Scientific Reports, 2018, 8, 15426.	3.3	12
2055	miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1. Oncology Research, 2018, 26, 1191-1200.	1.5	19
2056	A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction. Cancer Management and Research, 2018, Volume 10, 3069-3082.	1.9	18
2057	Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in <i>EGFR</i> â€mutant non–small cell lung cancer: Multicenter, singleâ€arm, phase 2 trial (ABC Study). Cancer, 2018, 124, 3830-3838.	4.1	37
2058	Stem cell fate in cancer growth, progression and therapy resistance. Nature Reviews Cancer, 2018, 18, 669-680.	28.4	458
2059	Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients. Analytical Chemistry, 2018, 90, 11203-11209.	6.5	24
2060	LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells inÃ ⁻ Â;¼2vitro by inhibiting Akt-NF-κB activation. Oncology Letters, 2018, 15, 7168-7174.	1.8	12
2061	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics, 2018, 19, 727-740.	1.3	20
2062	Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Delivery, 2018, 25, 1127-1136.	5.7	14
2064	Acquired Resistance to Drugs Targeting Tyrosine Kinases. Advances in Cancer Research, 2018, 138, 71-98.	5.0	65
2065	A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell, 2018, 33, 801-815.	16.8	181

	CITATION	Report	
#	Article	IF	CITATIONS
2066	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research, 2018, 24, 5610-5621.	7.0	43
2067	PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Cellular Physiology and Biochemistry, 2018, 47, 1909-1924.	1.6	36
2068	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature, 2018, 559, 125-129.	27.8	223
2069	Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations. BioMed Research International, 2018, 2018, 1-9.	1.9	6
2070	The lncRNA myocardial infarction associated transcript-centric competing endogenous RNA network in non-small-cell lung cancer. Cancer Management and Research, 2018, Volume 10, 1155-1162.	1.9	17
2071	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 2018, 7, 192.	2.4	27
2072	Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer. Medicinal Chemistry Research, 2018, 27, 2160-2170.	2.4	13
2073	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	2.4	21
2074	A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. Cancer Management and Research, 2018, Volume 10, 115-121.	1.9	16
2075	RASPELD to Perform Highâ€End Screening in an Academic Environment toward the Development of Cancer Therapeutics. ChemMedChem, 2018, 13, 2065-2072.	3.2	5
2076	mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Cancer Letters, 2018, 434, 152-159.	7.2	18
2077	Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA. Cancer Management and Research, 2018, Volume 10, 1209-1218.	1.9	26
2078	A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2018, 82, 541-550.	2.3	3
2079	Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicology and Applied Pharmacology, 2018, 356, 1-7.	2.8	58
2080	Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncology, 2018, 14, 29-40.	2.4	18

2081	The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. Journal of Hematology and Oncology, 2018, 11, 74.	17.0	60
2082	Epidermal growth factor receptor (<i>EGFR</i>) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in nonâ€small cell lung cancer progression during firstâ€generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Communications, 2018, 38, 1-14.	9.2	29
2083	An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression. Biochemistry, 2018, 57, 4675-4689.	2.5	37

#	Article	IF	CITATIONS
2084	Non–Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation–positive Cancer. Radiology, 2018, 289, 227-237.	7.3	19
2085	Overexpression of Napsin A resensitizes drug‑resistant lung cancer A549 cells to gefitinib by inhibiting EMT. Oncology Letters, 2018, 16, 2533-2538.	1.8	6
2086	Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 38-44.	2.2	30
2087	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.9	47
2088	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. Clinical Lung Cancer, 2018, 19, e655-e665.	2.6	7
2089	Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer. Gene, 2018, 667, 62-69.	2.2	6
2090	Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer, 2018, 17, 48.	19.2	796
2091	Label-free real-time ultrasensitive monitoring of non-small cell lung cancer cell interaction with drugs. Biomedical Optics Express, 2018, 9, 4149.	2.9	4
2092	Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 3335-3343.	2.0	20
2093	Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018, 8, 11926.	3.3	74
2094	Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nature Communications, 2018, 9, 3198.	12.8	61
2095	Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. Cell Chemical Biology, 2018, 25, 1359-1371.e2.	5.2	17
2096	EGFR T790M Mutation in TKI-NaÃ ⁻ ve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. Oncology Research and Treatment, 2018, 41, 634-642.	1.2	8
2097	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. Nature Reviews Clinical Oncology, 2018, 15, 694-708.	27.6	255
2098	Implementation of genomic medicine for gastrointestinal tumors. Annals of Gastroenterological Surgery, 2018, 2, 246-252.	2.4	0
2099	Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. Anticancer Research, 2018, 38, 3559-3566.	1.1	14
2100	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6030-E6038.	7.1	44
2101	Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opinion on Pharmacotherapy, 2018, 19, 1049-1056.	1.8	0

#	Article	IF	CITATIONS
2103	Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinibâ€Resistant Nonâ€6mall Cell Lung Cancer Cells. Proteomics, 2018, 18, e1700388.	2.2	20
2104	A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i> V600E-Mutant Brain Tumor. Cancer Discovery, 2018, 8, 1130-1141.	9.4	56
2105	Afatinib restrains K-RAS–driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
2106	A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. PLoS ONE, 2018, 13, e0199264.	2.5	16
2107	A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Angewandte Chemie - International Edition, 2019, 58, 3300-3345.	13.8	48
2108	Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. Angewandte Chemie, 2019, 131, 3336-3383.	2.0	5
2109	Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR. International Journal of Molecular Sciences, 2019, 20, 4020.	4.1	7
2110	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	7.3	45
2111	Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2019, 12, 831-840.	3.1	4
2112	Suppression of EGFR/STAT3 activity by lupeol contributes to the induction of the apoptosis of human non‑small cell lung cancer cells. International Journal of Oncology, 2019, 55, 320-330.	3.3	33
2113	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	5.9	160
2114	Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in nonâ€smallâ€cell lung carcinoma harbouring EGFR T790M mutations. British Journal of Pharmacology, 2019, 176, 4609-4624.	5.4	31
2115	Identification of ryuvidine as a KDM5A inhibitor. Scientific Reports, 2019, 9, 9952.	3.3	21
2116	Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. , 2019, 7, 172.		26
2117	Building a Hybrid Physical-Statistical Classifier for Predicting the Effect of Variants Related to Protein-Drug Interactions. Structure, 2019, 27, 1469-1481.e3.	3.3	6
2118	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	2.0	22
2119	Circular RNAs in drug resistant tumors. Biomedicine and Pharmacotherapy, 2019, 118, 109233.	5.6	63
2120	Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance. BioMed Research International, 2019, 2019, 1-10.	1.9	14

#	Article	IF	CITATIONS
2121	BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell and Bioscience, 2019, 9, 60.	4.8	9
2122	<p>Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 5467-5484.	2.0	36
2123	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics, 2019, 18, 1593-1601.	4.1	4
2124	ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT. Cancer Research, 2019, 79, 4283-4292.	0.9	21
2125	Cell signaling and cancer: a mechanistic insight into drug resistance. Molecular Biology Reports, 2019, 46, 5645-5659.	2.3	63
2126	Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case. Anticancer Research, 2019, 39, 5867-5877.	1.1	7
2127	Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2019, 18, 2124-2134.	4.1	9
2128	A case of <i>EGFR</i> mutationâ€positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFRâ€TKI treatment. Cancer Communications, 2019, 39, 1-5.	9.2	5
2129	Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. JCO Precision Oncology, 2019, 3, 1-6.	3.0	5
2130	Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer. JCO Precision Oncology, 2019, 3, 1-7.	3.0	14
2131	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Frontiers in Medicine, 2019, 6, 233	2.6	8
2132	Patientâ€derived xenograft models of nonâ€small cell lung cancer for evaluating targeted drug sensitivity and resistance. Cancer Science, 2019, 110, 3215-3224.	3.9	32
2133	Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 764.	7.4	720
2134	A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. Scientific Reports, 2019, 9, 12329.	3.3	26
2135	Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. Scientific Reports, 2019, 9, 12620.	3.3	72
2136	<p>Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 6535-6548.	2.0	26
2137	Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. Journal of Thoracic Disease, 2019, 11, 3004-3014.	1.4	22
2138	1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. European Journal of Medicinal Chemistry, 2019, 182, 111607.	5.5	26

• Atticle IP Citation 1010 Targetting Autophagy for Overcoming Resistance to Anti-EGR Treatments. Cancers, 2019, 11, 1374. 3.7 6.1 1110 Description autophagy for Overcoming Resistance to Anti-EGR Treatments. Cancers, 2019, 11, 1374. 1.8 2.0 1111 Description autophagy for Overcoming Resistance to Anti-EGR Treatments. Cancers, 2019, 11, 1374. 1.8 2.0 1111 Epidermal growth factor receptor (EGR) tyrosine lanese infibitors in non-small cell lung cancer Accessing anti-atom Edge and 2134 Classes for the autophagy for Overcommon EGR mutations. Focus on afathin. Seminars in Oncology, 2019, 46, 271-283. 2.8 0.0 11214 Definitization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106. 4.4 2.0 11214 Discovery of a Functore for Managet Epidermal Growth Factor Research (2019, 8.4). 2.8 3.0 1212 Discovery of a Functore freatment in the Frequency Domain. AAPS Journal, 2019, 21, 106. 4.4 2.0 1213 Discovery of a Functore for Managet Epidermal Growth Factor Research (2019, 8.4). 3.4 3.0 1214 Discovery of a Functore for Managet Epidermal Growth Factor Research (2019, 8.4). 3.4 3.0 1214 Discovery of a Functore for Managet Epidermal Growth Factor Research (2019, 8.4). 3.7		Сітат	ion Report	
2139 Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments. Cancers, 2019, 11, 1374. 3.7 61 2140 Prognostic value of EGFR 194C/dci and 214C1355R mutations in patients with hon5/Csmail cell lung cancer. 1.8 2.6 2141 Endermal growth factor receptor (EGFR) tyroothe kinase inhibitors in non-smail cell lung cancer. 2.8 61 2142 Calenactinib in first line setting: for Asian patients. Translational Lung Cancer Research, 2019, 8, 271-283. 2.8 0 2143 Optimization of Cancer Treatment in the Frequency Domain. AVPS Journal, 2019, 21, 106. 4.4 2 2144 Discovery of a Furanopythildine-Based Epidemial Growth factor Receptor Infibitor (DBPR112) as a Colinact Gandbacter for the Treatment of Non Smail Cell Lung Cancer. Journal of Medicinal Chemistry. 6.4 20 2145 Cancer Research, 2019, 8, 461-475. 7.0 52 2146 Cancer Research, 2019, 8, 461-475. 7.0 52 2147 Reterming long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 11, 63 7.0 52 2148 Discovery of a paraboxity the Microtubule Network in Non-Smail Cell Lung Cancer. Cancers, 2019, 0.3, 7 1 37 2147 Canchoration of Meefformin an	#	Article	IF	CITATIONS
2140Prognostic value of ECR 194Cidel and 214CL858R mutations in patients with non4Csmall cell lung cancer. harboring uncommon ECR mutations: Focus on statints. Seminars in Oncology. 2019, 46, 271-283.2.2642141Epidermal growth factor receptor (ECRR) tyrosine kinase inhibitors in non-small cell lung cancer sports in the prognostic value of the constructions: Focus on statints. Seminars in Oncology. 2019, 46, 271-283.2.2642142Osimertinib In first line setting: for Asian patients. Translational Lung Cancer Research, 2019, 8, 2019, 62, 21008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBRP112) as a 2019, 62, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receptor Pider Coding 2019, 22, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receiptor Pider Coding 2019, 22, 01008 Discovery of a Furanopytimidine-Based Epidermal Crowth Factor Receiptor Pider Coding 2019, 23, 646 Cider Coding RNA predictors of anticancer drug sensitivity beyond protein-coding 2019, 25, 666 Cider Coding, RNA predictors of anticancer drug sensitivity beyond protein-coding 2019, 22, 647 Cider Coding RNA predictors of anticancer drug sensitivity beyond protein-coding 2019, 2020 Discovering long none coding RNA predictors of anticancer drug sensitivit	2139	Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments. Cancers, 2019, 11, 1374.	3.7	61
2141Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGRR mutations: Focus on afatinb. Seminars in Oncology, 2019, 46, 271-283.2.2612142Ostimettinib in first line setting: for Asian patients. Translational Lung Cancer Research, 2019, 8, 50 5552.2.802143Optimization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106.4.422144Obtional Candodara for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2019, 62, 10108-10123.6.4202145Cancer in Spain: information from the Thoracic Lumors Registry (TTR study). Translational Lung 2019, 62, 10108-10123.8.4382146Combination of Metformin and Ceftinib as First-Line Therapy for Nondiabetic Advanced NSCLC 2019, 62, 667-6973.7.08.22147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the Lunded States of America, 2019, 116, 2020-2020.3.73.72149Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the Lunded States of America, 2019, 116, 2020-2020.3.712149Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the Lunded States of America, 2019, 11, 10.12149Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the Lung C	2140	Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung canc Oncology Letters, 2019, 18, 3887-3895.	er. 1.8	26
2142Ostmertinib in first line setting: for Asian patients. Translational Lung Cancer Research, 2019, 8, \$50:552.2.802143Optimization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106.4.422144Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer, Journal of Medicinal Chemistry, 2019, 62, 10108-10123.6.4202145Lung cancer in Splan: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.7.08.22146Combination of Metformin and Celfthib as First-Line Therapy for Nondiabetic Advanced NSCLC 	2141	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Seminars in Oncology, 2019, 46, 271-283.	2.2	61
2143Optimization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106.4.422144Discovery of a Furanopyrimidine-Based Epidermal Crowth Factor Receptor Inhibitor (DBPR112) as a Chickal Candidate for the Treatment of Non-Small Cell Lung Cancer, Journal of Medicinal Chemistry, 20, 10105 10123.0.4202145Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.7.06.22146Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EOFR Mutations: A Randomized, Double Billind Phase I Trial. Clinical Cancer Research, 2019, 23, 6067-6795.7.06.22147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2019, 23, 6067-6795.7.1372148IOSSB4C*PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.3.712159Questionnaire survey on patient awareness of Invasive rebiopsy in advanced nona-Esmall cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.112161Trinschroäck Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.7.79.72151Trinschröäck Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.7.79.72162Beyond ECFR Inhibition: mutilateral combat strategies to stop the progressi	2142	Osimertinib in first line setting: for Asian patients. Translational Lung Cancer Research, 2019, 8, 550-552.	2.8	0
2144Discovery of a FuranopyInitidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer, Journal of Medicinal Chemistry, 2019, 62, 10108-10123.6.4202145Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.382146Combination of Metformin and Cefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGR Mutrations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.7.0522147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 32020-20209.7.1372148FOSBBC*PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.3.7172159Questionnaire survey on patient awareness of Invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.12151Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors cortex the Acquisition of Mondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, 2262.6112152Sepond ECFR Inhibition: multilaterial combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 517.2.6112153SciTanschoracic Calcer, 2019, 23, 2431-2441.10272154Growth Factor Receptorse*Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019	2143	Optimization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106.	4.4	2
2145Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.382146Combination of Metformin and Cefitinib as First-Line Therapy for Nondiabetic Advanced NSCIC Patients with ECFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.50522147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11, 107.7.1372148FOSB36"PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.3.7172149Mechanism of Resistance to Third-Generation Inhibitors., 2019, 163-171.112150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâCsmall cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.112161Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, earler. Experimental and Molecular Medicine, 2019, 51, 114.7.7972162ebyond ECFR Inhibition: multilateral combat strategies to stop the progression of head and neck wolecular Medicine, 2019, 51, 114.7.7972173«OrTransc/Ib368, 5, 4Å36trimethoxystilbene reduced gefitinib resistance in cscp>NSCICC/scpps via suppressing (scp>Mark/(scp)/Akt/Bcla62 pathway by upregulation of miRa6494 and miRa6498, Journal of Cellular and Molecular Medicine, 2019, 32, 32431-2441.102184«OrTransc/Ib368, 5,	2144	Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2019, 62, 10108-10123.	6.4	20
2146Combination of Metformin and Cefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with ECFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.7.0522147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22020-22029.7.1372148FOSBá€"PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.8.7172149Mechanism of Resistance to Third-Generation Inhibitors., 2019, , 163-171.12150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.1.92151for the Acquistion of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, 	2145	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.	2.8	38
2147Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20202-22029.7.1372148FOSB&G"PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.3.7172149Mechanism of Resistance to Third-Generation Inhibitors. , 2019, , 163-171.12150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonaCsmall cell lung 	2146	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.	7.0	52
2148FOSBaE®PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.3.7172149Mechanism of Resistance to Third-Generation Inhibitors., 2019,, 163-171.12150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.1.92151for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.2.6112152Beyond ECFR Inhibition: multilateral combat strategies to stop the progression of head and neck (scp>MAPK /Akt/Bcla62 pathway by upregulation of miRã6445 and miRã64498. Journal of Cellular and Molecular Medicine, 2019, 23, 2431-2441.3.6272154Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Orowth Factor ReceptorãeC"Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 11102155Asafety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the 	2147	Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22020-22029.	7.1	37
2149Mechanism of Resistance to Third-Generation Inhibitors., 2019,, 163-171.12150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.1.962151Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.2.6112152Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.7.7972153 <i>>Trans</i> > MAPK./scp>/Akt/Bcla€2 pathway by upregulation of miRâ€345 and miRâ€498. Journal of Cellular and Molecular Medicine, 2019, 23, 2431-2441.3.6272154Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor〔Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 357, 29-36.1.1102155Asafety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdã€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. 2.59	2148	FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019 11, 107.	3.7	17
2150Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.1.962151Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.2.6112152Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck 	2149	Mechanism of Resistance to Third-Generation Inhibitors. , 2019, , 163-171.		1
2151Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.2.6112152Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.7.7972153<\i>>Trans> & <i>>Trans</i> > & <i>>Trans</i>	2150	Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 501-507.	1.9	6
2152Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.7.7972153 <i>Trans</i> > <i>Trans</i> >3.6272154Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptorâ€"Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 357, 29-36.1.1102155A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers.2.59	2151	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.	2.6	11
<i>Trans</i> , â€3,5,4´â€trimethoxystilbene reduced gefitinib resistance in <scp>NSCLC</scp> s via suppressing 3.6 27 2153 <scp>MAPK</scp> /Akt/Bclâ€2 pathway by upregulation of miRâ€345 and miRâ€498. Journal of Cellular and 3.6 27 2154 Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal 1.1 10 2154 Growth Factor Receptorâ€"Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 357, 29-36. 1.1 10 2155 thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. 2.5 9	2152	Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.	7.7	97
Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal 2154 Growth Factor Receptorâ€"Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 357, 29-36. 1.1 10 A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the 2.5 9	2153	<i>Trans</i> â€3,5,4´â€ŧrimethoxystilbene reduced gefitinib resistance in <scp>NSCLC</scp> s via suppr <scp>MAPK</scp> /Akt/Bclâ€2 pathway by upregulation of miRâ€345 and miRâ€498. Journal of Cellular a Molecular Medicine, 2019, 23, 2431-2441.	essing Ind 3.6	27
A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the 2155 thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. 2.5 9	2154	Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor—Thyroxine Kinase Inhibitors. American Journal of the Medical Sciences, 2019, 357, 29-36.	1.1	10
Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381.	2155	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381.	2.5	9
Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. , 2019, 202, 140-148.	2156	Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. , 2019, 202, 140-148.		43

#	Article	IF	CITATIONS
2157	mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines. Prostaglandins and Other Lipid Mediators, 2019, 143, 106344.	1.9	5
2158	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1311-1320.	1.2	249
2159	Prospects for a personalized peptide vaccine against lung cancer. Expert Review of Vaccines, 2019, 18, 703-709.	4.4	9
2160	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma. IScience, 2019, 16, 453-467.	4.1	14
2161	Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Molecular Medicine Reports, 2019, 20, 593-603.	2.4	19
2162	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 2019, 146, 104297.	7.1	29
2163	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 6382-6391.	7.0	39
2164	Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. Cell Reports, 2019, 27, 3331-3344.e6.	6.4	19
2165	Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. European Journal of Pharmacology, 2019, 856, 172409.	3.5	16
2166	Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non–small cell lung cancer cell survival. Journal of Biological Chemistry, 2019, 294, 10530-10543.	3.4	23
2167	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 222.	8.6	45
2168	A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series. Journal of Contemporary Brachytherapy, 2019, 11, 174-179.	0.9	8
2169	Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Journal of Experimental and Clinical Cancer Research, 2019, 38, 254.	8.6	115
2170	Discovery of 7-bromo-1,4-dihydrothieno[3',2':5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors. Medicinal Chemistry Research, 2019, 28, 1000-1009.	2.4	2
2171	Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer. Bioorganic Chemistry, 2019, 89, 102994.	4.1	7
2172	Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 350-362.e4.	2.6	10
2173	Implementing Companion Diagnostic Testing in the Clinic. , 2019, , 413-427.		0
2174	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discovery, 2019, 9, 926-943.	9.4	220

		CITATION R	EPORT	
#	Article		IF	CITATIONS
2175	Clinical Validation of a Cell-Free DNA Gene Panel. Journal of Molecular Diagnostics, 201	9, 21, 632-645.	2.8	15
2176	Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of t kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon. Cytopathology, 2019, 47, 845-850.	yrosine Diagnostic	1.0	2
2177	The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or Compensation. Drug Resistance Updates, 2019, 43, 29-37.	target	14.4	33
2178	Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 61-72.	EGFR-positive	2.3	6
2179	Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discover 587-604.	y, 2019, 9,	9.4	13
2180	Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor Sensors, 2019, 4, 1399-1408.	. ACS	7.8	54
2181	Emerging therapies for non-small cell lung cancer. Journal of Hematology and Oncolog	y, 2019, 12, 45.	17.0	111
2182	Combination Therapy of Chloroquine and C2-Ceramide Enhances Cytotoxicity in Lung H1299 Cells. Cancers, 2019, 11, 370.	Cancer H460 and	3.7	24
2183	Pulmonary Adenocarcinomaâ \in "Pathology and Molecular Testing. , 2019, , 13-33.			1
2184	A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast C <i>EGFR</i> -Mutant Non-Small Cell Lung Cancer. Oncolo Treatment, 2019, 42, 107-114.	ancer and gy Research and	1.2	5
2185	Identification of mutations associated with acquired resistance to sunitinib in renal cel International Journal of Cancer, 2019, 145, 1991-2001.	cancer.	5.1	32
2186	Application of amplicon-based targeted sequencing with the molecular barcoding syste uncommon minor EGFR mutations in patients with treatment-naÃ ⁻ ve lung adenocarcin 2019, 19, 175.	em to detect oma. BMC Cancer,	2.6	1
2187	Protective autophagy decreases osimertinib cytotoxicity through regulation of stem ce properties in lung cancer. Cancer Letters, 2019, 452, 191-202.	II-like	7.2	48
2188	TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells. Life 224, 23-32.	Sciences, 2019,	4.3	16
2189	Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small c cancer. Clinical and Translational Oncology, 2019, 21, 1287-1301.	ell lung	2.4	73
2190	TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing <i>EGFR</i> Mutations Including T790M and Uncommon Mutations G719X. Molecular Therapeutics, 2019, 18, 920-928.	Various Cancer	4.1	11
2191	Polytherapy and Targeted Cancer Drug Resistance. Trends in Cancer, 2019, 5, 170-182		7.4	183
2192	miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance t in lung adenocarcinoma. Nature Metabolism, 2019, 1, 460-474.	o EGFR inhibitors	11.9	57

#	Article	IF	CITATIONS
2193	Discovery of a novel EGFR targeting antibody-drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies. Molecular Cancer Therapeutics, 2019, 18, molcanther.0854.2018.	4.1	11
2194	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	8.6	170
2196	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Seminars in Cancer Biology, 2019, 59, 3-22.	9.6	29
2197	Detection of Solid Tumor Molecular Residual DiseaseÂ(MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis and Therapy, 2019, 23, 311-331.	3.8	123
2198	<i>LINC00261</i> Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response. Cancer Research, 2019, 79, 3050-3062.	0.9	75
2199	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI) Tj ETQq1 1	0. 78 4314	rgBT /Over
2200	Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. Tumori, 2019, 105, NP12-NP16.	1.1	9
2201	QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors. Chemical Biology and Drug Design, 2019, 94, 1306-1315.	3.2	6
2202	EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. Targeted Oncology, 2019, 14, 197-203.	3.6	33
2203	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. , 2019, , 21-38.		1
2204	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. Journal of Thoracic Disease, 2019, 11, S113-S126.	1.4	45
2205	<p>Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis</p> . Lung Cancer: Targets and Therapy, 2019, Volume 10, 1-10.	2.7	29
2206	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. Journal of Molecular Medicine, 2019, 97, 1657-1668.	3.9	7
2207	Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. Journal of Experimental and Clinical Cancer Research, 2019, 38, 481.	8.6	26
2208	A Repeated Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung Cancer Patient. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 129-131.	1.4	2
2209	MicroRNAs in nonâ€small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacology Research and Perspectives, 2019, 7, e00528.	2.4	58
2210	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 432-439.	1.3	21
2211	Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression. International Journal of Molecular Sciences, 2019, 20, 6074.	4.1	42

#	Article	IF	CITATIONS
2212	Tetrandrine Increases the Sensitivity of Human Lung Adenocarcinoma PC14 Cells to Gefitinib by Lysosomal Inhibition. Anticancer Research, 2019, 39, 6585-6593.	1.1	8
2213	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S247-S264.	2.8	59
2214	Covalent vs. Non ovalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective. Chemistry and Biodiversity, 2019, 16, e1800518.	2.1	8
2215	Knowledge base toward understanding actionable alterations and realizing precision oncology. International Journal of Clinical Oncology, 2019, 24, 123-130.	2.2	9
2216	Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. Chemical Biology and Drug Design, 2019, 93, 798-810.	3.2	7
2217	Cancer biomarker discovery and translation: proteomics and beyond. Expert Review of Proteomics, 2019, 16, 93-103.	3.0	107
2218	The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series. European Journal of Medicinal Chemistry, 2019, 163, 610-625.	5.5	14
2219	Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer, 2019, 128, 33-39.	2.0	34
2220	Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors. Redox Biology, 2019, 25, 101073.	9.0	90
2221	Emerging drugs for EGFR-mutated non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2019, 24, 5-16.	2.4	10
2222	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 2019, 62, 3171-3183.	6.4	105
2223	Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 187-192.	2.8	23
2224	Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Drug Safety, 2019, 42, 181-198.	3.2	64
2225	IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. Cancers, 2019, 11, 36.	3.7	17
2226	Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Targeted Oncology, 2019, 14, 93-105.	3.6	28
2227	Selective and reversible modification of kinase cysteines with chlorofluoroacetamides. Nature Chemical Biology, 2019, 15, 250-258.	8.0	90
2228	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research, 2019, 79, 546-556.	0.9	59
2229	Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 2019, 83, 399-410.	2.3	12

#	Article	IF	CITATIONS
2230	Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 <i>H</i> -pyrazol-4-yl)-1 <i>H</i> -imidazol-1-yl)-1 <i>H</i> -pyrazolo[3,4- <i>b (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 531-551.</i>]pyridi	n-1-yl)benza
2231	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among firstâ€line gefitinib, erlotinib and afatinibâ€treated nonâ€small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer, 2019, 144, 2887-2896.	5.1	56
2232	Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 20-26.	1.8	46
2233	Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of Cellular Physiology, 2019, 234, 5613-5627.	4.1	64
2234	Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Journal of Cellular Biochemistry, 2019, 120, 4180-4191.	2.6	3
2235	New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Seminars in Cancer Biology, 2019, 54, 162-173.	9.6	16
2236	A PET study in healthy subjects of brain exposure of ¹¹ C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 799-807.	4.3	36
2237	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
2238	Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA. Oncology, 2020, 98, 23-28.	1.9	5
2239	Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. Journal of Medicinal Chemistry, 2020, 63, 40-51.	6.4	9
2240	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. Clinical Oncology, 2020, 32, e1-e9.	1.4	6
2241	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
2242	Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. International Journal of Surgical Pathology, 2020, 28, 51-59.	0.8	6
2243	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
2244	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
2245	Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural and Molecular Biology, 2020, 27, 92-104.	8.2	30
2246	Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. Journal of Medicinal Chemistry, 2020, 63, 1216-1232.	6.4	111
2247	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations. Clinical Lung Cancer, 2020, 21, e216-e228.	2.6	89

#	Article	IF	Citations
2248	Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples. Archives of Pathology and Laboratory Medicine, 2020, 144, 997-1002.	2.5	6
2249	β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Journal of NeuroImmune Pharmacology, 2020, 15, 27-36.	4.1	35
2250	Acquired Resistance in Lung Cancer. Annual Review of Cancer Biology, 2020, 4, 279-297.	4.5	13
2251	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	5.9	29
2252	Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa125.	0.7	12
2253	Molecular Pathology of Primary Non-small Cell Lung Cancer. Archives of Medical Research, 2020, 51, 784-798.	3.3	55
2254	Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain. Biochemistry, 2020, 59, 3965-3972.	2.5	2
2255	A self-powered bidirectional partition microfluidic chip with embedded microwells for highly sensitive detection of EGFR mutations in plasma of non-small cell lung cancer patients. Talanta, 2020, 220, 121426.	5.5	16
2256	Chemical strategies to overcome resistance against targeted anticancer therapeutics. Nature Chemical Biology, 2020, 16, 817-825.	8.0	41
2257	Structural Basis of AZD9291 Selectivity for EGFR T790M. Journal of Medicinal Chemistry, 2020, 63, 8502-8511.	6.4	71
2258	Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. Journal of Thoracic Disease, 2020, 12, 2883-2895.	1.4	19
2259	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	4.1	46
2260	Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. Translational Lung Cancer Research, 2020, 9, 1952-1962.	2.8	10
2261	Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction. BMC Bioinformatics, 2020, 21, 520.	2.6	8
2262	Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy. Biochimie, 2020, 176, 128-137.	2.6	5
2263	Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115669.	3.0	14
2264	De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma. Cancers, 2020, 12, 3074.	3.7	3
2265	Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling. International Journal of Molecular Sciences, 2020, 21, 7770.	4.1	5

#	Article	IF	Citations
2266	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	12.4	101
2267	Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. Biochemistry (Moscow), 2020, 85, 967-993.	1.5	30
2268	Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR ^{WT} and EGFR ^{T790M} . Organic and Biomolecular Chemistry, 2020, 18, 7608-7634.	2.8	83
2269	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 2020, 12, 2394.	3.7	34
2270	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. Current Genetic Medicine Reports, 2020, 8, 109-119.	1.9	0
2271	Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling. Journal of Cancer, 2020, 11, 5746-5757.	2.5	3
2272	erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020, 5, e000724.	4.5	22
2274	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology, 2020, 3, 776.	4.4	34
2275	Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR. Frontiers in Medicine, 2020, 7, 594900.	2.6	9
2276	Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR. Diagnostics, 2020, 10, 1062.	2.6	10
2277	Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. ACS Medicinal Chemistry Letters, 2020, 11, 2484-2490.	2.8	26
2278	Anlotinib can overcome acquired resistance to <scp>EGFRâ€TKIs</scp> via <scp>FGFR1</scp> signaling in nonâ€small cell lung cancer without harboring <scp>EGFR T790M</scp> mutation. Thoracic Cancer, 2020, 11, 1934-1943.	1.9	18
2279	Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer, 2020, 20, 408.	2.6	14
2280	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer, 2020, 19, 90.	19.2	44
2281	Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients. Molecular Diagnosis and Therapy, 2020, 24, 451-460.	3.8	2
2282	Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy. European Journal of Medicinal Chemistry, 2020, 199, 112388.	5.5	15
2283	Current Landscape of Personalized Therapy. Thoracic Surgery Clinics, 2020, 30, 121-125.	1.0	2
2284	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	3.8	3

#	Article	IF	CITATIONS
2285	Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report. Clinical Lung Cancer, 2020, 21, e601-e606.	2.6	6
2286	Early Monitoring Drug Resistant Mutation T790M with a Two-Dimensional Simultaneous Discrimination Nanopore Strategy. Analytical Chemistry, 2020, 92, 8867-8873.	6.5	6
2287	Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-sma Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology and Oncology Research, 2020, 26, 2371-2379.	 1.9	4
2288	Development of bispecific antibodies in China: overview and prospects. Antibody Therapeutics, 2020, 3, 126-145.	1.9	20
2289	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 2020, 27, 146-155.	2.2	14
2290	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. Targeted Oncology, 2020, 15, 337-345.	3.6	4
2291	The top 100 cited articles in lung cancer – a bibliometric analysis. Wspolczesna Onkologia, 2020, 24, 17-28.	1.4	7
2292	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2020, 12, 2859-2876.	1.4	11
2293	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56
2294	Clinical Cohort Analysis of Germline <i>EGFR</i> T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precision Oncology, 2020, 4, 170-175.	3.0	10
2295	Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents. International Journal of Molecular Sciences, 2020, 21, 1721.	4.1	31
2296	Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Biochemistry, 2020, 59, 1428-1441.	2.5	35
2297	Landscape and function of multiple mutations within individual oncogenes. Nature, 2020, 582, 95-99.	27.8	79
2298	Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. Npj Precision Oncology, 2020, 4, 15.	5.4	20
2299	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884.	2.4	5
2301	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 2896-2909.	1.4	5
2302	Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. European Journal of Medicinal Chemistry, 2020, 203, 112511.	5.5	20
2303	Analysis of Single Nucleotide-Mutated Single-Cancer Cells Using the Combined Technologies of Single-Cell Microarray Chips and Peptide Nucleic Acid-DNA Probes. Micromachines, 2020, 11, 628.	2.9	10

#	Article	IF	CITATIONS
2304	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	5.0	32
2305	<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases</p> . OncoTargets and Therapy, 2020, Volume 13, 647-656.	2.0	7
2306	Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Science Advances, 2020, 6, eaav7416.	10.3	29
2307	Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells. Diagnostics, 2020, 10, 84.	2.6	10
2308	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. Journal of Drug Targeting, 2020, 28, 861-872.	4.4	11
2309	Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization. Cell Death and Disease, 2020, 11, 143.	6.3	39
2310	Diagnostic Molecular Pathology. , 2020, , 2145-2159.		0
2311	ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target. Cancer Science, 2020, 111, 951-961.	3.9	26
2312	Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. EBioMedicine, 2020, 53, 102689.	6.1	11
2313	Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy. Cancers, 2020, 12, 181.	3.7	20
2314	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. International Journal of Molecular Sciences, 2020, 21, 401.	4.1	48
2315	Abivertinib in patients with T790Mâ $\!$	1.9	14
2316	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Reports, 2020, 31, 107568.	6.4	15
2317	Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127167.	2.2	34
2318	Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell, 2020, 37, 496-513.	16.8	411
2319	Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell, 2020, 37, 443-455.	16.8	444
2320	Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. ACS Medicinal Chemistry Letters, 2020, 11, 1137-1144.	2.8	24
2321	Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 883-892.	1.4	5

#	Article	IF	CITATIONS
2322	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nature Communications, 2020, 11, 1923.	12.8	79
2323	Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers. Anticancer Research, 2020, 40, 1855-1866.	1.1	12
2324	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers, 2020, 12, 927.	3.7	6
2325	BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). Journal of Biomolecular Structure and Dynamics, 2021, 39, 2838-2856.	3.5	24
2326	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. Acta Clinica Belgica, 2021, 76, 224-231.	1.2	1
2327	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	9.6	39
2328	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. European Journal of Medicinal Chemistry, 2021, 209, 112904.	5.5	45
2329	Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. Journal of Ethnopharmacology, 2021, 265, 113302.	4.1	30
2330	Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 211, 113022.	5.5	13
2331	When compared to plasmaâ€based detection, osimertinibâ€ŧreated nonâ€small cell lung cancer (NSCLC) with tissue rebiopsyâ€confirmed acquired T790M mutation is associated with better survival. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e35-e39.	1.1	3
2332	COTI-2, a novel small molecule that is active against multiple human cancer cell lines <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 0, 7, 41363-41379.	1.8	124
2333	Olmutinib in T790Mâ€positive non–small cell lung cancer after failure of firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	4.1	17
2334	Development of a sensitive UHPLC–MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1â€[4â€(4â€{5â€Chloroâ€4â€[2â€(propaneâ€2â€sulfonyl)â€phenylamino]â€pyrimidinâ€2â€ylamino}â€phenyl) rats. Biomedical Chromatography, 2021, 35, e5059.	â€piperaz	inã€1â€yl]â€
2335	<pre><scp>HSP90</scp> inhibition overcomes <scp><i>EGFR</i></scp> amplificationâ€induced resistance to thirdâ€generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642.</pre>	1.9	14
2336	The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 75.	0.2	0
2337	Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discovery, 2021, 11, 575-590.	9.4	193
2338	BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Translational Oncology, 2021, 14, 100961.	3.7	1
2339	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	1.1	11

#	Article	IF	CITATIONS
2340	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook. Cureus, 2021, 13, e13470.	0.5	4
2341	Allosteric Inhibition of the Epidermal Growth Factor Receptor. Biochemistry, 2021, 60, 500-512.	2.5	1
2342	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. BMJ Open, 2021, 11, e041345.	1.9	3
2343	Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Frontiers in Oncology, 2021, 11, 621992.	2.8	13
2344	Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance. Cancer Research, 2021, 81, 3051-3066.	0.9	38
2345	Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations. Cancers, 2021, 13, 1120.	3.7	10
2346	Zincâ€finger Eâ€boxâ€binding homeobox 1 <scp>(ZEB1)</scp> plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. Thoracic Cancer, 2021, 12, 1536-1548.	1.9	9
2347	mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications. Frontiers in Oncology, 2021, 11, 656738.	2.8	36
2348	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. Scientific Reports, 2021, 11, 6685.	3.3	8
2349	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Molecular Medicine, 2021, 13, e13144.	6.9	13
2350	Structural Insight of the Anticancer Properties of Doxazosin on Overexpressing EGFR/HER2 Cell Lines. , 0, , .		1
2351	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Reports, 2021, 34, 108870.	6.4	12
2352	Long-Term Survival of Over 6ÂYears with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation, 2021, 41, 483-488.	2.2	0
2353	Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer, 2021, 2, 377-391.	13.2	198
2354	Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. Npj Precision Oncology, 2021, 5, 32.	5.4	11
2355	Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior. Nano Letters, 2021, 21, 4878-4886.	9.1	31
2356	SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene, 2021, 40, 3331-3346.	5.9	6
2358	Stem cells and lung cancer. , 2021, , 340-352.		1

ARTICLE IF CITATIONS Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer 2359 1.7 15 Agents. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 825-838. Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2021, 81, 3862-3875. Unveiling mutational dynamics in nonâ€small cell lung cancer patients by quantitative <i>EGFR</i> 2361 4.6 10 profiling in vesicular RNA. Molecular Oncology, 2021, 15, 2423-2438. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in 2362 Non-Small Cell Lung Cancer: A Review. Cells, 2021, 10, 1206. A data-independent acquisition-based global phosphoproteomics system enables deep profiling. Nature 2365 12.8 44 Communications, 2021, 12, 2539. A systematic analysis of signaling reactivation and drug resistance. Cell Reports, 2021, 35, 109157. 2366 6.4 Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through 2367 2.8 19 regulation of PI3K/Akt signaling. Toxicology and Applied Pharmacology, 2021, 419, 115518. Antiâ€HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal 2368 2.6 adenocarcinoma. Oncology Reports, 2021, 46, . Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in 2369 12.8 14 advanced EGFR-mutant non-small cell lung cancer. Nature Communications, 2021, 12, 3697. Re-use of erlotinib in a patient using osimertinib after erlotinib, case report. Journal of Oncology 2370 Pharmacy Practice, 2022, 28, 211-214. Highâ€throughput CRISPRâ€mediated 3D enrichment platform for functional interrogation of 2371 3 3.3 chemotherapeutic resistance. Biotechnology and Bioengineering, 2021, 118, 3187-3199. The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. 5.0 Expert Opinion on Drug Discovery, 2021, 16, 1091-1103. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748. 2373 3.7 148 Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung 2374 7.2 cancer. Cancer Letters, 2021, 508, 76-91. Clinical implementation and current advancement of blood liquid biopsy in cancer. Journal of Human 2375 2.316 Genetics, 2021, 66, 909-926. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naìve <i>ALK-, ROS1-</i>, or <i>EGFR</i>-altered Nonâ€"small Cell Lung Cancer. Molecular 2376 Cancer Therapeutics, 2021, 20, 1653-1662. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative 2377 3.8 32 Breast Cancer. Pharmaceuticals, 2021, 14, 589. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in 2378 Metastatic Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.

		CITATION RE	PORT	
#	Article		IF	Citations
2379	PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs. Cells, 2021, 10, 167	9.	4.1	11
2380	EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosin May Respond to Osimertinib in Patients With Lung Adenocarcinoma. JTO Clinical and R 2021, 2, 100185.	e Kinase Inhibitor esearch Reports,	1.1	0
2381	The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Frontiers in Pharmacology, 2021, 12, 702445.	? Targeting.	3.5	32
2382	Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma ir promoting epidermal growth factor receptor phosphorylation. Journal of Cancer Resear Clinical Oncology, 2021, 147, 3245-3254.	i vitro by ch and	2.5	2
2383	Vision Improvement after Osimertinib Treatment in Paraneoplastic Optic Neuropathy A Lung Adenocarcinoma. Case Reports in Ophthalmological Medicine, 2021, 2021, 1-7.	ssociated with	0.5	0
2384	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Lung Cancer. Cancer Research, 2021, 81, 4835-4848.	Inhibitors in	0.9	31
2385	Angiogenic activities are increased via upregulation of HIF‑1α expression in gefitiniba cell lung carcinoma cells. Oncology Letters, 2021, 22, 671.	쀑resistant non‑small	1.8	2
2386	Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione Derivatives. Frontiers in Pharmacolo	Clinical and gy, 2021, 12, 691234.	3.5	17
2387	Quantification of HER family dimers by proximity ligation assay and its clinical evaluatic non–small cell lung cancer patients treated with osimertinib. Lung Cancer, 2021, 158	on in 3, 156-161.	2.0	4
2388	New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. International J Molecular Sciences, 2021, 22, 9453.	Nonapoptotic ournal of	4.1	29
2389	STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated no cancer cells. Human Cell, 2021, 34, 1855-1865.	n-small cell lung	2.7	8
2391	A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circ DNA From Peripheral Blood. JTO Clinical and Research Reports, 2021, 2, 100212.	culating Tumor	1.1	2
2392	The relevance of liquid biopsy in surgical oncology: The application of perioperative circ nucleic acid dynamics in improving patient outcomes. Journal of the Royal College of St Edinburgh, 2021, , .	ulating urgeons of	1.8	1
2393	Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolee Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC. Cancers, 20	cular Complexes 21, 13, 4133.	3.7	5
2394	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1597-1607.		1.2	47
2395	Molecular Pathology of Lung Cancer. Surgical Pathology Clinics, 2021, 14, 369-377.		1.7	9
2396	Identifying transcriptional programs underlying cancer drug response with TraCe-seq. N Biotechnology, 2022, 40, 86-93.	lature	17.5	23
2397	Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head an cells. Annals of Translational Medicine, 2021, 9, 1455-1455.	e (HDAC) and hd neck cancer	1.7	0

#	Article	IF	CITATIONS
2398	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	3.7	5
2399	Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening. Molecules, 2021, 26, 5324.	3.8	10
2400	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a037820.	6.2	9
2401	Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor. ACS Applied Materials & Interfaces, 2021, 13, 42513-42521.	8.0	12
2402	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. Genes and Diseases, 2022, 9, 1181-1193.	3.4	8
2403	Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Translational Lung Cancer Research, 2021, 10, 3823-3839.	2.8	13
2404	New strategies for targeting kinase networks in cancer. Journal of Biological Chemistry, 2021, 297, 101128.	3.4	18
2405	Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer. Current Problems in Cancer Case Reports, 2021, 4, 100114.	0.1	0
2406	Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors. Cancer Treatment and Research Communications, 2021, 29, 100463.	1.7	2
2407	Humoral immune response to epidermal growth factor receptor in lung cancer. Immunologic Research, 2021, 69, 71-80.	2.9	6
2408	Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199307.	1.3	8
2409	Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Current Cancer Drug Targets, 2021, 21, 55-69.	1.6	8
2410	Drug Resistance in Cancer Cells. , 2009, , .		3
2411	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
2412	Oncogene Addiction in Solid Tumors. Current Clinical Pathology, 2015, , 3-7.	0.0	2
2413	Targeting Receptor Tyrosine Kinases in Cancer. , 2015, , 225-278.		11
2414	HTRF Kinase Assay Development and Methods in Inhibitor Characterization. Methods in Molecular Biology, 2016, 1360, 1-18.	0.9	9
2415	Phosphoproteomics Profiling to Identify Altered Signaling Pathways and Kinase-Targeted Cancer Therapies. Methods in Molecular Biology, 2020, 2051, 241-264.	0.9	3

#	Article	IF	CITATIONS
2416	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
2417	Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays. Methods in Molecular Biology, 2012, 795, 233-253.	0.9	1
2418	Resistance to Anti-Cancer Therapeutics. , 2019, , 65-82.		1
2419	Genomic Applications in Pulmonary Malignancies. , 2019, , 363-392.		1
2420	Targeting ERBB Receptors in Cancer. , 2007, 172, 45-57.		8
2421	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 1307-1366.		7
2422	Cancer of the Lung. , 2014, , 1143-1192.e13.		5
2423	Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorganic Chemistry, 2020, 101, 103970.	4.1	14
2424	[11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nuclear Medicine and Biology, 2017, 52, 7-15.	0.6	6
2425	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da Associação Médica Brasileira, 2012, 58, 263-268.	0.7	4
2426	Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer. DNA Research, 2017, 24, 585-596.	3.4	53
2427	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 635-647.	1.1	26
2428	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 1010-1019.	1.1	17
2436	Mouse Models of Human Non-Small-Cell Lung Cancer: Raising the Bar. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 241-250.	1.1	57
2437	Oncogenes Come of Age. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 1-9.	1.1	27
2438	Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 483-488.	1.1	7
2439	Glycogen synthase kinaseâ€3 inhibition overcomes epithelialâ€mesenchymal transitionâ€associated resistance to osimertinib in <i>EGFR</i> â€mutant lung cancer. Cancer Science, 2020, 111, 2374-2384.	3.9	17
2440	Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation. BMJ Case Reports, 2014, 2014, bcr2014204809-bcr2014204809.	0.5	2

#	Article	IF	CITATIONS
2441	EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens. Analytical Cellular Pathology, 2007, 29, 257-264.	1.4	53
2442	Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma. JCI Insight, 2019, 4, .	5.0	43
2443	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 2019, 4, .	5.0	42
2444	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation, 2006, 116, 2695-2706.	8.2	423
2445	New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation, 2007, 117, 2740-2750.	8.2	180
2446	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. Journal of Clinical Investigation, 2007, 117, 3846-3856.	8.2	574
2447	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Journal of Clinical Investigation, 2008, 118, 2609-19.	8.2	443
2448	Mechanisms of resistance to ErbB-targeted cancer therapeutics. Journal of Clinical Investigation, 2008, 118, 2389-92.	8.2	22
2449	Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
2450	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. Journal of Clinical Investigation, 2012, 122, 2637-2651.	8.2	79
2451	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation, 2013, 123, 1732-1740.	8.2	166
2452	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Journal of Clinical Investigation, 2014, 124, 3003-3015.	8.2	84
2453	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. Journal of Clinical Investigation, 2018, 128, 4098-4114.	8.2	31
2454	Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. Journal of Experimental and Clinical Cancer Research, 2020, 39, 22.	8.6	50
2455	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 99-132.		1
2456	Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer. Medical Science Monitor, 2017, 23, 3627-3634.	1.1	13
2457	Anticancer Effect of Radix Astragali on Cholangiocarcinoma In Vitro and Its Mechanism via Network Pharmacology. Medical Science Monitor, 2020, 26, e921162.	1.1	8
2458	Customised , Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) = العلاØ- Sultan Oaboos University Medical Journal, 2013, 13, 202-217	¬ اù"ùø	e ≇g⁻ùš ù^ Ø

#	Article	IF	CITATIONS
2459	Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Computational Biology, 2016, 12, e1005077.	3.2	20
2460	The Need for an Individual Approach to Lung Cancer Treatment. PLoS Medicine, 2006, 3, e206.	8.4	5
2461	Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Medicine, 2017, 14, e1002230.	8.4	60
2462	Epidemiology of Doublet/Multiplet Mutations in Lung Cancers: Evidence that a Subset Arises by Chronocoordinate Events. PLoS ONE, 2008, 3, e3714.	2.5	21
2463	The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo. PLoS ONE, 2008, 3, e3774.	2.5	29
2464	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. PLoS ONE, 2009, 4, e7464.	2.5	205
2465	Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling. PLoS ONE, 2010, 5, e8919.	2.5	24
2466	The Therapeutic Implications of Plasticity of the Cancer Stem Cell Phenotype. PLoS ONE, 2010, 5, e14366.	2.5	52
2467	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e20351.	2.5	338
2468	Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy. PLoS ONE, 2011, 6, e23756.	2.5	95
2469	A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death. PLoS ONE, 2011, 6, e24071.	2.5	141
2470	Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR. PLoS ONE, 2011, 6, e25191.	2.5	96
2471	Sensitivity to TOP2 Targeting Chemotherapeutics Is Regulated by Oct1 and FILIP1L. PLoS ONE, 2012, 7, e42921.	2.5	22
2472	A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor. PLoS ONE, 2012, 7, e49702.	2.5	19
2473	Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e54170.	2.5	89
2474	EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS ONE, 2013, 8, e61561.	2.5	61
2475	Synergistic Antitumor Effect between Gefitinib and Fractionated Irradiation in Anaplastic Oligodendrogliomas Cannot Be Predicted by the Egfr Signaling Activity. PLoS ONE, 2013, 8, e68333.	2.5	3
2476	EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation. PLoS ONE, 2013, 8, e78389.	2.5	29

#	Article	IF	CITATIONS
2477	Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification. PLoS ONE, 2013, 8, e78656.	2.5	39
2478	DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma. PLoS ONE, 2013, 8, e79526.	2.5	12
2479	Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data. PLoS ONE, 2013, 8, e81468.	2.5	61
2480	Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints. PLoS ONE, 2013, 8, e82059.	2.5	26
2481	Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 2013, 8, e83607.	2.5	76
2482	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 2014, 9, e89518.	2.5	32
2483	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e0143333.	2.5	21
2484	Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. PLoS ONE, 2016, 11, e0149370.	2.5	57
2485	Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells. PLoS ONE, 2016, 11, e0158395.	2.5	28
2486	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS ONE, 2016, 11, e0160004.	2.5	33
2487	Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. PLoS ONE, 2017, 12, e0177761.	2.5	3
2488	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS ONE, 2017, 12, e0177822.	2.5	5
2489	High-throughput full-length single-cell mRNA-seq of rare cells. PLoS ONE, 2017, 12, e0188510.	2.5	7
2490	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e141-e149.	3.8	49
2491	Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 179-185.	3.8	3
2492	A <scp>CIN</scp> ful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction. EMBO Molecular Medicine, 2020, 12, e12017.	6.9	5
2493	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. Journal of Cancer Prevention, 2015, 20, 57-63.	2.0	24
2494	Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer. Journal of Cancer Prevention, 2019, 24, 217-223.	2.0	9

#	Article	IF	CITATIONS
2495	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget, 2016, 7, 54137-54156.	1.8	27
2496	FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. Oncotarget, 2016, 7, 59245-59259.	1.8	15
2497	Clinical outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> mutation, <i>ALK</i> rearrangement and <i>EGFR</i> / <i>ALK</i> co-alterations. Oncotarget, 2016, 7, 65185-65195.	1.8	31
2498	Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors. Oncotarget, 2016, 7, 68597-68613.	1.8	16
2499	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016, 7, 68933-68942.	1.8	26
2500	Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer. Oncotarget, 2016, 7, 77342-77347.	1.8	18
2501	Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget, 2016, 7, 85917-85928.	1.8	6
2502	The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 50941-50948.	1.8	9
2503	Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget, 2017, 8, 55760-55765.	1.8	1
2504	Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations. Oncotarget, 2017, 8, 56714-56725.	1.8	6
2505	Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget, 2017, 8, 63014-63025.	1.8	27
2506	Intersecting transcriptomic profiling technologies and long non-coding RNA function in lung adenocarcinoma: discovery, mechanisms, and therapeutic applications. Oncotarget, 2017, 8, 81538-81557.	1.8	21
2507	MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor. Oncotarget, 2017, 8, 57012-57023.	1.8	28
2508	FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget, 2014, 5, 5908-5919.	1.8	92
2509	Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study. Oncotarget, 2017, 8, 67810-67820.	1.8	23
2510	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget, 2017, 8, 100801-100818.	1.8	35
2511	Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget, 2017, 8, 63846-63856.	1.8	21
2512	Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 99429-99437.	1.8	7

#	ARTICLE	IF	Citations
2513	metastasis and pathological types in solid tumors. Oncotarget, 2017, 8, 68746-68757.	1.8	6
2514	Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 2017, 8, 86056-86065.	1.8	13
2515	Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction. Oncotarget, 2017, 8, 93825-93838.	1.8	22
2516	CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget, 2018, 9, 1091-1106.	1.8	5
2517	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget, 2014, 5, 8544-8557.	1.8	56
2518	ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. Oncotarget, 2018, 9, 12020-12034.	1.8	25
2519	A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget, 2018, 9, 20524-20538.	1.8	26
2520	Monitoring <i>EGFR</i> -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	1.8	8
2521	Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells. Oncotarget, 2018, 9, 31549-31558.	1.8	8
2522	Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?. Oncotarget, 2018, 9, 34765-34771.	1.8	7
2523	Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. Oncotarget, 2011, 2, 336-346.	1.8	114
2524	Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 2018, 9, 37589-37607.	1.8	52
2525	DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model. Oncotarget, 2019, 10, 5152-5167.	1.8	37
2526	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of <i>EGFR</i> mutations in NSCLC: a new algorithm for patient selection and personalized treatment. Oncotarget, 2020, 11, 982-991.	1.8	13
2527	Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Oncotarget, 2020, 11, 3531-3557.	1.8	13
2528	Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. Oncotarget, 2015, 6, 814-824.	1.8	17
2529	Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget, 2015, 6, 5735-5748.	1.8	16
2530	Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget, 2015, 6, 5832-5845.	1.8	32

# 2531	ARTICLE Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget, 2015, 6, 10146-10160.	IF 1.8	CITATIONS
2532	<i>MLH1</i> V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with <i>EGFR</i> L858R-positive lung adenocarcinoma. Oncotarget, 2015, 6, 8407-8417.	1.8	17
2533	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget, 2015, 6, 11357-11368.	1.8	13
2534	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	1.8	24
2535	JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncotarget, 2015, 6, 14329-14343.	1.8	27
2536	NF- \hat{I}^2B drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget, 2015, 6, 42717-42732.	1.8	31
2537	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget, 2015, 6, 31313-31322.	1.8	38
2538	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget, 2015, 6, 32602-32609.	1.8	15
2539	<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer. Oncotarget, 2015, 6, 38789-38803.	1.8	137
2540	244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Oncotarget, 2015, 6, 44274-44288.	1.8	15
2541	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget, 2015, 6, 38458-38468.	1.8	19
2542	Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget, 2016, 7, 610-621.	1.8	37
2543	TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun. Oncotarget, 2016, 7, 6748-6764.	1.8	40
2544	Dosing <i>de novo</i> combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget, 2016, 7, 11310-11320.	1.8	50
2545	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget, 2016, 7, 12404-12413.	1.8	209
2546	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget, 2016, 7, 19559-19574.	1.8	20
2547	Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget, 2016, 7, 13797-13809.	1.8	7
2548	Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. Oncotarget, 2013, 4, 118-127.	1.8	33

#	Article	IF	CITATIONS
2549	Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget, 2016, 7, 22005-22015.	1.8	61
2550	Clinicopathologic characteristics of <i>EGFR</i> , <i>KRAS</i> , and <i>ALK</i> alterations in 6,595 lung cancers. Oncotarget, 2016, 7, 23874-23884.	1.8	62
2551	IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget, 0, 7, 42031-42044.	1.8	48
2552	Adaptive response of resistant cancer cells to chemotherapy. Cancer Biology and Medicine, 2020, 17, 842-863.	3.0	30
2553	Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Annals of Translational Medicine, 2018, 6, 140-140.	1.7	14
2554	Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma. Translational Cancer Research, 2019, 8, 2151-2163.	1.0	8
2555	Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research: 2017, 29, 204,212	2.2	6
2556	Biomarkers for the targeted therapies of non-small cell lung cancer. Current Biomarker Findings, 0, , 7.	0.4	3
2557	Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance. Current Medicinal Chemistry, 2019, 26, 6282-6303.	2.4	14
2558	ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Current Pharmaceutical Design, 2014, 20, 793-807.	1.9	441
2559	Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib's Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach. Combinatorial Chemistry and High Throughput Screening, 2021, 25, 149-166.	1.1	25
2560	Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. Current Drug Metabolism, 2011, 12, 944-955.	1.2	15
2561	Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance. Current Drug Metabolism, 2020, 21, 199-210.	1.2	10
2562	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	1.6	61
2563	Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 17, 4-15.	2.1	60
2564	Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer. Current Topics in Medicinal Chemistry, 2019, 19, 457-466.	2.1	3
2565	Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications. Current Topics in Medicinal Chemistry, 2020, 20, 227-243.	2.1	7
2566	Lung Cancer Mutations and Use of Targeted Agents in Hispanics. Reviews on Recent Clinical Trials, 2015, 9, 225-232.	0.8	19

#	Article	IF	CITATIONS
2567	The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1343-1350.	1.7	9
2568	Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study. Anticancer Research, 2018, 38, 3145-3150.	1.1	16
2569	Association of BIM Deletion Polymorphism and BIM- $\hat{1}^3$ RNA Expression in NSCLC with EGFR Mutation. Cancer Genomics and Proteomics, 2016, 13, 475-482.	2.0	9
2570	Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo, 2017, 31, 475-479.	1.3	7
2571	Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2012, 52, 131-135.	0.1	1
2572	Three Cases of <i>EGFR</i> Mutation-positive Lung Adenocarcinoma with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib. Japanese Journal of Lung Cancer, 2016, 56, 290-296.	0.1	1
2573	Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. International Journal of Molecular Sciences, 2020, 21, 1102.	4.1	408
2574	Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273.	3.8	28
2576	Long non‑coding RNA RFPL3S is a novel prognostic biomarker in lung cancer. Oncology Letters, 2020, 20, 1270-1280.	1.8	4
2577	GLI1 activation is a key mechanism of erlotinib resistance in human non‑small cell lung cancer. Oncology Letters, 2020, 20, 76.	1.8	8
2578	Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells. Oncology Reports, 2020, 43, 1569-1579.	2.6	12
2579	Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition. Oncology Reports, 2020, 45, 459-468.	2.6	7
2580	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2015, 30, 891-898.	1.7	10
2581	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. Journal of Thoracic Disease, 2010, 2, 144-53.	1.4	10
2582	T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. Journal of Thoracic Disease, 2011, 3, 10-8.	1.4	141
2583	Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 639-42.	1.4	11
2584	Thymic neoplasm: a rare disease with a complex clinical presentation. Journal of Thoracic Disease, 2013, 5, 173-83.	1.4	24
2585	The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 72-81.	1.4	11

#	Article	IF	CITATIONS
2586	MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications. Translational Lung Cancer Research, 2012, 1, 194-207.	2.8	8
2587	Irreversible EGFR-TKIs: dreaming perfection. Translational Lung Cancer Research, 2013, 2, 40-9.	2.8	20
2588	Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, 226-37.	2.8	35
2589	ROR1 as a novel therapeutic target for ECFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Translational Lung Cancer Research, 2014, 3, 122-30.	2.8	25
2590	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 370-2.	2.8	47
2591	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research, 2015, 4, 67-81.	2.8	241
2592	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Translational Lung Cancer Research, 2015, 4, 809-15.	2.8	43
2593	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 584-97.	2.8	52
2594	Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Translational Lung Cancer Research, 2015, 4, 576-83.	2.8	26
2595	From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer. Pathology Research International, 2011, 2011, 1-8.	1.4	15
2596	Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf. Biomolecules and Therapeutics, 2013, 21, 114-120.	2.4	21
2597	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation, 2010, 1, 10.	0.8	2
2598	Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma. Korean Journal of Family Medicine, 2016, 37, 351.	1.2	8
2599	T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 73-78.	0.2	3
2600	Detection of epidermal growth factor receptor T790M mutation by allele-specific loop mediated isothermal amplification. Journal of Carcinogenesis, 2020, 19, 3.	2.5	5
2601	Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital. Lung India, 2018, 35, 390.	0.7	9
2602	The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer. Lung India, 2018, 35, 384.	0.7	3
2603	Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. Cancer Informatics, 2015, 14, 95-103.	1.9	17

#	Article	IF	CITATIONS
2604	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Research and Treatment, 2019, 51, 718-726.	3.0	10
2605	The Anticancer Mechanism of an Approved Disease Modifying Herb Medicine:Total Glucosides of Paeony Target both EGFR and HER-2 in Lung Cancer Cell Lines. Translational Medicine (Sunnyvale, Calif) Tj ETQq1	100478431	L 4 2rgBT /Ov
2606	JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. World Journal of Biological Chemistry, 2015, 6, 409.	4.3	8
2607	Pharmacology of epidermal growth factor inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	19
2608	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World Journal of Clinical Oncology, 2013, 4, 29.	2.3	11
2609	Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World Journal of Clinical Oncology, 2014, 5, 806.	2.3	22
2610	Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2016, 7, 425.	2.3	7
2611	Non-small cell lung cancer - genetic predictors. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2013, 157, 125-136.	0.6	34
2612	Protocol for the Examination of Specimens From Patients With Primary Non–Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung. Archives of Pathology and Laboratory Medicine, 2009, 133, 1552-1559.	2.5	22
2613	Molecular Diagnostics of Lung Carcinomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 622-629.	2.5	30
2614	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
2615	Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 228.	4.9	343
2616	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	4.9	185
2617	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	2.5	106
2618	MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1391-1396.	1.2	48
2619	Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4147-4156.	1.2	34
2620	Clinical Efficacy and Possible Applications of Genomics in Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1693-1698.	1.2	3
2621	Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4,	6.0	95

#	Article	IF	CITATIONS
2622	Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC. ELife, 2019, 8, .	6.0	31
2623	Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding. Annals of Oncology, 2021, 32, 1463-1465.	1.2	Ο
2624	Computational identification of 2,4-disubstituted amino-pyrimidines as L858R/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulation. In Silico Pharmacology, 2021, 9, 54.	3.3	37
2625	IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nature Cancer, 2021, 2, 1055-1070.	13.2	9
2626	Design of a "Two-in-One―Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. Journal of Medicinal Chemistry, 2022, 65, 1370-1383.	6.4	13
2627	LW1497, an Inhibitor of Malate Dehydrogenase, Suppresses TGF-β1-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells by Downregulating Slug. Antioxidants, 2021, 10, 1674.	5.1	4
2628	Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Scientific Reports, 2021, 11, 19667.	3.3	28
2629	Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. Molecular Diversity, 2022, 26, 1715-1730.	3.9	7
2630	Thoracic surgery improved overall survival in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 162, 29-35.	2.0	3
2631	Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2006, 46, 237-240.	0.1	Ο
2632	A Novel Anti-EGFR Monoclonal Antibody, Cetuximab (Erbitux®). Japanese Journal of Lung Cancer, 2006, 46, 267-275.	0.1	0
2633	Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. Translational Medicine Series, 2007, , 97-122.	0.0	0
2634	Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. , 2007, , 19-44.		2
2635	Utilizing combinations of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. , 2008, , 356-369.		Ο
2636	ll è,ºç™Œã®å†ç§'的治ç™,. Okayama Igakkai Zasshi, 2008, 119, 285-292.	0.0	0
2637	Molecular Genetics of Lung and Pleural Neoplasms. , 2008, , 47-157.		2
2638	Structure-function of EGFR kinase domain and its inhibitors. , 2008, , 30-44.		1
2639	Monoclonaux contre inhibiteurs de tyrosine kinase. , 2008, , 81-97.		0
#	Article	IF	CITATIONS
------	---	-----	-----------
2640	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
2641	Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. , 2008, , 103-126.		0
2642	EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. , 2008, , 281-324.		0
2643	Pharmacogenetics in Cancer Chemotherapy. , 2008, , 113-128.		1
2644	Targeting Signaling Pathways in Cancer Therapy. , 2009, , 309-326.		0
2645	Modulation of Survival Pathways in Ovarian Carcinoma Cells Resistant to Platinum Compounds. , 2009, , 195-200.		0
2646	Development of A Simple Genotyping Method for Somatic Mutations of EGFR and Its Clinical Application. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2009, 35, 468-477.	0.1	0
2647	A Case of Lung Adenocarcinoma with Multiple Brain Metastasis Responded to Gefitinib by Epidermal Growth Factor Receptor Mutation. Japanese Journal of Lung Cancer, 2009, 49, 282-286.	0.1	0
2648	Retrospective Analysis of Acquired Resistance During the Treatment with Gefitinib in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations. Japanese Journal of Lung Cancer, 2009, 49, 257-261.	0.1	0
2649	Clinical Analysis of 24 Cases Treated Twice or More with Gefitinib for Recurrent Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2009, 49, 831-835.	0.1	0
2650	Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. OncoTargets and Therapy, 2009, 2, 161.	2.0	3
2651	EGFR-Directed Monoclonal Antibodies. , 2010, , 407-436.		0
2652	Biology of Non–Small Cell Lung Cancer. , 2010, , 1080-1097.		2
2653	A resected case of lung metastasis after treatment with gefitinib. The Journal of the Japanese Association for Chest Surgery, 2010, 24, 166-169.	0.0	0
2654	Pharmacogenetics in Lung Cancer. , 2010, , 87-99.		0
2655	Pharmacogenetics of Lung Cancer. , 2010, , 87-106.		0
2656	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. , 2010, , 205-226.		2
2657	Effects of Antacids on Clinical Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2010, 36, 832-839.	0.1	3

		CITATION RI	EPORT	
#	ARTICLE		IF	CITATIONS
2658	Selection Changes the Fate of Gefitinib. Clinical Medicine Reviews in Oncology, 0, 2, 23	3h;Patient 1-244.	0.0	0
2659	Mining Natural Product-Derived Molecules Against Cancer Targets: The Case of the And Receptor in Prostate Cancer. , 2010, , 671-692.	rogen		0
2660	DNA Biomarkers in the Diagnosis and Management of Cancer. , 2010, , 165-184.			0
2661	Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer. , 2010	D, , .		0
2663	Biologia dei tumori squamocellulari. , 2011, , 81-89.			0
2664	Lung Adenocarcinoma. , 2011, , 177-183.			0
2665	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. , 2011, , 1-31			0
2666	Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor T790M mutation in vivo. Okayama Igakkai Zasshi, 2011, 123, 13-18.	receptor	0.0	0
2668	Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling Kinase Inhibitors in Cancer. , 2012, , 215-229.	by Tyrosine		0
2669	Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine.	, 2012, , 569-589.		1
2670	Oncogene Addiction: Mouse Models and Clinical Relevance for Molecularly Targeted Th , 527-547.	erapies. , 2012,		1
2671	Targeting HER2+and trastuzumab-resistant metastatic breast cancer. , 2011, , 035-049			0
2673	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.			0
2674	Genetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development. , 0,	y•		0
2675	Erlotinib Responds to Brain Metastasis of Lung Adenocarcinoma where Gefitinib Failed : Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2012, 38	: A Case Report. 3, 332-336.	0.1	2
2676	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.			0
2677	JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Ine Expression and Apoptosis. Journal of Cancer Therapy, 2012, 03, 424-434.	duced BIM	0.4	1
2678	Clinical Significance of T790M After Acquiring Resistance to Gefitinib or Erlotinib in Nor Lung Cancer Patients with Epidermal Growth Factor Receptor Gene Mutation. Japanese Cancer, 2012, 52, 279-283.	i-small Cell Journal of Lung	0.1	0

#	Article	IF	CITATIONS
2679	Mutations and Tumorigenesis Pathways Driving Personalized Treatment in Non-Small Cell Lung Cancer. , 2012, 02, .		0
2680	Comparison of the KRAS/EGFR mutation profile and survival of "collegiate smokers―and never smokers with advanced lung cancers Journal of Clinical Oncology, 2012, 30, 7580-7580.	1.6	0
2681	Overcoming VEGF resistance in renal cancer: biologic and therapeutic implications. Clinical Investigation, 2012, 2, 615-621.	0.0	1
2683	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
2684	A Case of Squamous Cell Carcinoma of the Lung Diagnosed During Long Term Pemetrexed Chemotherapy for Recurrent Large Cell Carcinoma of the Lung. Japanese Journal of Lung Cancer, 2013, 53, 29-34.	0.1	0
2685	Hsp90 Inhibitors in Clinic. RSC Drug Discovery Series, 2013, , 336-378.	0.3	0
2686	Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases. Korean Journal of Medicine, 2013, 84, 446.	0.3	0
2687	Stress-Driven Endocytosis of Tyrosine-Phosphorylated EGFR Leads to Tumorigenesis: The Critical Role of Oxidative Stress. , 2013, , 303-325.		0
2688	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
2689	Systemic Therapy for Lung Cancer. , 2013, , 125-135.		0
2690	Differential response to targeted therapy in non-small cell lung carcinoma patients harbouring epidermal growth factor receptor mutations-a demand for diagnostic procedure optimization-a critical review. OA Molecular Oncology, 2013, 1, .	0.3	0
2691	Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. Tang [humanitas Medicine], 2013, 3, 10.1-10.8.	0.2	0
2692	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118.		0
2693	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0
2694	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
2696	Pathology, Biomarkers, and Molecular Diagnostics. , 2014, , 226-252.e6.		1
2697	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.		0
2698	The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara) Tj ETQq1	1 0.7843	14 _. rgBT /Ove

	Сітатіо	n Report	
#	Article	IF	CITATIONS
2699	Personalized treatment options in Non-small Cell Lung Cancer. Receptors & Clinical Investigation, 0, , .	0.9	0
2700	Genomic Applications in Pulmonary Malignancies. , 2015, , 383-413.		0
2701	Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine. , 2015, , 39-55.		0
2702	The EGFR/ERBB Receptor Family. , 2015, , 107-164.		3
2703	Methods to Study Primary Tumor Cells and Residual Tumor Cells in Mouse Models of Oncogene Dependence. Methods in Molecular Biology, 2015, 1267, 381-394.	0.9	0
2704	Lung Cancer: Diagnosis and Treatment Approach. , 2015, , 97-144.		2
2705	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. F1000Research, 2015, 4, 160.	1.6	2
2706	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
2707	Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 89-105.	0.1	0
2710	MicroRNAs expression profile of gefitinib resistant non-small cell lung cancer HCC827 cells. Journal of Biology (Vietnam), 2016, 37, .	0.0	0
2712	The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus, 2016, 8, e533.	0.5	3
2713	Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2016, 26, 1-2.	0.1	0
2714	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. F1000Research, 2015, 4, 160.	1.6	2
2716	The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior. , 2017, , 217-239.		0
2717	Heterogeneity and clonal evolution of colorectal cancer. Uspehi Molekularnoj Onkologii, 2017, 4, 24-34.	0.3	1
2718	Accurate Nodal Staging and Biomarker Testing with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. , 2017, , 79-96.		0
2719	Understanding the Biology Behind the EGFR to Improve NSCLC Patients' Treatment. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2017, 11, .	0.1	0
2720	Targeted Therapies for Lung Cancer. Molecular Pathology Library, 2018, , 239-255.	0.1	0

#	Article	IF	CITATIONS
2721	Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS ONE, 2017, 12, e0175484.	2.5	1
2725	Analysis of Adverse Drug Reactions on Osimertinib in T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 355-362.	0.1	0
2726	Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy. Heat Shock Proteins, 2019, , 359-395.	0.2	1
2727	BRAF: Novel Therapies for an Emerging Target. Current Cancer Research, 2019, , 79-100.	0.2	0
2730	Synthesis and Biological Evaluation of Oxopyrido[2,3-d] Pyrimidine-7- ones Derivatives as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. Letters in Drug Design and Discovery, 2019, 16, 826-834.	0.7	1
2732	Efficacy and Safety of Salvage Surgery After Molecular Targeting Drug Treatment for Advanced Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 463-466.	0.1	4
2734	Rational approach to the treatment of EGFR-positive lung cancer. Meditsinskiy Sovet, 2019, , 51-56.	0.5	0
2735	Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 724-733.	1.7	4
2736	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	46.4	41
2737	Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology, 2022, 40, 325-334.	17.5	15
2738	Molecular and Biological Basis of Lung Cancer-Part I. , 2020, 01, .		0
2739	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. Topics in Medicinal Chemistry, 2020, , 125-153.	0.8	0
2740	Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report. Tumori, 2021, 107, 030089162097326.	1.1	6
2741	Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment. Cancer Translational Medicine, 2020, 6, 40.	0.2	0
2743	Precision Medicine in Lung Cancer. European Medical Journal Oncology, 0, , .	0.0	0
2744	Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters. Cureus, 2020, 12, e7316.	0.5	0
2745	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Revista Espanola De Patologia, 2020, 53, 140-148.	0.2	0
2747	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1

#	Article	IF	CITATIONS
2748	Molecular pathology. , 0, , 95-118.		2
2749	Achievements in targeted therapies. , 0, , 215-233.		0
2750	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
2751	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Annals of Translational Medicine, 2015, 3, 81.	1.7	9
2752	Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. Cancer Informatics, 2007, 3, 275-84.	1.9	2
2753	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2010, 36, 19-27.	3.9	4
2754	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Annals of Thoracic and Cardiovascular Surgery, 2009, 15, 213-20.	0.8	9
2755	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. American Journal of Cancer Research, 2011, 1, 823-33.	1.4	19
2758	The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. Transactions of the American Clinical and Climatological Association, 2012, 123, 114-23; discussion 123-5.	0.5	10
2760	RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. International Journal of Clinical and Experimental Pathology, 2013, 6, 1493-504.	0.5	20
2761	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. American Journal of Translational Research (discontinued), 2013, 5, 481-96.	0.0	13
2762	Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Research, 2014, 34, 1629-35.	1.1	7
2764	EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 1967-78.	1.3	16
2765	Advances on EGFR mutation for lung cancer. Translational Lung Cancer Research, 2012, 1, 5-13.	2.8	46
2766	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, E1-3.	2.8	0
2767	10(th) Congress on Lung Cancer-updates on clinical trials: goal. Translational Lung Cancer Research, 2014, 3, 66-9.	2.8	1
2770	A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. American Journal of Cancer Research, 2017, 7, 1884-1898.	1.4	3
2784	Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. American Journal of Cancer Research, 2018, 8, 2575-2589.	1.4	0

#	Article	IF	Citations
2785	Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring. American Journal of Translational Research (discontinued), 2018, 10, 3911-3923.	0.0	13
2787	CDRgator: An Integrative Navigator of Cancer Drug Resistance Gene Signatures. Molecules and Cells, 2019, 42, 237-244.	2.6	2
2788	Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 2370-2381.	0.0	7
2790	Acquired rare recurrent mutations as mechanisms of resistance to Osimertinib in lung cancer and structural modelling. American Journal of Cancer Research, 2020, 10, 4005-4015.	1.4	3
2791	Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 724389.	3.7	0
2792	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188645.	7.4	52
2793	Clathrin adapters AP-1 and GGA2 support expression of epidermal growth factor receptor for cell growth. Oncogenesis, 2021, 10, 80.	4.9	9
2794	Dynamics of Acquired Resistance to Nivolumab Therapies Varies From Administration Strategies. Clinical Therapeutics, 2021, , .	2.5	0
2795	Targeting Oncogene Addiction for Cancer Therapy. , 0, , .		0
2796	The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 6005.	3.7	22
2797	Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors. Pharmaceuticals, 2021, 14, 1177.	3.8	12
2798	Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation. European Journal of Medicinal Chemistry, 2022, 228, 113984.	5.5	8
2799	Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). ACS Chemical Biology, 2021, 16, 2808-2815.	3.4	50
2800	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 2022, 526, 346-351.	7.2	10
2801	Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5639.	3.7	13
2802	The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. Cancers, 2021, 13, 5905.	3.7	9
2803	Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. European Journal of Cancer, 2022, 160, 189-205.	2.8	9
2804	Impact of epidermal growth factor receptor T790M testing in relapsed non-small cell lung cancer: A narrative review of the T790M reflex testing algorithm. Cancer Research Statistics and Treatment, 2021, 4, 692.	0.6	3

#	Article	IF	CITATIONS
2805	Utility of the Ba/F3 cell system for exploring onâ€ŧarget mechanisms of resistance to targeted therapies for lung cancer. Cancer Science, 2022, 113, 815-827.	3.9	11
2806	Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bioorganic Chemistry, 2022, 119, 105564.	4.1	15
2807	Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 724389.	3.7	8
2808	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 2022, 27, 819.	3.8	32
2809	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. Npj Systems Biology and Applications, 2022, 8, 2.	3.0	0
2810	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering, 2022, 6, 232-245.	22.5	56
2811	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. Frontiers in Oncology, 2022, 12, 766066.	2.8	3
2812	Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in <i>EGFR</i> -Mutant Lung Cancer. Cancer Discovery, 2022, 12, 1002-1021.	9.4	22
2813	Effects of Different Centrifugation Protocols on the Detection of <i>EGFR</i> Mutations in Plasma Cell-Free DNA. American Journal of Clinical Pathology, 2022, 158, 206-211.	0.7	3
2814	Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene, 2022, 41, 1235-1251.	5.9	13
2815	GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells. BMC Pulmonary Medicine, 2022, 22, 36.	2.0	2
2816	A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. BMC Pulmonary Medicine, 2022, 22, 27.	2.0	5
2817	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	7.7	21
2818	Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 85-98.	3.3	12
2819	Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 2021, 59, 100796.	14.4	122
2822	New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFR ^{WT} and EGFR ^{T790M} Inhibitors: Microwave-Assisted Synthesis, Anticancer Evaluation, and Molecular Docking Study. ACS Omega, 2022, 7, 7155-7171.	3.5	30
2823	MARIPOSA: phase 3 study of first-line amivantamabÂ+Âlazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncology, 2022, 18, 639-647.	2.4	44
2824	Paradigms for the development of transformative medicines—lessons from the EGFR story. Annals of Oncology, 2022, , .	1.2	2

#	Article	IF	CITATIONS
2825	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Cancers, 2022, 14, 1512.	3.7	1
2826	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular Cancer, 2022, 21, 79.	19.2	219
2827	Aumolertinib: A Review in Non-Small Cell Lung Cancer. Drugs, 2022, 82, 577-584.	10.9	9
2828	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	1.1	50
2829	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. Pharmaceuticals, 2022, 15, 450.	3.8	6
2830	Therapeutic advances in nonâ€small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm, 2021, 2, 692-729.	7.2	38
2831	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. Cancers, 2021, 13, 6228.	3.7	33
2832	Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells. Chinese Medical Journal, 2014, 127, 2091-2096.	2.3	1
2834	Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research, 2022, 82, 1448-1460.	0.9	24
2835	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology, 2022, 85, 253-275.	9.6	61
2836	The Ascension of Targeted Covalent Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 5886-5901.	6.4	55
2837	Deregulated signaling networks in lung cancer. , 0, , 421-442.		0
2849	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.		0
2850	Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. Scientific Reports, 2022, 12, 6693.	3.3	21
2853	A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid. Tumori, 2014, 100, e45-8.	1.1	0
2872	Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. Annals of Palliative Medicine, 2014, 3, 19-21.	1.2	5
2873	Drifting EGFR mutation. Chinese Clinical Oncology, 2013, 2, 3.	1.2	5
2874	The changing world of oncology drug development-A global pharmaceutical company's perspective. Chinese Clinical Oncology, 2014, 3, 20.	1.2	6

#	Article	IF	CITATIONS
2875	Amethod of Evaluation False-positive EGFR T790M Mutation Based on Deamining 5-methylcytosine. Bunseki Kagaku, 2022, 71, 59-68.	0.2	2
2876	Molecular docking of the pentapeptide derived from rice bran protein as anticancer agent inhibiting both receptor and non-receptor tyrosine kinases. Journal of Biomolecular Structure and Dynamics, 2022, , 1-23.	3.5	0
2877	LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells. Cancers, 2022, 14, 2222.	3.7	2
2878	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Science Advances, 2022, 8, eabn1229.	10.3	9
2879	Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 497-530.	4.9	530
2880	Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO Open, 2022, 7, 100473.	4.5	0
2881	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomedicine and Pharmacotherapy, 2022, 150, 113064.	5.6	14
2882	Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 722-734.	2.8	9
2883	Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling. Stem Cells and Development, 2022, 31, 604-620.	2.1	3
2885	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 2022, 170, 41-51.	2.0	33
2886	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular Cell, 2022, 82, 2443-2457.e7.	9.7	9
2887	Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer. Cells, 2022, 11, 1694.	4.1	18
2888	Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Journal of Molecular Biology, 2022, 434, 167626.	4.2	4
2889	Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. Frontiers in Pharmacology, 0, 13, .	3.5	17
2890	Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 124-141.	1.7	1
2891	Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	2
2892	Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study. Respiratory Research, 2022, 23, .	3.6	7
2894	Platelet Activation in High D-Dimer Plasma Plays a Role in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Mutant Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	2.8	3

#	Article	IF	CITATIONS
2895	EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. Journal of Thoracic Disease, 2022, 14, 2254-2267.	1.4	4
2896	<i>LINC00116</i> Is a Novel Prognostic Biomarker of Nonsmall Cell Lung Cancer. Genetic Testing and Molecular Biomarkers, 2022, 26, 340-347.	0.7	0
2897	Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation. Pakistan Journal of Medical Sciences, 2022, 38, .	0.6	3
2898	Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential ECFRWT and ECFRT790M inhibitors and apoptosis inducers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1053-1076.	5.2	16
2899	Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	12
2900	Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 3430.	3.7	4
2901	Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 9662-9677.	6.4	50
2903	The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry, 2022, 14, 1267-1288.	2.3	11
2904	AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discovery, 2022, 12, 2666-2683.	9.4	32
2905	Lazertinib: on the Way to Its Throne. Yonsei Medical Journal, 2022, 63, 799.	2.2	7
2906	Extracellular Vesicles from <i>EGFR T790M/L858R</i> -mutant Non-small Cell Lung Cancer Promote Cancer Progression. Anticancer Research, 2022, 42, 3835-3844.	1.1	3
2907	Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 8526.	4.1	2
2908	EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome. Frontiers in Oncology, 0, 12, .	2.8	3
2909	Benzimidazoleâ€based protein kinase inhibitors: Current perspectives in targeted cancer therapy. Chemical Biology and Drug Design, 2022, 100, 656-673.	3.2	15
2910	<i>EGFR</i> -mutant NSCLC: monitoring the molecular evolution of tumors in 2022. Expert Review of Anticancer Therapy, 2022, 22, 1115-1125.	2.4	2
2911	Discovery of new 1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidine derivatives as anticancer agents targeting EGFR ^{WT} and EGFR ^{T790M} . Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2283-2303.	5.2	17
2912	Optimal treatment strategy of cancers with intratumor heterogeneity. Mathematical Biosciences and Engineering, 2022, 19, 13337-13373.	1.9	2

#	Article	IF	CITATIONS
2914	SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14.	1.9	2
2915	New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies. Molecules, 2022, 27, 5859.	3.8	20
2916	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Frontiers in Oncology, 0, 12, .	2.8	3
2918	Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of Medicinal Chemistry, 2022, 65, 13052-13073.	6.4	11
2919	Generation of genetically engineered mice for lung cancer with mutant EGFR. Biochemical and Biophysical Research Communications, 2022, 632, 85-91.	2.1	1
2920	Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Medicine, 2022, 10, 205031212211323.	1.8	1
2921	Synthesis and in Vitro Anti-tumor Activity of Novel Spliced Compounds of Zidovudine and 4-Anilinoquinazolines. Chinese Journal of Organic Chemistry, 2022, 42, 2793.	1.3	0
2922	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2022, 23, 1626-1644.	3.0	10
2923	Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. Journal of Personalized Medicine, 2022, 12, 1684.	2.5	6
2924	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	17.0	59
2925	Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel's activity by suppressing the NF-kB signaling pathway. Frontiers in Oncology, 0, 12, .	2.8	4
2927	ADAMTS6: Emerging roles in cardiovascular, musculoskeletal and cancer biology. Frontiers in Molecular Biosciences, 0, 9, .	3.5	2
2928	Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients. Translational Lung Cancer Research, 2022, 11, 2064-2078.	2.8	3
2930	Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications, 2022, 13, .	12.8	9
2931	Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. Frontiers in Pharmacology, 0, 13, .	3.5	3
2932	Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer. Journal of Surgical Research, 2023, 283, 674-682.	1.6	0
2933	Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. Cancer Biomarkers, 2022, , 1-12.	1.7	0
2934	An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and Molecular Life Sciences, 2023, 80, .	5.4	1

#	Article	IF	CITATIONS
2935	In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer. Cell and Bioscience, 2022, 12, .	4.8	2
2936	Clinical case of long-term disease control in a patient with <i>EGFR</i> -positive non-small cell lung cancer. Meditsinskiy Sovet, 2022, , 154-159.	0.5	1
2937	Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor. International Journal of Molecular Sciences, 2022, 23, 15828.	4.1	3
2938	Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers, 2023, 15, 504.	3.7	14
2939	Lung Cancer: Recent Advances. Annals of the Academy of Medicine, Singapore, 2010, 39, 819-821.	0.4	1
2941	Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small-cell lung cancer patients. Translational Lung Cancer Research, 2023, 12, 14-26.	2.8	1
2942	Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 725-732.	1.1	1
2943	Ku–DNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks. NAR Cancer, 2023, 5, .	3.1	1
2944	Targeted Therapies Used in the Treatment of Non–Small-Cell Lung Cancer: An Overview. , 2023, , 111-158.		0
2945	Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib. Journal of Natural Medicines, 0, , .	2.3	0
2946	Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. British Journal of Cancer, 2023, 128, 2186-2196.	6.4	2
2947	Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review. Journal of Oncology Pharmacy Practice, 2023, 29, 1187-1195.	0.9	1
2948	The development and implementation of EGFR inhibitors in advanced NSCLC. , 2023, , 13-36.		0
2949	Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges. Journal of Personalized Medicine, 2023, 13, 303.	2.5	2
2950	Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. Medicine (United States), 2023, 102, e32697.	1.0	1
2951	Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. Neoplasia, 2023, 38, 100888.	5.3	2
2952	Hereditary cancer syndromes. World Journal of Clinical Oncology, 0, 14, 40-68.	2.3	8
2953	Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. Scientific Reports, 2023, 13, .	3.3	5

#	Article	IF	CITATIONS
2954	Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC. Frontiers in Oncology, 0, 13, .	2.8	8
2955	Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. BMC Medicine, 2023, 21, .	5.5	1
2956	In silico target specific design of potential quinazoline-based anti-NSCLC agents. Journal of Biomolecular Structure and Dynamics, 2023, 41, 10725-10736.	3.5	0
2957	A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine, 2023, 12, 1936.	2.4	3
2958	EGFR and MMP-9 are associated with neointimal hyperplasia in systemic-to-pulmonary shunts in children with complex cyanotic heart disease. Mammalian Genome, 2023, 34, 285-297.	2.2	0
2959	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC Cancer, 2023, 23, .	2.6	5
2960	Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Non–Small Cell Lung Cancer. Chromatography, 2023, , .	1.7	1
2961	Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present). Pharmaceuticals, 2023, 16, 534.	3.8	7
2962	The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2023, , .	1.5	0
2062			
2903	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
2903	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27.	0.0	0
2964 2965	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553.	0.0	0 0 1
2963 2964 2965 2966	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27.Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553.Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 717-725.	0.0 5.5 4.1	0 0 1 3
2963 2964 2965 2966 2966	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27.Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553.Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 717-725.Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical Development and Technology, 2023, 28, 460-478.	0.0 5.5 4.1 2.4	0 0 1 3 4
2963 2964 2965 2966 2967 2968	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 717-725. Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical Development and Technology, 2023, 28, 460-478. Computer aided drug discovery (CADD) of a thieno[2,3- <i>d</i>]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. Journal of Biomolecular Structure and Dynamics, 2024, 42, 2369-2391.	0.0 5.5 4.1 2.4 3.5	0 0 1 3 4 5
2963 2964 2965 2966 2966 2968 2968	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 717-725. Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical Development and Technology, 2023, 28, 460-478. Computer aided drug discovery (CADD) of a thieno[2,3- <i>d<<i>l</i>i>jpyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. Journal of Biomolecular Structure and Dynamics, 2024, 42, 2369-2391. Case report: Neuroendocrine breast carcinoma with a germline ECFR T790M mutation. Frontiers in Oncology, 0, 13, .</i>	0.0 5.5 4.1 2.4 3.5 2.8	0 0 1 3 4 5 1
2963 2964 2965 2966 2967 2968 2969 2971	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta, 2023, 259, 124553. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 717-725. Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical Development and Technology, 2023, 28, 460-478. Computer aided drug discovery (CADD) of a thieno[2,3- <i><i><i><i><<i><<i><<</i></i></i></i></i></i>	0.0 5.5 4.1 2.4 3.5 2.8 12.8	0 1 3 4 5 1 2

#	Article	IF	CITATIONS
2973	Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer. , 2015, 1, 20-25.		0
2974	Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics. Journal of Biomolecular Structure and Dynamics, 2024, 42, 2464-2481.	3.5	3
2975	A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Nature Biotechnology, 0, , .	17.5	14
2976	Development of Kinase entric Drugs: A Computational Perspective. ChemMedChem, 2023, 18, .	3.2	2
2977	Molecular imaging of biomarkers in breast cancer. , 2022, , 1-23.		0
2978	Role of EGFR and FASN in breast cancer progression. Journal of Cell Communication and Signaling, 2023, 17, 1249-1282.	3.4	3
2979	Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role. , 2023, 40, .		7
2980	L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Reports Medicine, 2023, 4, 101142.	6.5	3
2981	Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines. Biomedicines, 2023, 11, 2406.	3.2	0
2982	Synthesis and Preclinical Evaluation of [<i>Methylpiperazine</i> - ¹¹ C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry, 2023, 66, 12130-12140.	6.4	3
2983	Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer. BioTech, 2023, 12, 57.	2.6	0
2984	Nivolumab as maintenance therapy following platinumâ€based chemotherapy in <scp><i>EGFR</i></scp> â€mutant lung cancer patients after tyrosine kinase inhibitor failure: A singleâ€arm, openâ€label, phase 2 trial. Thoracic Cancer, 2023, 14, 3080-3088.	1.9	0
2985	Molecular tumour boards — current and future considerations for precision oncology. Nature Reviews Clinical Oncology, 2023, 20, 843-863.	27.6	6
2986	Histology and molecular testing. , 2024, , 69-100.		0
2987	Molecular testing in lung cancer. , 2024, , 319-337.		0
2988	Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations. Experimental and Therapeutic Medicine, 2023, 26, .	1.8	0
2989	Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. Clinical Cancer Research, 2023, 29, 4586-4595.	7.0	3
2991	Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science. Cancer Discovery, 2023, 13, 2131-2149.	9.4	1

IF

ARTICLE #

2992	Molecular	Carcinogenesis	of Lung Cance	er., 2023,	, 1-21.
------	-----------	----------------	---------------	------------	---------

2993	Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC. International Journal of Molecular Sciences, 2023, 24, 14742.	4.1	1
2994	Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse. Cold Spring Harbor Perspectives in Medicine, 0, , a041385.	6.2	0
2995	Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects. Expert Opinion on Drug Metabolism and Toxicology, 2023, 19, 653-664.	3.3	0
2996	Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators. Cancers, 2023, 15, 5009.	3.7	2
2997	Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications. , 2023, , 1-19.		0
2998	New 3-aminorhodanine derivatives: Synthesis, characterization, docking study and biological activates. F1000Research, 0, 12, 1365.	1.6	0
2999	Targeting the up-regulated CNOT3 reverses therapeutic resistance and metastatic progression of EGFR-mutant non-small cell lung cancer. Cell Death Discovery, 2023, 9, .	4.7	0
3000	Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Scientific Reports, 2023, 13, .	3.3	0
3001	Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease. Archives of Medical Research, 2023, , 102899.	3.3	1
3002	Molecular modeling, dynamic simulation, and metabolic reactivity studies of quinazoline derivatives to investigate their anti-angiogenic potential by targeting wild EGFR ^{wt} and mutant EGFR ^{T790M} receptor tyrosine kinases. Journal of Biomolecular Structure and Dynamics, 0, , 1-23.	3.5	0
3003	Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Communications, 2023, 43, 1326-1353.	9.2	1
3004	The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treatment Reviews, 2024, 122, 102664.	7.7	2
3005	Network pharmacology‑based investigation of potential targets of triptonodiol acting on non-small-cell lung cancer. European Journal of Medical Research, 2023, 28, .	2.2	1
3006	To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors. Current Topics in Medicinal Chemistry, 2023, 23, 2877-2972.	2.1	2
3007	Binding Thermodynamics of Fourth-Generation EGFR Inhibitors Revealed by Absolute Binding Free Energy Calculations. Journal of Chemical Information and Modeling, 0, , .	5.4	0
3008	Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase. Journal of Physical Chemistry B, 2023, 127, 10749-10765.	2.6	1
3009	Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment. Bioorganic Chemistry, 2024, 143, 107004.	4.1	0

#	Article	IF	CITATIONS
3010	A newly identified 45â€kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance. Molecular Oncology, 2024, 18, 415-430.	4.6	0
3011	Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages. Acta Pharmacologica Sinica, 0, , .	6.1	0
3012	Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment. Frontiers in Oncology, 0, 13, .	2.8	1
3013	Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology, 2024, 56, 192-204.	0.6	2
3014	Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells, 2024, 13, 47.	4.1	1
3015	A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition. Npj Precision Oncology, 2024, 8, .	5.4	2
3016	Research Advances of Small Molecule EGFR-TKIs in NSCLC. Pharmacy Information, 2024, 13, 1-9.	0.0	0
3017	Secondary metabolites of Trichoderma spp. as EGFR tyrosine kinase inhibitors: Evaluation of anticancer efficacy through computational approach. PLoS ONE, 2024, 19, e0296010.	2.5	0
3018	Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy. Cancers, 2024, 16, 778.	3.7	0
3019	Electrochemotherapy for head and neck cancers: possibilities and limitations. Frontiers in Oncology, 0, 14, .	2.8	0
3020	Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present). Molecules, 2024, 29, 875.	3.8	0
3021	Harnessing the potential of reverseâ€phase protein array technology: Advancing precision oncology strategies. Cancer Science, 0, , .	3.9	0
3022	Droplet Digital PCR as a Molecular Tool for the Detection of the <i>EGFR</i> T790M Mutation in NSCLC Patients with the <i>EGFR</i> Activating Mutations. Balkan Journal of Medical Genetics, 2023, 26, 21-26.	0.5	0